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Abstract  
A key point in the administration of biopharmaceuticals is the recognition of appropriate, 
effective, safe and biocompatible nanocarriers allowing overcoming extracellular and 
intracellular biological barriers without loss of drug stability and adequate therapeutic 
response at the target sites. Since their description by Rainer Müller in the early 1990’s, 
solid lipid nanoparticles (SLN) have been developed as an effective colloidal drug carrier. 
Under optimized conditions, SLN can be produced for the entrapment of lipophilic or 
hydrophilic drugs with the essential requirements for an optimum nanoparticulate carrier. 
Its colloidal size and the controlled release behaviour allow protection and management 
when administered by parenteral and non-parenteral routes (e.g., oral, nasal and 
pulmonary).  
The pulmonary route has gained interest to the non-invasive administration of 
biopharmaceuticals on account of the promising anatomical features of the lung, 
particularly its large absorptive epithelial surface area, low thickness and avoiding the 
first-pass effect. The lung region where the particles are deposited depends on their 
aerodynamic diameter. The complex structure of the respiratory tree and the natural 
defence mechanisms of the lung are fundamental aspects for the design of a proper 
pulmonary delivery system.  
Although pulmonary delivery of nanoparticles has an unquestionable interest, it still 
requires a complex setup and an aerosolization technique, due to their low inertia and 
small size, which hindering the deposition in the lung, facilitating the exhalation with air. 
A promising alternative is the formulation of nanoparticles in inhalable microspheres that 
ensure their release after pulmonary administration. Microspheres have recently been 
proposed for pulmonary inhalation as dry powders, since they can be designed to achieve 
appropriate morphological and aerodynamic characteristics. Previous studies have shown 
that polymeric nanocarriers loaded in microparticulate systems present a great potential 
for pulmonary delivery of therapeutic macromolecules and genetic material. These 
microspheres act only as inert vehicles of the nanoparticles, which remain unaltered after 
the spray-drying process, not affecting the properties or the release profile of the 
encapsulated active agents, thus constituting a suitable microparticulate carrier for the 
pulmonary delivery of drug-containing nanoparticles. 
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In this context a research project has been designed to explore the application and 
versatility of these micro-nanostructured systems as carriers for therapeutic drugs/proteins 
and genetic material. The SLN containing an anti-tuberculosis drug, a model peptide or a 
model plasmid (rifabutin, papain and pEGFP-C1, respectively) were formulated and 
optimized. Then, for pulmonary administration, SLN were spray-dried using common 
pharmaceutical excipients (mannitol and trehalose). The integrity and stability of all 
biomacromolecules studied were not affected by the SLN and microspheres formulation 
and preparation procedures, which were then considered as suitable for the encapsulation 
of labile therapeutic molecules. Particularly mannitol and trehalose and the SLN 
themselves acted as stabilizers of the pharmaceutics during spray-drying. The prepared 
spray-dried powders displayed good flow and aerosolization properties for pulmonary 
administration and exhibited high deposition in the lower regions of the respiratory tract 
determined through a twin-stage liquid impinger, Moreover, the spray-drying process 
preserved the peculiar nanoparticles features after their disintegration from dry 
microspheres, exhibiting a sustained release profile of antibiotic and peptide after contact 
with an aqueous medium containing a lung surfactant. Studies in cell cultures and animal 
models have revealed the biocompatibility and ability of these nanoparticles to promote 
the absorption of drugs and peptides through pulmonary epithelium, as well as their 
excellent potential in gene therapy. 
In conclusion, all the results obtained in this experimental work showed the interest of 
these systems as vehicles for the pulmonary administration of antibiotic drugs and 
therapeutic proteins and nucleic acids. 
 
Keywords: Microspheres, pulmonary administration, solid lipid nanoparticles, spray-
drying. 
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Resumen 
La vía pulmonar presenta un gran interés para la administración no invasiva de 
biofármacos. Los dispositivos inhaladores de polvo seco, que presentan la ventaja de su 
esterilidad y estabilidad a largo plazo, revisten hoy un gran interés para la aerosolización 
pulmonar de fármacos. La liberación pulmonar de nanopartículas presenta un 
incuestionable interés pero también requiere una compleja puesta a punto y una técnica de 
aerosolización precisa ya que las nanopartículas individuales, por su baja inercia 
inherente al pequeño tamaño, no se depositan de manera eficaz en los pulmones sino que 
son fácilmente exhaladas con el aire. Una alternativa muy prometedora consiste en la 
formulación de nanopartículas en microesferas fácilmente aerosolizables y que garanticen 
su liberación tras su administración pulmonar. Desde la primera descripción por Müller, 
las nanopartículas lipídicas sólidas (SLN) preparadas ya sea com lípidos fisiológicos o 
lípidos utilizados como excipientes farmacéuticos, han atraído una creciente atención 
como eficaz transportador coloidal de fármacos. Bajo condiciones optimizadas, SLN 
pueden ser producidos para incorporar/asociar un amplio abanico de moléculas 
terapéuticas (fármacos lipofílicos o hidrofílicos, péptidos, proteínas, DNA, siRNA). 
En este trabajo de tesis se desarrolló una nueva plataforma de liberación consistente en 
sistemas nanotransportadores microencapsulados, con indiscutible potencial para la 
administración pulmonar de antibióticos, macromoléculas terapéuticas y material 
genético. Las SLN, elaboradas a partir de lípidos sólidos, utilizando el método de 
dispersión-fusión fueron posteriormente encapsuladas en microesferas de manitol y 
trehalosa mediante un procedimiento de atomización-secado, resultando en sistemas 
micro-nanoestructurados (polvos secos) con propiedades superficiales, estructurales y 
aerodinámicas adecuadas para administración pulmonar. Las microesferas únicamente 
actúan como vehículos inertes de las SLN, que permanecen inalteradas tras el proceso de 
co-atomización y son fácilmente recuperadas intactas en medio acuoso, no viéndose 
afectado su tamaño, carga superficial ni perfil de liberación de la biomacromolécula 
encapsulada. Con el objeto de explorar la aplicación y versatilidad de estos sistemas 
micro-nanoestructurados como vehículos de antibióticos, proteínas terapéuticas y material 
genético, se procedió a investigar la asociación y liberación de un fármaco utilizado 
contra la tuberculosis (rifabutina), de un péptido modelo (papaína) y un plásmido modelo 
(pEGFP-C1). Se comprobó que las biomacromoléculas no habían visto afectada su 
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estabilidad por su procesado mediante las técnicas de dispersión-fusión y atomización. El 
procedimiento resulta interesante para la encapsulación de moléculas terapéuticas lábiles, 
actuando tanto el manitol y la trehalosa como las propias SLN como estabilizantes de los 
biofármacos durante la atomización. Los polvos obtenidos por atomización mostraron 
propiedades adecuadas de flujo y aerosolización para administración pulmonar, 
depositándose de manera elevada en las regiones inferiores del tracto respiratorio, 
preservando las peculiares características de las nanopartículas después de su 
desintegración a partir de microesferas secas. Además, el proceso de secado por 
pulverización no alteró las características de las SLN nativas, exhibiendo un perfil de 
liberación sostenida de antibiótico y péptido después del contacto con un medio acuoso 
que contenía un tensioactivo pulmonar. Estudios realizados en cultivos celulares y 
modelos animales, han revelado la biocompatibilidad y capacidad de estas nanopartículas 
de promover la absorción de medicamentos y péptidos a través de lo epitelio pulmonar, 
así como su excelente potencial en terapia génica. La interacción in vitro de las 
nanopartículas fluorescentes con los macrófagos demostró que los macrófagos 
representan una de las vías de eliminación de nanopartículas del pulmón. 
En definitiva, el conjunto de los resultados obtenidos en este trabajo experimental pone de 
manifiesto el interés de estos sistemas como vehículos para la administración pulmonar 
de fármacos y proteínas terapéuticas. 
 
Palabras-claves: Administración pulmonar, atomización, microesferas, nanopartículas 
lipídicas sólidas. 
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Resumo 
Um ponto-chave na administração de substâncias activas é a formulação de 
nanotransportadores apropriados, eficazes, seguros e biocompatíveis, que permitam 
transpor barreiras biológicas extracelulares e intracelulares sem perda da estabilidade e 
resposta terapêutica do fármaco até atingir os locais alvo. Desde a sua primeira descrição 
por Rainer Müller no princípio da década de 1900, as nanopartículas lipídicas sólidas 
(SLN) têm sido estudadas como um eficaz transportador coloidal dos mais variados tipos 
de fármacos, incluindo moléculas de natureza peptídica e material genético. As SLN são 
preparadas com lípidos fisiológicos e tensioactivos que permitem a sua estabilização. Sob 
condições optimizadas, as SLN podem incorporar fármacos lipofílicos ou hidrofílicos e o 
seu tamanho coloidal e comportamento de libertação controlada permitem a protecção das 
moléculas encapsuladas após administração por vias não parentéricas e parentéricas. 
Nos últimos anos, a via pulmonar tem ganho interesse na administração não invasiva de 
substâncias activas. A região pulmonar onde as partículas são depositadas depende 
sobretudo do seu diâmetro aerodinâmico. Por outro lado, a estrutura complexa da árvore 
respiratória, bem como os mecanismos naturais de defesa do pulmão, são aspectos 
fundamentais para a formulação de um sistema para administração pulmonar adequado. 
Neste contexto, os dispositivos de inalação de pó seco apresentam vantagens, como a sua 
fácil esterilização e estabilidade a longo prazo e, por isso, têm ganho um enorme interesse 
na aerossolização de fármacos. Também a administração pulmonar de nanopartículas tem 
ganho um interesse inquestionável. No entanto, devido à sua baixa inércia e tamanho 
reduzido, as nanopartículas apresentam dificuldades de deposição nos pulmões, 
favorecendo a sua exalação. Assim, a formulação de nanopartículas em microesferas 
inaláveis, que asseguram a sua libertação após a administração pulmonar mantendo as 
características primárias, tem sido amplamente investigada. Estudos anteriores 
demostraram que nanopartículas poliméricas microencapsuladas apresentam um grande 
potencial na libertação pulmonar de macromoléculas terapêuticas. Para tal, as 
nanopartículas são incorporadas em microesferas através de um processo de secagem por 
atomização (spray-drying), resultando em sistemas micro-nanoestruturados (pó seco) com 
adequadas propriedades estruturais e aerodinâmicas para administração pulmonar. Estas 
microesferas são constituídas por excipientes inertes e não-tóxicos e autorizados pelas 
agências regulamentares, actuando como veículo inerte das nanopartículas e como 
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termoprotectores das nanopartículas. Por outro lado, os nanotransportadores devem-se 
manter inalterados após o processo de atomização, não afectando as propriedades físico-
químicas ou o perfil de libertação dos agentes activos encapsulados. 
Assim sendo, o objetivo geral deste projeto centra-se no desenvolvimento de novos 
sistemas micro-nanoestruturados compostos por SLN encapsuladas em microesferas de 
manitol e trealose com propriedades adequadas para a administração pulmonar de 
substâncias activas. As substâncias activas usadas foram um antibiótico tuberculostático, 
uma proteína modelo e um plasmídeo, respectivamente, rifabutina (RFB), papaína (PAP) 
e pEGFP-C1. Para a sua incorporação nas SLN, diferentes métodos de associação foram 
usados. No caso da RFB, este antibiótico foi encapsulado na própria matriz lipídica 
durante a formulação das SLN. Por outro lado, a PAP foi adsorvida à superfície das 
nanopartículas enquanto o plasmídeo ficou confinado entre duas camadas poliméricas 
com carga positiva que por sua vez estavam adsorvidas à carga negativa da superfície das 
SLN. Nestes últimos dois casos, as moléculas foram associadas às SLN após a sua 
formulação. Os fármacos modelos incorporados nos diferentes nanoveículos foram 
utilizados com o intuito de caracterizar intensivamente as novas formulações 
desenvolvidas, e compreender os mecanismos de libertação, assim como estudar a sua 
eficácia terapêutica in vitro e in vivo. 
Dois diferentes tipos de SLN foram formulados e optimizados pela técnica de 
homogeneização de alta pressão a altas temperaturas, um à base de dibe-henato de 
glicerilo e outro de triestearato de glicerilo. Esta técnica apresenta a vantagem de não usar 
solventes orgânicos nem necessitar da aplicação de ultrassonicação. Em seguida, as 
nanopartículas foram caracterizadas em termos físico-químicos e de estabilidade, 
concluindo-se que as SLN apresentam um tamanho na escala nanométrica, com uma 
polidispersão homogénea, carga superfície dependente do método de associação da 
substância activa sem perda de estabilidade física e actividade da própria molécula 
terapêutica. Estudos de citotoxicidade e de internalização em linhas celulares pulmonares 
relevantes (A549, Calu-3 e em monócitos diferenciados em macrófagos) confirmaram a 
biocompatibilidade das nanopartículas e revelaram ainda que as SLN apresentam 
capacidade de internalização por macrófagos. 
Numa fase seguinte, as SLN, através da técnica de atomização, foram microencapsuladas 
usando manitol e trealose como excipientes. As propriedades aerodinâmicas de 
densidade, tamanho, fluidez e humidade residual foram avaliadas, apresentando 
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resultados aceitáveis para administração pulmonar. Estudos de deposição e de 
aerossolização revelaram que os pós, quando administrados por um dispositivo adequado, 
apresentam características apropriadas para serem depositados na zona alveolar. 
As SLN contendo RFB demonstraram ter uma elevada eficiência de encapsulação do 
antibiótico, próxima da solubilidade do fármaco na matriz lipídica. Por análise térmica 
observou-se que a RFB encontra-se dissolvida na matriz das nanopartículas, que as 
nanoformulações eram estáveis quando sujeitas a altas temperaturas e que, após 
arrefecimento, recuperavam o seu tamanho nanométrico e a sua morfologia esférica e 
compacta. As SLN foram facilmente internalizadas por monócitos humanos, sendo uma 
característica importante, uma vez que o bacilo da Tuberculose (TB) é um parasita 
intracelular alojado nos macrófagos alveolares. Após incubação das SLN-RFB com 
células pulmonares, não foi observada citotoxicidade, confirmando assim que as SLN são 
potenciais sistemas transportadores para a administração pulmonar de fármacos anti-TB.  
Numa fase posterior, estas RFB-SLN foram encapsuladas em microesferas de mannitol e 
trealose por um processo de secagem por atomização, resultando em pós secos com 
propriedades aerodinâmicas e estruturais adequadas para administração pulmonar. Esta 
técnica de microencapsulação permite superar os problemas de estabilidade das 
formulações de nanopartículas líquidas, bem como atingir a zona alveolar após inalação. 
A análise estrutural por microscopia electrónica de varrimento e por microscopia de 
confocal indicou que as microesferas são esféricas com limites bem definidos e que as 
SLN foram eficientemente encapsulados nas microesferas, apresentando uma distribuição 
homogénea dentro das microesferas. A caracterização física por calorimetria de titulação 
isotérmica demonstrou que as SLN têm maior afinidade para o manitol do que para a 
trealose durante o processo de atomização, favorecendo as interacções entre as SLN e o 
manitol. Após dissolução in vitro das microesferas de manitol e trealose, as SLN 
permitiram a libertação da RFB ao final de 24 h de incubação em meio contendo o 
tensioactivo pulmonar (> 95% de libertação no caso das SLN microencapsuladas em 
manitol e cerca de 80% para as SLN microencapsuladas em trealose). As micro-
nanoformulações mantiveram a actividade intracelular anti-TB da RFB. Estudos in vivo 
demonstraram que os pós são eficazes para administração pulmonar da RFB, reduzindo o 
índice de crescimento da infecção nos órgãos estudados. Desta forma, confirma-se que as 
SLN microencapsuladas são uma plataforma promissora para a administração pulmonar 
de antibióticos terapêuticos, podendo contribuir para a melhoria do tratamento da TB. 
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Numa etapa posterior, foi utilizado um processo de adsorção para associar uma proteína 
modelo, PAP, à superfície das SLN de dibe-henato de glicerilo e de triestearato de 
glicerilo, previamente optimizadas com o intuito de serem passíveis de administração 
pulmonar. A adsorção da PAP à superfície das SLN segue uma isotérmica de adsorção do 
tipo Freundlich sobre o intervalo de concentrações estudado, sugerindo um modelo de 
multicamadas de proteína na superfície das SLN através da interação eletrostática entre os 
grupos amina da PAP e a carga negativa das SLN. O processo de adsorção, bem como o 
processo de microencapsulação das PAP-SLN em manitol e trealose, foram confirmados 
por diferentes técnicas de caracterização de superfície. Os pós obtidos por atomização, 
para além de possuírem características aceitáveis para deposição pulmonar, permitiram 
também manter a actividade enzimática da PAP. Em conjunto, estes resultados são um 
indicador encorajador da utilização das SLN microencapsuladas como transportadores de 
proteínas para administração pulmonar. 
Por forma a analisar a versatilidade das SLN de dibe-henato de glicerilo e de triestearato 
de glicerilo como transportadores de material genético, estas dispersões foram 
modificadas com um polímero catiónico, o quitosano (CS). Posteriormente, o plasmídeo 
modelo (pEGFP-C1) foi incorporado à superfície das SLN e protegido pelas camadas de 
CS. Os nanosistemas policatiónicos demonstraram ter uma afinidade elevada para o 
plasmídeo, proporcionando protecção ao pEGFP-C1 encapsulado quando sujeito à 
degradação por endonuclease específicas. As nanoformulações demonstraram baixa 
citotoxicidade celular e uma elevada taxa de transfecção em células pulmonares. As SLN 
modificadas foram atomizadas com manitol e trealose, formando microesferas com 
características adequadas para administração de genes ao nível pulmonar. Por sua vez, 
estas microesferas garantiram a estabilidade, protecção e funcionalidade do pEGFP-C1.  
No geral, estes resultados evidenciam a versatilidade das SLN como veículos 
transportadores seguros e eficazes de substâncias activas para o desenvolvimento de 
sistemas de libertação ao nível pulmonar, podendo ser utilizados em abordagens 
terapêuticas inovadoras. 
 
Palavras-chaves: Administração pulmonar, microesferas, nanopartículas lipídicas 
sólidas, secagem por atomização. 
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Aims and Organization of the Thesis 
Over the last years, absorption of therapeutic macromolecules administered by pulmonary 
route has received great attention. The large alveolar surface area suitable for drug 
absorption, low thickness epithelial barrier, extensive vascularization and relatively low 
proteolytic activity compared to other administration routes, together with the absence of 
the first-pass effect, make the pulmonary delivery an outstanding target. However, the 
issue for a reliable and specific lung protein delivery is the design of adequate carrier 
systems. The delivery of biopharmaceuticals as dry powders with suitable characteristics 
for inhalation presents advantages when compared with liquid formulations, for instance 
where stability and patient compliance are concerned.   
Microspheres have been proposed for pulmonary administration because they can be 
designed to achieve appropriate morphological and aerodynamic characteristics for that 
purpose. The success of the inhaled particles depends mostly on their size and density, 
and hence, aerodynamic diameter (daer). The respirable fraction of these powders, 
generally the fraction of particles with an daer ranging from 1 to 5 μm, should be as high 
as possible to guarantee a maximum deposition in the deep lung and, consequently, a 
systemic adsorption.  
The main objective of this doctoral thesis, which began 1
st
 January 2013, was the 
investigation of microencapsulation of solid lipid nanoparticles (SLN) as a hybrid 
particulate delivery system for pulmonary delivery of different kinds of 
biopharmaceutical agents, such as, low molecular weight drugs, proteins and nucleic 
acids. It involved the study and optimization of SLN formulation containing the three 
model drugs, the feasibility of the spray-drying technique for SLN microencapsulation, as 
well as the in vitro and in vivo performance of the resulting dry powders. 
The emphasis of this research work was put on the development and in-depth 
characterization of microencapsulated SLN in a dry powder form intended for pulmonary 
administration with therapeutic purposes. This microencapsulation technique allowed 
improving the nanoparticles efficiency for inhalation. In addition, the versatility of these 
developed lipidic carriers was also investigated as carriers of drugs, proteins and peptides 
or nucleic acids through different association mechanisms of the biopharmaceuticals in 
the nanoparticles. 
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All the research and scientific work results from a joint partnership between the Faculty 
of Pharmacy, University of Lisbon, Portugal and the Faculty of Pharmacy and the Faculty 
of Physics, University of Santiago de Compostela, Spain. The financial support of the 
entire research project was given through a PhD grant (SFRH/BD/89520/2012) by 
Portuguese Foundation for Science and Technology, between January 2013 and 
December 2016. The experimental work that supports this thesis was performed at the 
Departamento de Farmácia Galénica e Tecnologia Farmacêutica of the Faculty of 
Pharmacy, University of Lisbon, at the Departamento de Farmacología, Farmacia y 
Tecnología Farmaceútica, Faculty of Pharmacy, University of Santiago de Compostela 
and at the Departamento de Física de la Materia Condensada, Faculty of Physics, 
University of Santiago de Compostela. 
 
The present thesis is divided into 6 chapters. The first chapter corresponds to the general 
introduction of the thesis. The following 4 chapters provide detailed information on the 
obtained experimental results and their discussion. The last chapter compiles the final 
remarks and the future perspectives in the context of this research project. The chapters of 
this thesis are all based on peer-reviewed papers, either published or submitted for 
publication. The following paragraphs summarize the content of each chapter. 
↠ Chapter 1 reviews the literature on microencapsulation of nanoparticles intended for 
pulmonary administration, describing the suitable aerodynamic characteristics of these 
hybrid particles for lung delivery of biopharmaceuticals, such as drugs, proteins and 
genetic material. It also analyzes and discusses the potential and the future directions for 
inhalation therapy using dry powders composed of microencapsulated nanoparticles. 
↠ Chapter 2 describes the formulation, optimization and characterization of rifabutin 
(RFB)-loaded SLN prepared by a hot high shear homogenization technique, using 
glyceryl dibehenate and glyceryl tristearate as the lipidic phase. Studies included 
morphology and stability analysis, physical characterization, in vitro cytotoxicity tests 
and in vitro release, as well as, in vitro uptake. 
↠ Chapter 3 reports the microencapsulation studies of the previous developed RFB-
loaded SLN via spray-drying using the biocompatible and safe excipients, mannitol and 
trehalose. The optimal dry powder formulations were selected and fully characterized in 
terms of morphology by microscopy techniques, aerodynamic and powder flow properties 
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(for instance, daer, density, moisture residual content), as well as in vitro deposition 
studies using a twin-stage liquid impinger (Ph. Eur. 2.9.18. Apparatus A). In vitro drug 
release from the nanoparticles and from the SLN-containing microparticles (i.e. dry 
powders) was also evaluated, as well as bacteriological studies aiming to evaluate the 
RFB activity throughout the formulation procedures. In vivo studies using a murine model 
were performed to establish the effective drug dose by the inhalation route. 
↠ Chapter 4 comes in the sequence of the previous chapters, now applying the 
formulation strategy to a model protein molecule (papain). This enzyme was associated to 
the preformed SLN using adsorption procedure, to avoid the harsh temperature and 
agitation conditions involved in the nanoencapsulation procedure. The protein-loaded 
SLN were then microencapsulated in mannitol or trehalose microparticles using spray-
drying. Full characterization was performed in terms of morphology, adsorption process 
and molecular interactions between the protein and the nanoparticles. Furthermore, a 
complete physical characterization of the obtained dry powders was also done. 
↠ Chapter 5 describes the formulation and characterization studies of dry powders 
composed by hybrid microencapsulated SLN containing a model plasmid for pulmonary 
administration. The model plasmid (pEGFP-C1) was associated to chitosan-coated SLN. 
The nanoparticle structure consisted of a lipidic core coated with two polymeric layers 
between which the plasmid was entrapped. After microencapsulation by spray-drying, the 
physical and aerodynamic characteristics of both complex structured dry powders systems 
were studied to evaluate their potential for pulmonary applications. In vitro 
characterization included transfection in relevant pulmonary cell lines (Calu-3 and A549). 
pEGFP-C1 stability and integrity studies after nanoformulation and subsequent 
microencapsulation was also performed in order to highlight this strategy for pulmonary 
delivery of genetic material.  
 ↠ Chapter 6 describes the general discussion and main conclusions of the developed 
work, focusing on the current limitations and the future perspectives of the formulation 
strategy herein investigated and proposed. 
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Abstract 
The lung offer a large surface area for absorption, rich blood circulation, high 
permeability and limited proteolytic activity when compared with other administration 
routes, which makes it an ideal route for non-invasive administration of therapeutics. 
Localized delivery shows great promise not only in the treatment of respiratory diseases 
(such as asthma, tuberculosis (TB), influenza, cystic fibrosis), but also reduces the 
systemic toxicity. Alternatively, systemic drug delivery can be achieved by targeting the 
alveolar region where the active agents can be absorbed through a thin layer of epithelial 
cells and into the systemic circulation, leading to enhanced permeability, a rapid onset of 
action and avoidance of first-pass metabolism. Nanotechnology has potential in the 
development of novel and effective delivery systems of drugs for pulmonary 
administration. Different strategies have been utilized for pulmonary delivery of 
therapeutics, including the use of lipid-based delivery systems (liposomes, solid lipid 
nanoparticles), polymeric matrix and polysaccharide particulates (poly(lactic-co-glycolic 
acid), poly (caprolactone), cynoacrylates, gelatin, chitosan, alginate), biocompatible 
metallic inorganic particles (iron, gold, zinc), among others. Due to their extremely small 
sizes, the nanoparticles suffer many problems related to their surface and thermal 
stability, shape preservation, handling and others. It is therefore an important challenge to 
overcome these issues by developing larger particles (e.g., on the micrometer scale) in 
which the characteristics from the included nanocarriers are preserved. One approach to 
this is to trap nanoparticles in a micrometer-sized inert matrix. A novel particulate form 
incorporating nanoparticles into micron-scale structures has been engineered through 
suitable techniques, such as spray-drying, spray-freeze-drying and supercritical fluid 
technology, aiming to overcome the problems of storing and delivering nanoparticles to 
the lung. This chapter highlights various microencapsulated nanoparticles approaches in 
the form of lipids, polymers, metals, polysaccharides, or emulsions based for pulmonary 
drug delivery with proper aerodynamic characteristics for this purpose that could provide 
an increased biological efficacy and better local and systemic action. 
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1.1. Drug delivery systems based on nanoparticles 
Particulate systems have been widely used as drug delivery carriers to prevent or treat a 
variety of diseases. In the particular case of pharmaceutical applications, the discovery of 
new active substances (e.g. peptides, proteins and nucleic acids) brings new challenges 
related to the needs of overcoming the deficient solubility/stability of a large number of 
these substances of both synthetic and biotechnological origin, as well as of improving 
the efficiency and safety profiles of old drugs as a way to extend their therapeutic and 
commercial value [1, 2]. The microencapsulation or nanoencapsulation of drugs into 
optimized particles is opening new opportunities. In general terms, encapsulation is the 
process to confine active agents in envelopes of polymeric, lipid or other protective 
materials, generally in a particulate form, in order to confer protection, control the release 
and/or even target the molecules to the site of action [3-5]. Its application to medicine and 
pharmacy has been extensively studied for taste masking, entrapment of irritant or 
unstable drugs and for sustained and site-specific release of drugs.  
The development of nanoparticles for drug delivery began in the 1960s by Birrenbach and 
Speiser [6]. The nanoparticles are most commonly referred as solid colloidal particles 
ranging in size from 1 to 1000 nm (1 μm). Moreover, nanoparticles have the potential to 
revolutionize a wide range of medical diagnostic and therapeutic interventions such as 
diagnostic imaging, implantable devices and, of particular interest in this review, drug 
delivery [7]. Due to their small sizes, the nanostructures exhibit unique physicochemical 
and biological properties (e.g., an enhanced reactive area as well as an ability to cross cell 
and tissue barriers) that make them a favorable material for biomedical applications. 
Their nanosize also promotes a uptake by cells more easily than larger particles [8]. They 
transport the therapeutic macromolecule to the site of action, thus its influence on healthy 
tissues and cells and undesirable side effects can be minimized. They also protect the 
drug from rapid degradation or clearance and enhance drug concentration in target 
tissues, therefore lower doses of drug are required [8]. 
In fact, nanoparticles can be used to deliver hydrophilic drugs, hydrophobic drugs, 
proteins, biological macromolecules and nucleic acids via a number of routes [9]. 
Additionally, several strategies have been proposed to regulate the association and, 
consequently, the drug release, playing with the materials used to produce the 
nanoparticles as well as with their structural design. For example, drugs can be entrapped 
Chapter 1 - General introduction - Particle engineering by nanoparticle microencapsulation for pulmonary delivery 
 
6  
 
in the nanocarrier matrix, encapsulated in a nanoparticle core, surrounded by a shell-like 
membrane, chemically conjugated to the nanoparticle matrix (e.g. covalent bonds, 
electrostatic interactions, among others) or bound to the particle’s surface by adsorption 
[8-10]. Besides the nanostructures, they can be formulated for targeted delivery to the 
lymphatic system, brain, arterial walls, lung, liver, spleen, or made for long-term systemic 
circulation [9]. After reaching the target site, the nanoparticles can release the associated 
therapeutic agent in a controlled manner which depends on their nature, pH, osmotic 
gradient and the surrounding environment [8].  
The nanoparticles used for medical applications must be biocompatible, biodegradable 
and non-toxic. Undesirable effects associated to nanoformulations strongly depend on 
their hydrodynamic size, shape, surface chemistry, administration route, interaction with 
the immune system and residence time in the bloodstream. Nanoparticulate systems as 
different as liposomes, solid lipid nanoparticles (SLN), polymeric nanoparticles, metallic 
nanoparticles or dendrimers have been used as drug carriers for routes of administration 
such as oral, transdermal, intravenous, subcutaneous and pulmonary [4].  
In addition to their controlled or triggered release properties, nanoparticles can also be 
designed to afford longer circulation times, reducing unwanted distribution and 
promoting targeting to the site of action. The ability to provide specific drug delivery to 
target sites is among the characteristics of an ideal drug delivery system. In this context, 
nanoparticles functionalization, resulting in a stealth surface avoiding the opsonisation 
phenomenon (adhesion of serum proteins at the nanoparticles surface), is necessary to 
increase circulation times by escaping the mononuclear phagocyte system. For example, 
nanoparticles may be conjugated, grafted or coated with hydrophilic polymers, e.g. 
poly(ethylene glycol) (PEG) (strategy called as PEGylation), affording steric 
stabilization, conferring stealth properties and being the most frequent and successful 
approach to delay the circulation time of nanoparticulate systems and protein drugs in the 
blood flow [11, 12]. Moreover, with the aim to improve targeting, the nanoparticles 
surface can also be functionalized using specific ligands (aptamers, peptides, 
antibodies/antibody fragments, small molecules, among others) (Figure 1.1) [5]. 
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Figure 1.1: Surface functionalization of nanoparticles with the aim to increase residence 
time in the blood, to reduce nonspecific distribution and to target tissues or specific cells. 
The chemistry at surface and bulk levels, as well as the physical features such as size, 
porosity, surface topography, shape and compartmentalization should be carefully 
considered during the design/optimization and targeting of particulate systems for 
biomedical applications [5]. 
 
The first nanoparticles licensed as a medicine was AmBisome® (Astellas Pharma), a 
liposomal amphotericin B formulation for the treatment of fungal infections, which led to 
the development of other successful liposomal nanoformulations, intended mainly for 
cancer treatment and infectious diseases, such as Doxil®/Caelyx® (doxorubicin (DOX), 
Janssen-Cilag) [13], Myocet® (DOX, Teva B.V.), Daunoxome® (daunorubicine, Galen 
Limited), Marqibo® (vincristine, Talon Therapeutics Inc.), Mepact® (mifamurtide, 
Takeda), Abelcet® (amphotericin B, Sigma-Tau Pharmaceuticals) and Depocyt® 
(cytarabine, Sigma-Tau Pharmaceuticals). More recently paclitaxel formulated as 
albumin-nanoparticles has been marketed for the treatment of metastatic breast cancer 
(Abraxane®, Celgene Corporation), while DOX-loaded polyalkylcyanoacrylate 
nanoparticles are in phase III clinical trials for the treatment of the multidrug resistant 
hepatocarcinoma (Transdrug®, Bioalliance) [14].  
Chapter 1 - General introduction - Particle engineering by nanoparticle microencapsulation for pulmonary delivery 
 
8  
 
However, currently available nanoparticulate formulations have not been able to enhance 
the activity for many active substances, with the exception of Abraxane® and Endorem® 
(dextran-stabilised superparamagnetic iron oxide nanoparticles, Guerbet). According to 
Couvreur [14], these failures may be caused by: (i) poor drug loading (DL) capacity 
impeding a pharmacologically suitable concentration at the target site, or the quantity of 
particles required is too high, leading to unwanted adverse reactions; (ii) too quick release 
i.e. burst release of the active substance after administration, generally corresponding to 
the immediate release of the drug that is located at the particle surface, leading to an early 
release before reaching the site of action; (iii) polymer cytotoxicity after internalization 
into cells, and (iv) the need of a large-scale production of polymeric nanoparticles which 
also reduces the current relevance of these carrier systems in the market. 
 
1.2. Types of nanoparticles 
The nanoparticles exist in a wide variety of natures, sizes, shapes and compositions, 
including metals and inorganic particles, such as gold, silver, and metal oxides, polymer-
based materials, such as poly (lactic-co-glycolic acid) (PLGA) and lipid-based particles, 
such as liposomes, SLN and nanoemulsions (Figure 1.2) [7, 15, 16]. Each substance 
exhibits its own inherent physicochemical properties, e.g. surface charge, 
hydrophilicity/hydrophobicity, solubility, size, shape and tendency to aggregation, which 
can be engineered to trigger different biological responses. Furthermore, in drug delivery 
it is crucial to evaluate the nanocarrier's biocompatibility to ensure safe drug release and 
minimize cytotoxicity [7]. The description of the several types of nanoparticles is out of 
the scope of the present thesis, which is focused only on lipid-based nanoparticles. 
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Figure 1.2: Different types of nanoparticles commonly used for biomedical 
applications [17]. 
 
1.2.1. Liposomes 
Liposomes have been the first system investigated as colloidal drug carriers about 40 
years ago [18]. They are spherical bilayers vesicles composed of phospholipids 
(phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine and 
phosphatidylserine) and steroids (e.g., cholesterol) or other surfactants, and they are 
formed spontaneously when certain lipids are dispersed in an aqueous media by 
sonication [8, 19]. Liposomes have been reported to improve the pharmacokinetic 
properties of drugs and the therapeutic index of chemotherapeutic agents, reduce 
unwanted side effects and increase in vitro and in vivo anticancer activity [8]. Indeed they 
were the first marketed nanoformulation (as such), being introduced in 1990 
(AmBisome®, Astellas Pharma). However, limitations of liposomes include low 
encapsulation efficiency (EE), rapid leakage of water-soluble drug in the presence of 
blood components and poor storage stability. Stability and structure integrity of liposomes 
after administration can be conferred by their surface functionalization by attaching 
polymers, such as poly (methacrylic acid-co-stearyl methacrylate). On the other hand, the 
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circulation time of liposomes in the blood can be enhanced by adding PEG chains or by 
surface conjugation of antibodies or ligands, such as lectins [8, 19]. 
There are many examples of liposomal drug formulations, such as anticancer drugs, 
neurotransmitters (serotonin), antibiotics, anti-inflammatory and anti-rheumatic drugs [8]. 
Despite their advantages, the unresolved problem of using drug delivery systems based on 
liposomes arises from their accumulation in cells (liver macrophages) outside the target 
tissues and the unpredictable effects dependent on the active agent they carry [8]. 
Applications of liposomes include transdermal drug delivery to enhance skin permeation 
of drugs with high molecular weight (MW) and poor water solubility [20] or 
chemotherapeutic drug delivery in cancer treatment [21], drug delivery to the lung by 
nebulisation [22], ocular drug delivery [23] and the treatment of parasitic infections. 
Other vesicular structures similar to liposomes have emerged mainly intended for 
transdermal delivery, including transferosomes, ethosomes, niosomes and marinosomes 
[24-26]. Briefly, transferosomes are developed by incorporation of surfactant molecules, 
such as sodium chlorate into liposomes, while ethosomes are liposomes presenting a high 
ethanol content (up to 45%). Niosomes are vesicles developed from non-ionic surfactants 
and marinosomes are liposomes produced from a natural marine lipid extract containing a 
high poly (unsaturated) fatty acid ratio [19]. 
 
1.2.2. Nanoparticles based on solid lipids 
The use of micro- and nanoparticles made of solid lipids was first reported by Speiser et 
al. [27], who described the production of lipid nanopellets intended for oral drug delivery. 
The technique then developed involved the cooling of an emulsion prepared with molten 
lipids. In 1993, Domb proposed a similar procedure to prepare the so-called lipospheres 
[28]. But it was in the mid 1990s, that lipid-based nanoparticles (SLN) emerged as an 
effective alternative particulate carrier system, prepared with solid physiological lipids 
used as common pharmaceutical excipients and stabilized by surfactants [29-31]. Initially, 
the two main formulation/preparation techniques described for producing SLN were the 
high-pressure homogenisation and the microemulsion-based techni ue, described by 
M ller and Luc s [32] and by Gasco [33], respectively. In contrast to most polymeric 
nanoparticulate systems, SLN formulation techniques do not necessarily need to use 
organic solvents minimizing the toxicological risk [34]. Their colloidal dimensions and 
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controlled release profiles allow both drug protection and improved administration by 
several routes. Moreover, the main manufacturing processes proposed for SLN are easy to 
scale up and the resulting formulations often withstand terminal sterilization [35-41]. 
Different solid mono-, di- and triacylglycerols have been exploited to produce SLN, such 
as tripalmitin, cetyl palmitate, glyceryl distearate, trimyristin, stearic acid and glyceryl 
stearate [42].  
SLN have received increased attention over the last years, because they present good 
physical stability and biocompatibility, provide drug protection, allow controlled (fast or 
sustained) and targeted drug release depending on the incorporation model [35-37, 39-41, 
43, 44]. Regarding the drug incorporation within the SLN, there are three models: (a) 
homogenous matrix, (b) drug-enriched shell and (c) drug-enriched core [39, 42, 45-48], as 
represented in Figure 1.3. The type of model depends basically on the formulation 
components (lipid, lipophilic or hydrophilic active compound and surfactant) and the 
production conditions [40, 45, 46]. In the first model, the drug is molecularly and 
homogeneously dispersed in the lipid matrix of the particles. Hence, drug release occurs 
via diffusion from the solid lipid matrix and/or by degradation of lipid matrix. As 
consequence of their structure, this type of SLN can show controlled release properties. In 
case of the second model (drug-enriched shell), the drug is concentrated on the outer shell 
of the nanoparticles [40, 42, 48]. An outer shell enriched with active compound can be 
obtained when phase separation occurs during the cooling process from the liquid oil 
droplet to the formation of a SLN, since the lipid precipitates first forming a practically 
compound-free lipid core [40, 48, 49]. This model is not suitable for prolonged drug 
release, nonetheless it may be used to obtain a burst release of the drug [40, 42]. In 
contrast to drug-enriched shell model, drug-enriched core model is formed when 
precipitation of the drug is faster than lipid during cooling of the nanoemulsion.  
Generally, prolonged drug release is observed from these SLN [40, 42, 48, 49]. 
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Figure 1.3: Models of incorporation of drugs (green) into SLN: (a) Type I - 
homogeneous matrix, (b) Type II - drug-enriched outer shell, and (c) Type III - drug-
enriched core with lipid shell (adapted from [40]). 
 
Several studies have been developed on the pulmonary delivery of SLN as local and 
systemic delivery nanocarriers for molecules [50]. Pandey and Khuller [51] investigated 
the chemotherapeutic potential of SLN associating rifampicin, pyrazinamide and 
isoniazid against Tuberculosis (TB), and verified the sustained-release of drugs from the 
SLN in vitro and in vivo. Liu et al. [50] developed a novel nebulizer-contained insulin-
SLN for pulmonary delivery. They observed that SLN could be successfully applied as a 
pulmonary carrier system for insulin, providing a systemic delivery of protein. Deposition 
and clearance of SLN were studied by Videira et al. [52, 53] after inhalation of 
aerosolized particles using gamma-scintigraphy imaging analysis. It was visualized that a 
few minutes post deposition, inhaled SLN translocated to regional lymph nodes indicating 
that pulmonary route can be an efficient via to deliver SLN to the lymphatic system. 
However, potential disadvantages such as insufficient loading capacity, drug expulsion 
after polymorphic transition during storage and relatively high water content of the 
dispersions (70-99.9%) have been reported for SLN. The DL capacity of conventional 
SLN is limited by the solubility of drug in the molten lipid, the structure of the lipid 
matrix and the polymorphic state of the lipid matrix [29, 47, 54-56]. If the lipid matrix 
consists of similar molecules, a perfect crystal with few imperfections is formed. Since 
incorporated drugs are located between fatty acid chains, between the lipid layers and also 
in crystal imperfections, a highly ordered crystal lattice cannot accommodate large 
amounts of drug [42, 55]. Expulsion of encapsulated drug molecules may be observed 
during storage, which leads to limited DL capacity of SLN. Therefore, amount of 
encapsulated drug and drug release profile of SLN may change throughout storage time 
[42, 57] as a consequence of the transition to a highly ordered lipid matrix. Immediately 
a b c
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after production, lipids crystallize partially in higher energy modifications (α, β′) with 
more imperfections in the crystal lattice [58-60]. The preservation of the α-modification 
during storage and transformation after administration (e.g. by temperature changes) 
could lead to a triggered and controlled release and has recently been investigated for 
topical formulations [61]. If, however, a polymorphic transition to β takes place during 
storage, the drug will be expelled from the lipid matrix and it can then neither be 
protected from degradation nor released in a controlled manner. 
In order to overcome some observed limitations of conventional SLN, modifications of 
the lipid structure have been introduced resulting in the so-called nanostructured lipid 
carriers (NLC) and lipid drug conjugate (LDC) [49, 62-64] (Figure 1.4). The aim was the 
development of a nanoparticulate lipid carrier with increased payload while preventing 
drug expulsion.  
 
 
Figure 1.4: SLN versus NLC. The main difference between SLN and NLC is the fact that 
the concept of the latter is performed by nanostructuring the lipid matrix, in order to 
increase the DL and to prevent leakage, conferring more flexibility for drug release 
modulation. This goal is achieved by mixing solid lipids with liquid lipids in NLC instead 
of highly purified lipids with relatively similar molecules in SLN. The result is a less-
ordered lipid matrix with many imperfections, which can accommodate a higher amount 
of drug. 
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The NLC are composed of blends of solid and liquid lipids, improving DL and drug 
retention during storage [40]. The resulting nanoparticulate matrix shows a melting point 
(m.p.) depression compared to the raw lipid while the particles still present a solid matrix 
at body temperature [65]. Actually, by conferring the lipid matrix a less ordered structure, 
the DL capacity is enhanced while the drug loss during storage is minimized by 
preventing the formation of perfect crystals [46].  
However, the main drawback of SLN is their reduced ability to carry hydrophilic drugs, 
which will preferentially partition to the outer aqueous phase during the production 
process. As a consequence, only highly potent low dose hydrophilic drugs may be 
encapsulated in SLN [29, 39, 65, 66]. For this reason LDC were developed aiming at 
increasing the loading capacity for hydrophilic drugs [39, 64, 65]. The preparation of 
LDC involves drug-lipid conjugation (e.g. by salt formation or covalent binding) and the 
so-formed insoluble drug-lipid conjugate will be processed with an aqueous surfactant 
solution to a nanoformulation using a method suitable for SLN preparation [39, 65].  
Overall, these three lipid-based nanosystems have been used for the incorporation of 
drugs with an enormous range of applications, such as diagnosis, prevention and 
treatment of diseases, as well as drug delivery by different administration routes (oral, 
rectal, topical, pulmonary, ocular, nasal, nose-to-brain and parenteral) [57, 67-69] (Table 
1.1). 
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Table 1.1: Examples of bioactive compounds incorporated into lipid nanoparticles (adapted from [70]). 
Encapsulated drug Lipid Advantages Nanosystem Ref 
3’-Azido-3’-deoxythymide palmitate Trilaurin 
Stable after autoclaving, lyophilisation and 
rehydration 
SLN [71] 
5-Fluorouracil Dynasan 114 and Dynasan 118 Prolonged release in simulated colonic medium SLN [72] 
Apomorphine 
Glyceryl monostearate, polyethylene 
glycol monostearate 
Enhanced the bioavailability in vivo SLN [73] 
Ascorbyl palmitate Imwitor 400 and Labrafil M1944  
Viscoelastic measurements is appropriate for topical 
application  
NLC [74] 
Baclofen Stearic acid Significantly higher drug concentrations in plasma SLN [75] 
Benzyl nicotinate Dynasan 116 Increased oxygenation in the skin SLN [76] 
Calcitonin Trimyristin 
Improvement of the efficacy of such carriers for 
oral delivery of proteins 
SLN [77] 
Camptothecin Monostearin and Soybean Oil 788 Stable and high performance delivery system NLC [78, 79] 
Clozapine Trimyristin, tripalmitin and tristearin Improvement of bioavailability SLN [80] 
Cyclosporin A 
Glyceryl monostearate and glyceryl 
palmitostearate 
Controlled release SLN [81, 82] 
Cytarabine Stearic acid Provided sustained drug release, stability and 
improved cytotoxicity 
LDC [83] 
Dexamethasone Compritol 888 ATO Drug delivery topical use SLN [84] 
Diazepam Compritol 888 ATO and Imwitor 900K Prolonged release SLN [85] 
Diminazenediaceturate Mixture of stearic- and palmitic acid Improvement of loading capacity for hydrophilic 
drugs for brain delivery 
LDC [64, 86] 
Doxorubicin Glyceryl caprate Enhanced apoptotic death SLN [87] 
  
Chapter 1 - General introduction - Particle engineering by nanoparticle microencapsulation for pulmonary delivery 
 
16  
 
Table 1.1: Continuation.     
Encapsulated drug Lipid Advantages Nanosystem Ref 
Gonadotropin release hormone Monostearin Prolonged release SLN [88] 
Hydrocortisone 
Monoglyceryde, chain length of the fatty 
acid moiety 
SLN stable with release properties SLN [45] 
Ibuprofen Stearic acid, trilaurin, tripalmitin Stable formulation and negligible cell cytotoxicity SLN [89] 
Idarubicin Emulsifying wax Potential to deliver anticancer drugs SLN [90] 
Insulin 
Stearic acid, octadecyl alcohol, cetyl 
palmitate, glyceryl monostearate, glyceryl 
palmitostearate, glyceryl tripalmitate, 
glyceryl behenate 
Promising for oral delivery of proteins SLN [91] 
Ketoprofen Mixture of beeswax and carnauba wax 
SLN with beeswax content exhibited faster drug 
release as compared carnauba wax 
SLN [92] 
Lopinavir Compritol 888 ATO Bioavailability enhanced SLN [93] 
Methotrexate Stearic acid 
Enhanced bioavailability and reduced drug 
associated gastrointestinal toxicity even in higher 
doses recommended for anticancer therapy 
LDC [94] 
Nimesulide 
Glyceryl behenate, palmitostearate, 
glyceryl tristearate 
Sustained drug release SLN [95] 
Oryzalin Tripalmitin 
Stable SLN after autoclaving and improvement of 
tolerability and therapeutic index of dinitroanilines 
SLN [35] 
Penciclovir Glyceryl monostearate Provide a good skin targeting SLN [96] 
Progesterone Monostearin, stearic acid and oleic acid Potential DDS for oral administration NLC [97, 98] 
Repaglinide Glyceryl monostearate and tristearin Toxicity indicated that the SLN were well tolerated SLN [99, 100] 
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Table 1.1: Continuation.     
Encapsulated drug Lipid Advantages Nanosystem Ref 
Salbutamol sulphate Monostearin and PEG2000 
Formulation accelerate release of hydrophilic small 
molecule drugs 
SLN [101] 
Tetracycline Glyceryl monostearate and stearic acid Sustained release SLN [102] 
SLN: solid lipid nanoparticles; NLC: nanostructured lipid carriers; LDC: lipid drug conjugate; DDS: drug delivery systems; PEG: polyethylene glycol.
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As shown in Table 1.2, only a few solid lipid-based nanoformulations are approved for 
human use, while there are some lipid-based drug product candidates currently in clinical 
trials, as described in Table 1.3 [103, 104]. 
 
Table 1.2: Lipids used in marketed lipid nanoparticles formulations (adapted from [67]). 
Lipid name Examples of marketed products Company 
Glyceryl palmitostearate Xifaxan  Salix Pharmaceuticals Inc. 
Cetyl palmitate Azelex Allergan 
Stearic acid Viokace Aptalis Pharma Inc. 
Tripalmitin Survanta Abbot 
Caprylic/capric triglycerides Avodart Glaxo SmithKline 
Lauroyl polyoxylglycerides Lipofen Cipher Pharmaceuticals Inc. 
 Glyceryl monostearate / 
glyceryl monopalmitate 
Terramycin Pfizer 
Soy lecithin Baycip Bayer 
Squalene Cutanova Dr.Rimpler Gmb 
 
Table 1.3: Examples of targeted lipid nanoparticles formulations currently in clinical 
trials (adapted from [103, 104]). 
Drug Target Disease Phase Company 
ALN-VSP02 KSP and VEGF Solid tumours I Alnylam Pharmaceuticals 
SiRNA-EphA2-
DOPC 
EphA2 Advanced tumours I 
MD Anderson Cancer 
Center 
Atu027 PKN3 Solid tumours I Silence Therapeutics 
TKM-100201 
VP24, VP35, Zaire 
Ebola-polymerase 
Ebola-virus infection I Tekmira Pharmaceutical 
PRO-040201 ApoB Hypercholesterolaemia I Tekmira Pharmaceutical 
TKM-080301 PLK1 Tumours I Tekmira Pharmaceutical 
ALN-PCS02 PCSK9 Hypercholesterolaemia I Alnylam Pharmaceuticals 
ALN-TTR02 TTR 
Transthyretin-mediated 
amyloidosis 
II Alnylam Pharmaceuticals 
KSP: kinesin spindle protein; VEGF: vascular endotelial growth factor; EphA2: erythropoietin-producing 
hepatocellular receptor tyrosine kinase class A2; PKN3: protein kinase N3; VP24: viral protein 24; VP35: 
viral protein 35; ApoB: apolipoprotein B; PLK1: polo-like kinase 1; PCSK9: proprotein convertase 
subtilisin/kesin type 9; TTR: transthyretin. 
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1.3. Inhaled drug delivery through nanoparticles  
Mucosal routes for systemic drug administration present a great advantage in comparison 
to the parenteral routes, since they are non-invasive. Thus, development of suitable non-
injectable delivery systems for mucosal drug administration could significantly enhance 
patient compliance, thereby leading to increased therapeutic benefits [105]. Among the 
mucosal routes, pulmonary administration has attracted remarkable scientific and 
biomedical interest in recent years for the treatment of systemic diseases, such as diabetes 
mellitus [106]. Aside from this, drugs are generally delivered to the respiratory tract for 
the treatment or prophylaxis of airways diseases, such as bronchial asthma and cystic 
fibrosis. The administration of a drug at its site of action can result in a rapid onset of 
activity, which may be highly desirable, for instance when delivering broncho-dilating 
drugs for the treatment of asthma. Additionally, smaller doses can be administered locally 
compared to those delivered by the oral or parenteral routes, thereby reducing the 
potential incidence of adverse systemic effects and reducing drug costs. The pulmonary 
route is also useful when a drug is poorly absorbed or when it is rapidly metabolized 
orally [107, 108]. Systemic delivery can be achieved through pulmonary administration, 
offering the advantage of bypassing the first pass effect in the liver, as well as offering a 
large alveolar area available for absorption with an extensive vascularization, a low 
thickness epithelium and low extracellular and intracellular enzyme activities. The high 
permeability of the epithelial barrier, the low proteolytic activity and the thinner mucus 
layer compared to the gastrointestinal mucosa, also make the airways suitable for both 
local and systemic applications [109-112]. 
Besides, many drugs, including hydrophilic high MW compounds, have demonstrated to 
be absorbed by the pulmonary route. However, their bioavailabilities are still low. The 
drugs administered by the pulmonary route must overcome important obstacles [113, 114] 
since the structure of the airways also prevents the entry airborne foreign particles, 
promoting their efficient removal [107]. These obstacles include the complex structure of 
the respiratory tree itself and the lung defense mechanisms (e.g., mucociliary clearance, 
lung surfactant) that oppose to drug absorption.  
In order to overpass the bioavailability limitation, nanoparticulate carriers arise as 
promising pulmonary drug delivery system [112-114]. An ideal pulmonary carrier system 
designed with a specific size, density and surface properties for lung drug delivery can 
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play a key role in increasing the drug therapeutic index by the following mechanisms: (i) 
improving lung deposition and the amount of drug that reaches the site of action (either 
extracellular or intracellular) and, as a consequence, decreasing adverse effects due to 
non-specific drug delivery to non-target tissues; (ii) protecting the therapeutic 
macromolecule and improving its in vivo stability and (iii) reducing clearance and 
prolonging the drug residence time at its site of action. In a study performed by 
Kawashima et al. [115], insulin-loaded PLGA nanoparticles were prepared to be 
administered in guinea pig lung. They demonstrated a significant reduction in blood 
glucose level, with a prolonged effect over 48 h as compared to insulin solution. 
Additionally, insulin-loaded nanoparticles using a different polymer, poly(butyl 
cyanoacrylate), delivered to the lung of rats were shown by Zhang et al. [116] to extend 
the duration of a hypoglycaemic effect over 20 h (glucose level below 80% of the original 
levels) as compared to pulmonary administration of insulin solution. 
Although nanoparticles are most often delivered to the airways by nebulization, these 
nanocarriers present technical issues, being unfeasible for pulmonary administration. For 
example, nanoparticles stored in an aqueous medium will, over time, suffer polymer 
hydrolysis or lipid transitions with significant loss of drug. Moreover, solution instability 
is another concern owing to particle agglomeration and settling, as well as a consequence 
of the small size and strong particle-particle interactions, leading to poor functionality of 
the nebulizer and, consequently, poor delivery efficiency due to exhalation of low-inertia 
nanoparticles [4, 7, 16, 17]. To prepare nanoparticles for ultimate commercial use, 
lyophilisation has been explored as a means to provide a storage form that can be 
rehydrated to deliver nanoparticles in suspension. There are, however, a number of 
drawbacks to lyophilisation, including the lengthy process time required for drying, low 
energy efficiency, high cost of purchasing and maintaining the equipment, and sensitivity 
of the product to freezing and various other processing-related stresses. Moreover, 
resuspension may be difficult and the retention, post-hydration, of the same nanoparticles 
size requires the use of stabilizers during the freeze-drying process [117]. These 
limitations have led to the search for next-generation drying methods that can be applied 
to therapeutics as will discussed in the following sections. 
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1.4. Deposition of inhaled particles in the respiratory tract 
The deposition of inhaled particles in the airways is dependent, mainly, on the 
formulation, the delivery device and the patient’s physiological characteristics (e.g., 
breathing patterns and clinical status) [107, 112]. There are three principal mechanisms 
that lead to particles pulmonary deposition: inertial impaction, gravitational sedimentation 
and Brownian diffusion, which are associated with the particle aerodynamic diameter 
(daer) [118] (Figure 1.5). The daer is the most appropriate measure of aerosol particle size, 
because it relates to particle dynamic behaviour and describes the main mechanisms of 
aerosol deposition [119]. Indeed, the daer is measured taking into account the geometric 
diameter and the density of the inhaled particles, which is defined as the diameter of a 
sphere of unit density characterized by the same settling velocity in air as the particle 
aerosol being measured [112, 120], as depicted by the following equation:  
              
  
   
                                                                                             (Eq. 1.1) 
where dgeo is the particle geometric diameter, ρs is 1 g/cm
3
, ρe is the effective particle 
density in the same unit as ρs and λ is the dynamic shape factor of the particle. This shape 
factor is theoretically defined as 1 for spherical particles. 
The inertial impaction occurs during the passage through the oropharynx and large 
conducting airways (i.e. upper tracheobronchial regions) and is the dominant deposition 
mechanism for particles larger than 5 µm. When the daer of particles ranges from 1 to 5 
µm, they are subject to sedimentation by gravitational force that occurs in smaller airways 
and respiratory bronchioles. Sedimentation is influenced by breath-holding. Particles with 
an daer of less than or equal to approximately 1 µm are deposited significantly by 
diffusion, based on the Brownian motion, and then exhaled. This diffusion is of little 
significance for particles >1 µm [10, 107, 118, 119, 121, 122].  
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Figure 1.5: Mechanisms involved in particle deposition in the different regions of 
airways. Electrostatic deposition is seen for charged particles and interception for 
elongated-shaped particles (adapted from [111, 123]). 
 
Thereby, a successful deposition into deep lung requires the particles be small enough to 
avoid deposition by inertial impaction on upper airways and can pass through the lower 
airways, while being large enough to avoid exhalation. So, the optimal particle size for 
achieving delivery deep into alveolar region has been established to be an daer between 1 
and 5 µm, as summarized in Figure 1.6 [110, 118, 124]. For these reasons, one of the 
metrics used to quantify the performance of an inhalable powder is the determination of 
the fine particle fraction (FPF), which is usually defined as the percentage of particles that 
are smaller than 5 µm of daer that can potentially achieve alveolar deposition [125]. 
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Figure 1.6: Effect of particle size on the deposition of aerosol particles in the human 
respiratory tract. Larger particles deposit in the airways or mouth and throat, whereas 
smaller particles deposit in the alveolar region. Particles <1 µm can be exhaled, thereby 
reducing deep lung deposition. This representation considers for a slow inhalation and a 
5-second breath hold (adapted from [124]). 
 
Regarding the practical aspects, values for daer of particles can be determined in vitro with 
cascade impactors based on particle impaction principles. Several methods are used to 
evaluate the aerodynamic performance of inhalable powder involving the following 
equipments: (i) twin-stage liquid impinger (TSLI); (ii) multistage liquid impinger 
(MSLI); (iii) Andersen cascade impactor (ACI) and (iv) next-generation impactor (NGI) 
(Figure 1.7) [126-128].  
These impactors were calibrated to separate the particles according to the daer in different 
stages, predicting the deposition patterns of particulate drug carriers in the respiratory 
tract. They operate on the principle of internal impaction, i.e. particle separation is 
provided on the basis of difference in inertia (a function of particle size and velocity). The 
TSLI is relatively easy to use as it operates on the principle of liquid impingement to 
divide the dose emitted from the inhaler into non-respirable and respirable fractions, 
having only two stages. The MSLI is a five-stage system while the ACI consists of 8 
stages. Both are constructed in a pattern such that larger particles will impact upon 
particular stage collection plate as the aerosol stream passes through, whereas relatively 
smaller particles will be carried in the air stream and pass to the next impaction stage. 
Further, the NGI was developed in 2000 and it comprises seven stages with a micro-
orifice collector [126, 127].  
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Apart from this, cascade impactors should not be considered as in vitro simulators of 
lung, chiefly due to the divergence in the flow rate when compared with that of a human 
lung. Since a cascade impactor functions with a constant flow rate but human lung have a 
varying flow rate due to the breathing cycle [126]. 
 
 
Figure 1.7: Schematic of cascade impactor systems evaluated for dry powder inhaler 
(DPI) testing. Several aerodynamic particle size measuring devices are available but the 
most commonly used in pharmaceutical aerosols are the liquid impingers, including the 
(A) twin-stage liquid impinger (TSLI) and the (B) multi-stage liquid impinger (MSLI), 
and the inertial impactors, including the (C) Andersen cascade impactor (ACI) and, more 
recently, the (D) next generation impactor (NGI). 
 
1.5. Fate of inhaled particles in the lung 
The fate of inhaled particles depends on various factors, such as regional distribution in 
the lung and particle size, because deposition within the lung is a complex function of 
absorption and non-absorptive clearance mechanisms [118, 123]. In order to succeed the 
pulmonary delivery of any therapeutic molecule, many obstacles and lung defense 
mechanisms that could hinder the path of foreign substances must be overcome, such as 
the effect of the airways’ structure (e.g., mucus barrier), mucociliary clearance and 
phagocytosis by alveolar clearance (Figure 1.8) [122, 129-131]. Once inhaled particles 
are deposited onto the lining of the respiratory tract, they first contact the mucous layer 
within the airways or the surfactant-lining fluid layer within the alveolar region. Then, the 
inhaled carriers that are soluble in these fluids and mucus undergo chemical dissolution in 
situ or binding to proteins and may be eventually cleared into blood and lymphatic 
circulation. Insoluble particles may undergo physical translocation and they are subjected 
A DB C
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at several post-defense mechanisms, including the mucocilliary escalator transport, 
phagocytosis by macrophages and endocytosis [118, 132]. 
 
 
Figure 1.8: Clearance mechanisms of inhaled particle in the bronchi, bronchioles and the 
alveolar region. (a) clearance via mucociliary escalator, (b) uptake by macrophages and 
(c) trans-epithelial clearance (adapted from [131]). 
 
In detail, particles that penetrate the lower respiratory tract but are not solubilized 
immediately may adhere to the epithelial lining and be cleared more slowly. However, the 
shortened drug action associated with the relatively rapid clearance represents a 
significant challenge to drug delivery to the lung. Particles of large volume diameter, such 
as porous particles, usually show a better bioavailability than solid particles of the same 
volume diameter either because of their improved dissolution rate (due to the larger 
specific surface area) which is advantageous for immediate release, or because of their 
size-related delaying effect on the phagocytic clearance, which can afford sustained 
action up to several days [133]. Indeed the mucociliary escalator dominates nanoparticles 
clearance from the upper airways, since nanoparticles that consist of slowly dissolving or 
insoluble materials in the airway mucus will be partly moved by action of the ciliated 
epithelial cells pushing the mucus along with the nanoparticles that deposited on the 
airway walls to the larynx, where they are swallowed to the gastro-intestinal tract or 
excreted through the mouth [107, 118]. A specific case can be made for ultrafine 
nanoparticles (<150 nm), which exhibit different interactions with both the trachea-
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bronchial and alveolar epithelia [133]. While the mucociliary escalator is the most 
efficient mechanism of clearance in the upper airways, particles are predominantly 
cleared by macrophage phagocytosis and lymphatic uptake and, afterwards, by epithelial 
endocytosis in the alveoli, which promotes a systemic effect [52, 107, 118]. Another 
possible fate for inhaled particles is not a generally recognized mechanism because it 
appears to be distinct for particles and involves their uptake by sensory nerve endings 
embedded in airway epithelia, followed by axonal translocation to ganglionic and central 
nervous system structures [132]. 
 
1.6. Techniques for nanoparticles microencapsulation by particle engineering 
Since nanoparticles are within a nanosize range which is not suitable for deep lung 
delivery, the major challenge for pulmonary delivery of nanoparticles is to find a proper 
carrier system and a suitable microencapsulation technique. Several researchers have 
prepared microcarrier systems to improve the delivery of nanoparticles to the alveolar 
area. In this context, the main goal of particle engineering is to design particles with 
desirable characteristics such as narrow size distribution, improved dispersibility, good 
drug stability, optimized bioavailability, sustained release and/or specific targeting, taking 
into account inhaler design and drug delivery requirements [133]. Different strategies to 
engineer micrometric nanoparticles-based dry powders have recently been explored: (a) 
nanoparticles on coarse inert carrier; (b) nanoparticle self-assembling (Trojan particles or 
porous nanoparticle-aggregate particles) and (c) nano-embedded microparticles (Figure 
1.9) [112].  
 
 
Figure 1.9: Nanoparticle-based inhaled dry powders can be obtained by: (a) adsorption 
on coarse inert carriers, (b) Trojan particles (nanoparticles-aggregate particles) or (c) 
embedding nanoparticles into an inert microparticle (adapted from [112]). 
a b c
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Among these, self-assembly of nanoparticles or their embedding within an inert 
microcarrier have been extensively investigated and, probably, represent the most 
promising technological approach. Thereby, the following sections will focus on 
microencapsulated nanoparticles using suitable techniques with the aim of improving 
nanoparticles handling and stability, obtaining dry powders with proper aerodynamic 
properties for pulmonary administration [110, 134]. Spray-drying and spray-freeze-drying 
(SFD) are the most common techniques to provide suitable aerodynamic characteristics to 
nanoparticles with their microencapsulation in inert excipients. 
 
1.6.1. Spray-drying 
The spray-drying technology was first described 150 years ago by Percy in a patent 
entitled “Improvement in drying and concentrating li uid substances by atomizing” [135]. 
Its growth took place during the 20
th
 century for the milk powder production, which still 
represents one of its major application [136]. Since the early 1940s [114, 137], it has been 
widely used as a procedure to transform an emulsion, suspension, dispersion or liquid into 
a micron-scale dry powder product [55, 108, 138-140]. Currently, some inhaled 
therapeutics had been successfully manufactured by spray-drying, being the most well-
known marketed inhalation products: Pulmosol (Nektar/Pfizer), PulmoSphere 
(Novartis) and TechnoSphere® (Mannkind) [141]. 
The spray-drying technique allows converting a suspension of nanoparticles into dry 
powder of non-aggregated nanoparticles dispersed in a matrix microsphere composed by 
excipients, such as sugars, surfactants and/or carbohydrates [110, 120]. It can also be 
employed as an alternative procedure to lyophilisation, since it is a faster and cheaper 
method than lyophilisation and provides better dry powders characteristics for inhalation 
[138]. It is particularly advantageous because it can be easily scaled to an industrial level 
[108]. Essentially, the typical spray-drying process comprises four fundamental steps: (i) 
atomization of feed into a spray, (ii) spray-air contact, (iii) drying of spray and (iv) 
separation of dried product from the drying air. First, this technique involves the 
preparation of a formulation by mixing the nanocarriers with an excipient solution before 
spray-drying. This solubilized liquid formulation is spray-dried into a spray of fine 
droplets and then brought into contact with the hot drying gas, typically air, in a drying 
chamber, promoting the evaporation of the volatile phase and forming dry particles under 
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controlled temperature and air-flow conditions. Dried particles then pass to a cyclone, 
where particles separation occurs, according their properties (such as size) under 
centrifugal and/or gravitational force and the product is collected in a reservoir. The 
schematic spray-drying process is depicted in Figure 1.10. An important feature of this 
process is that it is suitable for labile molecules because spray-drying conditions expose 
biological molecules only for a few milliseconds to seconds in the spray-dryer chamber, 
maintaining the integrity of the molecule. The type of spray-dryer, the inlet temperature 
(Tinlet), the most suitable air-flow pattern, the drying chamber design and the feed-flow 
rate are selected according to the drying characteristics of the product and powder 
requisites [108, 142-144].  
 
  
Figure 1.10: Büchi® Mini spray-dryer B-290 apparatus used in this research work (left) 
and spray-dryer apparatus scheme (right). 
 
Droplet drying starts instantaneously after atomization and particle formation happens by 
influence of two simultaneous phenomena: evaporation rate of the solvent while the 
solutes diffuse towards the droplet centre. Therefore, the particles morphology will be 
defined by two main driving forces: the solvent evaporation rate and the solute diffusion 
rate (Figure 1.11) [145-147]. In detail, the solvent evaporation rate is dependent on the 
Tinlet and outlet temperature (Toutlet) of the spray-drying process and the relative saturation 
profiles at the inlet of the drying chamber as well as at the outlet of the drying chamber. 
On the other hand, the solute diffusion rate is dependent on the solute properties and solid 
contents in the suspension. Usually, during a fast drying, where the evaporation rate is 
higher than the diffusion rate, the droplet life time is shorter, and the solute molecules do 
not have time to diffuse towards the droplet centre. This phenomenon leads to the 
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formation of a spherical and hollow particle or even open-hole or fragmented particles. 
Contrary, during a slow drying, the solute molecules are able to migrate to the droplet 
centre, giving rise to the formation of full solid particles, spherical particles or wrinkly 
particles [145, 146]. Apart of this, the raw material properties conjugated with the drying 
kinetics involved during the particle formation will mainly dictate the aerodynamic 
properties of the inhalable powders, such as particle size, density, morphology, surface 
roughness, flowability and residual water content. 
 
Figure 1.11: Scheme of particle formation from spray-drying process (adapted from [145, 
146]). 
 
Therefore, the product yield of spray-drying is another important feature that can be 
affected by the process parameters. The mass yield is determined by the amount of solids 
pumped into the spray-drying unit and the mass of particles collected. For laboratory-
scale, the yield is often low, between 20-50%, depending on the feed solution 
composition and spray-drying operating parameters. However, industrial-scale spray-
dryers can produce yields of up to 100%, due to higher wall deposits, since air residence 
times and radial distances from the atomiser to the drying chamber wall are shorter [108, 
148]. Other limitation of this microencapsulation process is inherent to the fact that it can 
be caused particle aggregation due to high temperatures, shear forces and partial melting 
of the particles when it is spray-drying sensitive nanoparticles, SLN for instance [55, 138, 
139]. Thus, a reduction of temperature effects can be achieved by spraying alcoholic 
instead of aqueous nanoparticles dispersions, due to lower necessary Tinlet [55, 139]. But 
then, the inconvenient will be the use of organic solvents and the remaining organic 
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solvents in the particles. This possible aggregation may also be avoided by including 
dispersibility enhancers such as leucine in the formulations for spray-drying [108].  
The spray-drying of lipid-based nanoparticles was first investigated and reported by 
Freitas and Müller [149]. In those studies, trehalose, mannitol, lactose, sorbitol, glucose 
and mannose were used as spray-drying excipients. In addition, spray-drying was also 
performed with ethanol and methanol in order to reduce the required Tinlet. It was found 
that mannitol, lactose and trehalose resulted in fine grained powders, while sorbitol, 
glucose and mannose were unsuitable as spray-drying excipients due to high moisture 
content and low yield of the resulting powders. Trehalose was identified as the optimum 
spray-drying excipient, since SLN were easily re-dispersed upon exposure to an aqueous 
environment without any change in size. In another initial attempt, Kawashima et al. 
[150] used ultrafine hydroxypropylmethyl cellulose phthalate nanospheres to improve the 
aerosolization properties of a dry powder for inhalation of a hydrophobic drug. Authors 
prepared drug-loaded nanospheres and then spray-dried the resulting suspension to obtain 
a dry powder using lactose as excipient. They demonstrated that the dry powder had 
desirable inhalation properties through in vitro inhalation test using a TSLI apparatus. 
Tsapis et al. [151] produced large spray-dried porous carriers of nanoparticles, presenting 
extremely thin walled structures. For that, two different lipidic surfactants, 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dimyristoyl-sn-glycero-3-
phophoethanolamine and lactose were added to the nanoparticles. Although the spray-
dried powder presented suitable characteristics for pulmonary delivery, it could only be 
re-dissolved in a mixture of ethanol/water. Poly(butylcyanoacrylate) (PBCA) and gelatin 
nanoparticles containing FITC-dextran were spray-dried by Sham et al. [152], resulting in 
a mixture of particles with hollow cores and continuous matrix. The distribution of the 
different nanoparticles in the resulting micron-sized particles varied, with gelatin 
nanoparticles mostly uniformly dispersed, while PBCA nanoparticles clustered in the 
lactose carrier matrix. The size of the gelatin nanoparticles of the dry powder increased 
after re-dispersion, in contrast with the size of PBCA nanoparticles that remained 
approximately the same. Nanoparticles of a hydrophilic model drug, terbutaline sulphate, 
were successfully entrapped within hydrophobic DPPC microspheres that exhibited a 
favourable FPF of 46.5±1.8% and mass median aerodynamic diameter (MMAD) of 
3.93±0.12 μm [153]. Taking into account the advantages of spray-drying as a valuable 
technique for producing dry powders adequate for pulmonary delivery, Grenha et al. 
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[154] developed chitosan (CS)/tripolyphosphate (TPP) nanoparticles that promoted 
peptide absorption across mucosal surfaces. Then, they subjected these nanoparticles to a 
spray-drying microencapsulation process using typical aerosol excipients, such as 
mannitol and lactose, producing microspheres as carriers of insulin-loaded nanoparticles 
to the lung. The results showed that the obtained microspheres were mostly spherical and 
possessed appropriate aerodynamic properties for pulmonary delivery. These 
nanoparticles showed a good protein loading capacity (65-80%), providing the release of 
75-80% insulin within 15 min, and can be easily recovered from microspheres after 
contact with an aqueous medium with no significant changes in size and zeta potential 
values. The plasmatic glucose levels following intratracheal administration revealed that 
the microencapsulated insulin-loaded CS nanoparticles induced a more pronounced and 
prolonged hypoglycemic effect compared to the controls (insulin solution, suspension of 
insulin loaded CS/TPP nanoparticles or mannitol microspheres including insulin) [110]. 
In later studies, the same authors formulated a new drug delivery system consisting of 
complexes formed between CS/TPP nanoparticles and phospholipids, named as lipid/CS 
nanoparticles (L/CS-nanoparticles) complexes. These protein-loaded L/CS-nanoparticles 
were microencapsulated by spray-drying using mannitol as excipient, corroborating the 
previous results concerning aerodynamic behaviour and the recovery of nanoparticles 
from the mannitol microspheres upon incubation in aqueous medium. Furthermore, the 
microencapsulation process did not have any effect on the insulin release profile [155]. 
Based on the same research line, Al-Qadi et al. [156] reported the preparation of a 
nanoparticle-based dry powder consisting of hybrid CS/hyaluronic acid nanoparticles by 
ionotropic gelation. Using mannitol as carrier, these nanoparticles were successfully 
microencapsulated presenting suitable aerodynamic and disintegration properties, 
corroborating the previous studies. Based on previous studies [154], recently, Rodrigues 
et al. [157], produced CS/carrageenan/TPP nanoparticles containing bovine serum 
albumin as a model protein, which were successfully microencapsulated by spray-drying 
in an aqueous suspension of L-leucine. The aerosol properties showed suitable FPF and 
MMAD suggesting a good deposition in the respiratory bronchiolar region of the lung 
[158]. 
Chougule et al. [159, 160] also investigated the feasibility of spray-dried liposomes 
encapsulating amiloride hydrochloride and dapsone. Two different excipients were 
identified as suitable liposomal carriers, mannitol and hydrolyzed gelatin. In vivo studies 
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involving intratracheal instillation demonstrated a prolonged drug activity and a slow 
pulmonary clearance of these liposomal dry powders. The encapsulation of superoxide 
dismutase in liposomes and the subsequent spray-drying with sucrose, lactose and 
trehalose were studied by Lo et al. [161]. Sucrose was capable of preserving the activity 
of the encapsulated drug and resulted in the highest aerosolization efficiency despite the 
high moisture content in the resulting particles. In addition to therapeutic drugs, plasmid 
DNA (pDNA) has also been encapsulated in liposomes, followed by spray-drying with 
lactose and trehalose [162]. In this study, the activity of the pDNA was not affected by 
the spray-drying process, while the post-mixing of spray-dried particles with CS was 
reported as resulting in increased surface roughness of the particles, thus improving the 
emitted dose compared to particles not modified with CS.  
Regarding the re-dispersion ability of nanoparticles from microspheres, Tewa-Tagne et 
al. [163] investigated the effect of different excipients on the re-dispersibility of the 
spray-dried poly(caprolactone) (PCL) nanocapsules. They observed that lactose and 
mannitol were the most suitable excipients to produce microparticles that are readily 
wetted yielding immediate aqueous re-dispersion. Tomoda et al. [164] investigated the 
effect of the Tinlet on the re-dispersibility of rifampicin-loaded PLGA nanoparticles and 
established that at high Tinlet, PLGA nanoparticles undergo aggregation leading to poorly 
re-dispersed nano-aggregates, in contrast to spray-drying at a lower Tinlet. Unfortunately, 
spray-drying at a lower temperature resulted in insufficiently dried nano-aggregates with 
high moisture content and daer unsuitable for inhalation. In order to overcome these 
limitations, L-leucine was added as spray-drying excipient, producing large hollow 
nanoparticulate aggregates. They observed that particles are more capable of re-
dispersing into individual nanoparticles in an aqueous environment than the first ones 
[164]. In another study, rifampicin-PLGA nanoparticles microencapsulated in mannitol 
showed a good in vitro aerosol performance and an in vivo imaging suggested that the 
rifampicin-PLGA nanoparticles were recognized by alveolar macrophages, increasing 
drug uptake [165].  
In order to evaluate the feasibility of microparticles containing SLN for pulmonary drug 
delivery, a hybrid system was designed containing thymopentin-loaded glyceryl 
monostearate SLN microencapsulated in mannitol and leucine [166]. The obtained 
microparticles showed a high aerosolization efficiency and SLN could be easily 
recovered from the microparticles without significant changes on their innate 
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characteristics and their drug release behaviour. Pharmacokinetic and pharmacodynamic 
studies showed the bioavailability and therapeutic efficacy of thymopentin were 
remarkably strengthened after pulmonary administration, compared to the i.v. 
thymopentin solution [166]. Pourshahab et al. [167] prepared isoniazid-loaded CS/TPP 
nanoparticles atomized with some excipients, such as lactose, mannitol and maltodextrin 
alone or in combination with leucine. Spray-dried particles with lactose in the presence of 
leucine resulted in the production of inhalable powders with the highest FPF ( 45%). A 
dry powder formulation based on cationic lipid-modified PLGA nanoparticles, intended 
for delivery of siRNA, had been reported [168]. Herein, the spray-drying process, using 
mannitol as an excipient, did not affect the physicochemical properties of the readily re-
dispersible nanoparticles. Most importantly, the siRNA activity was preserved throughout 
the spray-drying process. As X-ray powder diffraction analysis demonstrated that 
mannitol remained in a crystalline state upon spray-drying with PLGA nanoparticles, it 
was hypothesized that it might exert its stabilizing effect by sterical inhibition of the 
interactions between adjacent nanoparticles [168]. Ungaro et al. [169] developed PLGA 
nanoparticles embedded in an inert microcarrier made of lactose. Results showed that the 
spray-drying of the nanoparticles microencapsulated in lactose yielded particles with 
promising flow and aerosolization properties, while preserving the nanoparticles 
properties. Nonetheless, in vivo biodistribution studies showed that poly(vinyl alcohol) 
(PVA)-modified alginate/PLGA nanoparticles reached the deep lung, while CS-modified 
nanoparticles were found in great amounts in the upper airways [169].  
The aforementioned investigations performed in this area indicated the pulmonary 
delivery of nanoparticles formulated as dry powders, using a spray-drying technique, is a 
promising and feasible strategy for the treatment of lung diseases with potential systemic 
therapeutic effects, reducing possible side effects. However, the use of polymeric 
colloidal drug carriers in pulmonary formulations is often limited by the unknown toxicity 
of the carrier in the lung, and even biodegradable polymers have not yet undergone any 
thorough toxicity testing for ensuring safe delivery via the lung. It has been suggested that 
lipids have a faster biodegradation rate and higher tolerability in the lung compared to 
most polymer-based particles [133]. So, lipid-based nanoparticles emerged as a good 
strategy as alternative to others colloidal systems for pulmonary purposes. Table 1.4 
summarizes the published studies on pulmonary delivery of nanoparticles using dry 
powder carriers produced by spray-drying. 
Chapter 1 - General introduction - Particle engineering by nanoparticle microencapsulation for pulmonary delivery 
 
34  
 
Table 1.4: Summary of pulmonary delivery of microencapsulated nanoparticles using dry powder carriers developed by a spray-drying 
process. 
NPs type NPs size (nm) Carrier microparticle Microparticle size (µm) Drug Ref 
Hydroxypropylmethyl cellulose 
phthalate 
ca. 52 Lactose 0.6-9.3 Pranlukast [150] 
Carboxylate-modified PS and 
Nyacol 9950 colloidal silica 
PS NPs: 25, 170, 1000 
Nyacol NPs: 100 
Large porous particles, NPs attached to 
each other 
4.00.2 – [151] 
Gelatin and iso-butyl cyanoacrylate 173-242 Lactose 2.52.6 – [152] 
Terbutaline sulfate with sorbitan 
monostearate 
ca. 238 
DPPC, glyceryl behenate, tripalmitin and 
hydrogenated palm oil 
3.90.1 Terbutaline sulfate [153] 
PBCA 126±20 Lactose monohydrate 2.2±0.4 Ciprofloxacin [170] 
CS 388-419 Lactose 2.03.0 Insulin [154] 
CS/hyaluronic acid 173-233 Mannitol 2.60.1 - [156] 
Polyacrylate and silica 20-170 
Phosphatidylcholine from fat free 
soybean lecithin 
2.9±1.0 - [171] 
Polyacrylate (PMMA-
MeOPEGMa) 
50-220 Phospholipid (S100) ca. 3 
Salbutamol sulfate, 
aspirin 
[172] 
Polyacrylate, polystyrene and silica 5-150 Lactose ca. 10 - [173] 
PCL ca. 300 
Sugars (mannitol, lactose, maltodextrine) 
and polymers (PVP, HPC, HPMC) 
n.d. - [163] 
SPC, hydrogenated SPC and 
SPC:cholesterol lipossomes 
n.d. Lactose 3.5-7.0 Atropine sulfate [174] 
DPPC and cholesterol liposomes 137±15 and 198±15 Mannitol and hydrolyzed gelatin 2.3±0.1 and 2.4±0.1 
Amiloride hydrochloride 
and dapsone 
[159, 
160] 
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Table 1.4: Continuation. 
     
NPs type NPs size (nm) Carrier microparticle Microparticle size (µm) Drug Ref 
DPPC, DMPC, DSPC and DPPG 
liposomes 
150-200 Sucrose, lactose and trehalose 2.1±0.1-4.0±1.1 Superoxide dismutase [161] 
PLGA ca. 400 Trehalose and lactose 2.5-6.0 Rifampicin [164] 
PLGA 1954 ւ-leucine 4.20.1 Rifampicin [175] 
PLGA ca. 213 Mannitol 2.1-3.2 Rifampicin [165] 
n.d. n.d. CS/mannitol 2.8–3.3 Honokiol [176] 
Glyceryl monostearate ca. 147 Mannitol and ւ-leucine 4.10.1 Thymopentin [166] 
CS 241-449 
Lactose, mannitol and maltodextrin alone 
or in combination with leucine 
2.4-12.7 Isoniazid [167] 
PLGA 221-243 CS-grafted-PEG or CS 3.1-3.9 Curcumin [177] 
Cationic lipid-modified PLGA 207-261 Mannitol 3.70.2 siRNA [168] 
PLGA NPs modified with CS, 
alginate and PVA 
250-300 Lactose 
PVA-Alg NEM: 3.30.3 
CS-Alg NEM: 3.70.4 
Tobramycin [169] 
CS/carrageenan/TPP ca. 300 Mannitol 1.8±0.1 BSA [157] 
PGA-co-PDL NPs with a cationic 
surfactant DMAB 
1296 ւ-leucine 2.8±0.2 BSA [158] 
NPs: nanoparticles; PS: polystyrene; DPPC: dipalmitoyl phosphatidylcholine; PBCA: poly (butylcyanoacrylate); CS: chitosan; PMMA-MeOPEGMa: poly(methyl 
methacrylate)-methoxy(polyethylene glycol)methacrylate; PCL: poly(caprolactone); PVP: poly(vinylpyrrolidone); HPC: hydroxyproplycellulose; HPMC: 
hydroxypropylmethylcellulose; SPC: soybean phosphatidylcholine; DMPC: dimyristoyl phosphatidylcholine; DSPC: distearoyl phosphatidylcholine; DPPG: dipalmitoyl 
phosphatidyl glycerol; PLGA: poly(d,l-lactide-co-glycolide); PEG: polyethylene glycol; siRNA: small interfering RNA; PVA: poly(vinyl alcohol); Alg: alginate; NEM: 
nano-embedded micro-particles; TPP: tripolyphosphate; BSA: bovine serum albumin; PGA-co-PDL: poly(glycerol adipate-co-ɷ-pentadecalactone); DMAB: 
didodecyldimethylammonium bromide; n.d.: no data. 
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1.6.2. Spray-freeze-drying 
Although spray-drying is a convenient method to convert nanoparticulate suspensions 
into dry powders, the exposure of some heat sensitive nanoparticles formulations 
(including drugs and excipients) to the high temperatures involved in the process 
(˃100°C) may be not ideal. For example, the use of low m.p. polymers or solid lipids, 
such as PCL and Precirol ATO 5 may preclude the use of spray-drying [15, 178]. To 
overcome these limitations, the formulation of microencapsulated nanoparticles by SFD 
is employed as a viable alternative to spray-drying [179]. The SFD is a process that 
includes two-steps, i.e. atomization into a cryogen followed by lyophilisation, whereby 
the active material and excipients are sprayed into a freezing medium, such as liquid 
nitrogen, and then lyophilised (Figure 1.12). For that, SFD requires the selection of 
suitable cryoprotectants to reduce degradation of the active substance [108]. In detail, the 
first step involves channeling of the nanoparticles suspension through a nozzle to be 
atomized into tiny droplets. As the nanoparticles suspension is atomized into droplets, the 
cold temperature provided by the cryogen (i.e. liquid nitrogen) is sufficient to freeze the 
water molecules present within the air-borne droplets. The droplets are then completely 
frozen when immersed in the liquid nitrogen. The rapid freezing allows the water 
molecules to freeze into ice crystals that are interspersed among the dissolved or 
suspended materials (i.e. nanoparticles and freeze-drying excipients). Excess liquid 
nitrogen is subsequently removed from the slurry containing the frozen droplets by 
evaporation or decanting. Liquid nitrogen evaporation is carried out by holding the slurry 
at a temperature between its boiling point and the m.p. of ice (i.e. between -196°C and 
0°C) to ensure the droplets remain frozen while the liquid nitrogen is being evaporated. 
To obtain dry powders, the ice crystals are removed from the frozen droplets via 
sublimation in the lyophilisation stage. This step is carried out below the triple point of 
water to prevent the melting of ice crystals into liquid water that can destroy the solid 
structure of the nano-aggregates. As the ice crystals in the frozen droplets are sublimed 
interstitially, the frozen droplets retain their size and do not shrink. The SFD produces 
particles having larger geometric diameter compared to spray-drying, in which the 
atomized droplets shrink due to convective evaporation of the aqueous medium. 
Furthermore, due to the interstitial sublimation, particles produced by SFD exhibit highly 
porous structures attributed to the presence of voids previously occupied by the sublimed 
ice crystals [15, 179, 180]. 
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In SFD of nanoparticles suspension, freeze-drying excipients need also to be included in 
the formulation to: (i) function as cryoprotective agents protecting the nanoparticles from 
the sub-zero temperature, and (ii) facilitate re-dispersion of the nano-aggregates back into 
primary nanoparticles, so that the nanoparticles can perform their intended therapeutic 
functions. Aqueous re-dispersibility is an important characteristic as they must readily 
dissociate into primary nanoparticles upon exposure to the lung interstitial fluid, as 
discussed further. In this regard, excipient inclusion prevents the nanoparticles from 
irreversible coalescence upon freezing caused by mechanical stresses exerted by the ice 
crystal formation. The presence of excipients leads to the formation of excipient bridges 
that interconnect the nanoparticles preventing direct inter-nanoparticle contacts upon 
freezing [179]. 
 
 
Figure 1.12: Schematic representation of the SFD technique to transform nanoparticulate 
suspension into porous dry powders aerosol of nano-aggregates (NPs: nanoparticles). 
 
The SFD was primarily employed to produce dry powder proteins as the sub-zero 
temperature, unlike the high temperature, does not affect adversely protein structures and 
functions [179]. In a recent study, a suspension of DOX-loaded PBCA nanoparticles was 
converted by SFD into inhalable dry powder aerosol using lactose as a carrier. Upon 
dispersion in aqueous medium, the PBCA nanoparticles were easily recovered from the 
microcarriers. The cytotoxicity of DOX-nanoparticles was demonstrated to be higher than 
the corresponding free-DOX due to the higher uptake of DOX-loaded nanoparticles by 
NPs suspensionNozzle
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Freeze Dryer
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the cancer cells. The porosity of the nano-aggregates produced by SFD is evident from 
the large geometric diameter (10 µm) and the suitable daer for inhalation (approximately 
3.5 µm) [181]. This technique was also employed to produce a dry powder of liposomal 
ciprofloxacin, where lactose was also used as carrier [182]. The resulting SFD particles 
had a reduced particle mass and the liposomal ciprofloxacin was reconstituted when the 
dry powder aggregates were immersed in an aqueous medium [182]. 
In another study, a dry powder for inhalation containing insulin-loaded liposomes 
incubated with different lyoprotectants (lactose, sucrose, mannitol and glucose) were 
produced by the SFD process for a best preservation of the entrapped drug in the 
liposome bilayers [183]. The same authors developed another novel inhaled dry powder 
composed by insulin-loaded SLN, which provided prolonged drug release, improved 
stability and effective inhalation [184]. Cheow et al. [179] produced a dry powder of 
drug-loaded thermally sensitive PCL nanoparticles using SFD and mannitol and PVA as 
excipients. Importantly, the particles produced by SFD exhibited significantly higher 
aqueous re-dispersibility than those produced by spray-drying, supporting the suitability 
of SFD as a method for producing solid-dosage-form of thermally sensitive nanoparticles. 
In addition, the dry powders exhibited large, porous and spherical morphologies with 
good flowability and effective aerosolization [179].  
Overall, the nanocomposite microcarriers produced by SFD presented larger specific 
surface areas and lower densities than their corresponding nanoparticles-microparticles 
produced by spray-drying, conferring better aerodynamic characteristics to the particles. 
The authors have been concluded that the SFD into cooled air proved to be an efficient 
technique to prepare nanoparticles microencapsulated for pulmonary delivery while 
maintaining the stability of the original nanoparticulate formulation [185].  
Table 1.5 shows a summary of pulmonary delivery of microencapsulated- nanoparticles 
suspensions using SFD. 
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Table 1.5: Summary of pulmonary delivery of nanoparticle suspensions microencapsulated using SFD process. 
NPs type NPs size (nm) Carrier microparticle Carrier microparticle size (µm) Drug Ref 
PBCA 173±43 Lactose 104 Doxorubicin [181] 
DMPG 600 Lactose ca. 2.8 Ciprofloxacin [182] 
PCL 290±40 Mannitol and PVA ca. 5 Levofloxacin [179] 
PLGA, EDRL and EC for polymeric 
NPs. 
Miglyol 812, Kolliphor HS15 
and soybean lecithin for LNC. 
Witepsol H15 for SLN. 
PLGA: 81.7±11.5 
EDRL: 78.3±19.2 
EC: 111.4±10.2 
LNC: 36.2±2.6 
SLN: 441.7±7.5 
Maltodextrin and trehalose for 
polymeric and lipid NPs, 
respectively  
9.3-62.3 - [185] 
NPs: nanoparticles; PBCA: poly (butylcyanoacrylate); DMPG: dimyristoyl phosphatidylglycerol; PCL: poly(caprolactone); PVA: poly (vinyl alcohol); PLGA: poly (DL-
lactide-co-glycolide); EDRL: Eudragit RL; EC: ethyl cellulose; LNC: lipid nanocapsules; SLN: solid lipid nanoparticles. 
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1.6.3. Other microencapsulation techniques 
In addition to the most popular particle engineering techniques described above, there are 
some other methods that are not as well explored, such as milling and supercritical fluids 
(SCF) technology, or even alternative methods for preparing micron-sized drug particles 
that have been proposed, such as solvent evaporation, liquid-liquid emulsion and 
emulsion/coacervation techniques [186].  
 
1.6.3.1. Milling 
The traditional method for producing active drug particles within the respirable range 
involves high-intensity combination, usually in a fluid-energy (air-jet) mill [187]. 
Regarding milling technique, there are many different types of mills, but only a few are 
able to mill powders to the acceptable particle size range of 1-5 µm for pulmonary 
administration. The two main used types of mills are ball mills and fluid-energy mills, 
such as the jet mill, which is a well-established procedure used to produce dry powders 
intended for inhalation [119].  
Jet milling is the most useful technique, because the reduction of the particle size occurs 
via high velocity particle-particle collisions. Coarse particles are introduced into the 
milling chamber and air or nitrogen, fed through nozzles at high pressure, accelerates the 
solid particles to sonic velocities, inducing collision and fractures between them. While 
flying around the mill, larger particles are subjected to higher centrifugal forces and are 
forced to the outer perimeter of the chamber. Small particles exit the mill through the 
central discharge stream. Depending on the pressure and powder feed rate, particles with 
diameters down to approximately 1 µm can be produced [119].  
A ball mill is essentially a rotating cylinder loaded with drug and milling media (i.e., balls 
that grind the drug between each other as they tumble inside the mill). Ball milling is very 
slow and the process is poorly scalable, which is why tumbling-ball mills are only used 
for laboratory-scale [119]. However, strong mechanical processing, such as milling, has 
been shown to affect the crystallinity of the material [187]. The micronization process 
leads to small, irregularly shaped flat particles and extensive flat surfaces promote large 
contact areas, resulting in increased adhesion between the particles, leading that 
micronized powders show poor flow properties [188].  
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However, this can be viewed as an old process, providing only limited opportunity for 
control over potentially important particle characteristics such as size, shape and 
morphology. Intense milling might also cause unwanted changes in the physicochemical 
properties of the material. As a consequence the micronized material has intrinsically 
poor flow properties, leading to upstream processing problems, for example when filling 
the reservoir of a DPI, or a unit dose container such as a capsule or blister. Furthermore, 
cohesive micronized drug particles are generally resistant to redispersion following 
administration. It may not be suitable for fragile molecules and more complex engineered 
structures, such as porous/hollow particles and nanoaggregates, or for surface-modified, 
coated or encapsulated materials.The pharmaceutical industry has proposed several 
formulation strategies to allow these cohesive aggregates to be used in DPI. However, 
until now, classical milling processes are not suitable for the production of hybrid 
microencapsulated nanoparticles for pulmonary purposes.  
 
1.6.3.2. Supercritical fluids technology 
The SCF technology is a relatively recent particle engineering technology that can be 
used to manufacture respirable drug particles that are intrinsically more uniform in terms 
of crystallinity, morphology, particle size distribution and shape. It uses compressed gases 
or liquids above their critical pressures and temperatures. Several gases have been used 
(e.g. nitrogen), but carbon dioxide, because of its accessible critical point at 31°C and 74 
bar, low cost and low toxicity, is the most widely used solvent in SCF processes. Its 
critical temperature makes SCF suitable for processing heat-labile solutes at conditions 
close to room temperature [187, 189]. The added advantage of this technology is the 
ability of supercritical solvents to be efficiently separated by decompression from organic 
co-solvents and solid powders, facilitating a single-step, clean and solvent recyclable 
production. Since SCF are gases under ambient conditions, a key benefit of this process is 
the elimination of the harvesting and drying stages even a very small amount of water is 
used as a co-solvent [186]. Furthermore, fine drug particles produced by means of SCF 
presented better flow properties and are more dispersible following discharge from a DPI 
device. In fact, it has been demonstrated that salmeterol xinafoate particles produced by 
SCF have higher respirable fractions (defined as the percentage of the drug dose emitted 
from an inhaler that is within the respirable range) than those produced by conventional 
crystallization and micronization [187, 190]. 
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The SCF technology involves three main processes: (i) precipitation from supercritical 
solutions composed of supercritical fluid and solutions, where particles are formed as the 
result of rapid expansion of a supercritical fluid containing a dissolved solute; (ii) 
precipitation from gas saturated solutions, which involves rapid dispersion and mixing of 
the drug solution with the supercritical fluid, typically in a coaxial spray arrangement and 
extraction of the solvent into the supercritical fluid, leading to high supersaturation ratios 
and (iii) precipitation from saturated solutions using supercritical fluid as antisolvent, 
which relies on the capacity of a supercritical fluid to act as an antisolvent and cause 
precipitation within a liquid solution or droplet [187, 189, 191].  
Other advantages can be noted depending on the chosen process configuration: high 
purity of products, control of crystal polymorphism, possibility of processing 
thermolabile molecules, single-step process, easy downstream processing and 
environmentally acceptable technology [191]. Nevertheless, scale-up of these techniques 
is limited by particle aggregation and nozzle blockage caused expansion cooling. It is also 
limited to molecules that are soluble in carbon dioxide [189]. However, all techniques 
allow production of inhalable particles with a significant increase in FPF compared to jet-
milled products [133, 192].  
Among the drugs that have been successfully processed by SCF technology, there are 
many active substances relevant for pulmonary administration such as anti-asthmatic 
drugs, antibiotics and peptides [186, 192-194]. For example, cyclosporine was 
precipitated as nanospheres and dispersible in budesonide crystals with an daer between 1 
and 2 µm for dry powder formulations [189]. 
Particle engineering using this type of technology is the subject of intense research in the 
pharmaceutical industry [193, 195]. Despite its potential, SCF is still an emerging 
technology that is not much exploited in DPI products. As happens with milling 
processes, the nanoparticles microencapsulation by means of SCF technology is not yet 
developed and there are no studies about this research area of interest.  
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1.7. Nanoparticles recovery after microencapsulation 
In addition to the specific aerodynamic requirements of the inhaled particles, the 
nanoparticles-containing micron-sized formulations obtained by microencapsulation 
techniques must readily dissociate into the primary nanoparticles upon depositing in the 
lung interstitial fluid in order to retain the benefits of the original nanoparticles (i.e., 
availability of internalization and improvement of drug absorption, increased dissolution 
rate, sustained and prolonged release) [110, 114, 120, 154, 156, 196] (Figure 1.13). 
Furthermore, the re-dispersed nanoparticles must remain colloidally stable to prevent 
aggregation in the lung. For this purpose, the process for microencapsulation typically 
employs a wide range of pharmaceutical excipients. Hence, the ability of the 
nanoparticles to readily redisperse in an aqueous medium depends on the strength of the 
nanocarriers binding force as well as the degree of particle wetting (i.e., the excipient 
solubility in the lung interstitial fluid) [120]. 
 
 
Figure 1.13: Excipient bridges govern the nanoparticles redispersability (NPs: 
nanoparticles). 
 
Polymers, surfactants, carbohydrates and sugars (e.g., sorbitol, lactose, mannose) are 
widely used as the excipients for DPI, since they are approved by the main regulatory 
agencies (FDA and EMA) [112, 114, 120, 197]. This is due to their non-toxic, readily 
degradable properties after administration as well as their chemical and physical stability 
[111, 114, 198]. During the process, these substances act as drying excipients that protect 
the structural integrity of the nanoparticles, avoiding coalescence upon exposure to high 
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temperature and forming the so-called excipient bridges that occupy the interstitial space 
between the nanoparticles, hence preventing the nanoparticles from forming irreversible 
interparticle fusion upon heating above their glass transition or melting temperature [120, 
196].  
Despite the small number of excipients that are authorized for pulmonary delivery, a 
variety of new excipients is under investigation. Since lung have limited buffer capacity, 
only compounds that are biocompatible or endogenous to the lung and that are easily 
metabolized or cleared can be used in inhaled formulations [111]. Among the inert 
excipients available for nanoparticles microencapsulation, lactose is the first choice and 
the most commonly used in marketed DPI, being the only excipient used in DPI marketed 
in the USA. It has an established safety and stability profile, may be processed by 
different manufacturing techniques with tight controls over purity and physical properties, 
is easily available at different grades and is inexpensive. It is conceived that the fine 
particles of lactose reaching the lung are rapidly absorbed and metabolized by the 
intestinal epithelium and are mainly excreted in urine. Furthermore, lactose swallowed at 
the levels present in inhaled preparations is unlikely to present problems even in patients 
with lactose intolerance. However, a high number of excipients are under study, such as 
mannitol and trehalose [112].  
 
1.8. Conclusions 
Recent advances in inhalation therapy have brought considerable biomedical interest in 
the development of novel particle technologies for pulmonary drug formulation. This is 
due to the specific physiological environment of the lung as an absorption and treatment 
organ. Inhaled nanoparticulate therapy holds great potential for treating diseases that 
require direct lung delivery with reduced drug dosage and dosing frequency, leading to 
less systemic side effects and improved patient compliance. However their small size can 
bring some administration problems. Formulating nanoparticles into dry powder aerosols 
of micron-sized particles provides stability, ease of handling and delivery from simple 
inhalers. It is also demonstrated that dry powder delivery systems allow the absorption of 
molecules into the systemic circulation. Pulmonary drug delivery offers tremendous 
opportunities to improve drug therapies systemically and locally using advanced drug 
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delivery systems like nanoparticles. Nanotoxicological aspects of inhaled drug delivery 
systems have to be considered and in vitro methods can be established to ensure safety. 
In the light of current literature data, it can be concluded that microencapsulated 
nanoparticles are very promising systems for sustained delivery of conventional and 
biotech drugs in the lung. 
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Chapter 2 
Rifabutin-loaded solid lipid nanoparticles for inhaled 
antitubercular therapy: physicochemical and in vitro 
studies 
 
 
This chapter is based on the following publication: 
Gaspar DP, Faria V, Gonçalves LMD, Taboada P, Remuñán-López C and Almeida AJ. Rifabutin-loaded 
solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies. 
International Journal of Pharmaceutics. 2016, 497 (1-2), 199-209.  
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Abstract 
Systemic administration of antitubercular drugs can be complicated by off-target toxicity 
to cells and tissues that are not infected by Mycobacterium tuberculosis. Delivery of 
antitubercular drugs via nanoparticles directly to the infected cells has the potential to 
maximize efficacy and minimize toxicity. The present work demonstrates the potential of 
solid lipid nanoparticles (SLN) as a delivery platform for rifabutin (RFB). Two different 
RFB-SLN formulations were produced using glyceryl dibehenate or glyceryl tristearate as 
lipid components. Full characterization was performed in terms of particle size, 
encapsulation and loading efficiency, morphology by transmission electron microscopy 
and differential scanning calorimetry studies. Physical stability was evaluated when 
formulations were stored at 53°C and in the freeze-dried form. Formulations were stable 
throughout lyophilisation without significant variations on physicochemical properties 
and RFB losses. The SLN showed to be able to endure harsh temperature conditions as 
demonstrated by dynamic light scattering. Release studies revealed that RFB was almost 
completely released from SLN. In vitro studies with THP1 cells differentiated in 
macrophages showing a nanoparticle uptake of 463% and 269% for glyceryl 
dibehenate and glyceryl tristearate SLN, respectively. Cell viability studies using relevant 
lung cell lines (A549 and Calu-3) revealed low cytotoxicity for the SLN, suggesting these 
could be new potential vehicles for pulmonary delivery of antitubercular drugs. 
 
Graphical abstract 
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2.1. Introduction 
Rifabutin (RFB) has activity against mycobacteria including atypical organisms such as 
Mycobacterium avium and M. intracellulare, also referred to as M. avium-intracellulare 
complex (MAC). It is used as an alternative to macrolides, being generally more active in 
vitro than rifampicin against rifampicin-susceptible isolates of M. tuberculosis, and also 
for the prophylaxis of MAC infection in immunocompromised patients [1].  
Pulmonary TB remains the commonest form of this disease and the development of 
methods for delivering anti-tubercular drugs directly to the lung via the respiratory route 
is a rational therapeutic goal. The obvious advantages of inhaled therapy include direct 
drug delivery to the diseased organ, targeting to alveolar macrophages harbouring the M. 
tuberculosis, reduced risk of systemic toxicity and improved patient compliance [2]. As 
M. tuberculosis resides and multiplies within host mononuclear phagocytes, which 
internalize particles efficiently, encapsulation of antitubercular drugs within nanoparticles 
offers a mechanism for specific targeting of infected cells. Indeed, nanoparticles are taken 
up by the mononuclear phagocyte system and accumulate in macrophages, being ideally 
suited to treat M. tuberculosis. An additional advantage of nanoparticles delivery of 
antitubercular drugs is that it shields the drug from degradation or modification prior to 
delivery of the drug to infected tissues [3, 4]. 
SLN are colloidal lipid-based carriers prepared with lipids that are solid at room and body 
temperatures, and with surfactants generally recognized as safe, which are used to 
stabilize the nanocarriers avoiding aggregation [5, 6]. They have received increased 
attention over the last decade, presenting good physical stability, providing drug 
protection and allowing controlled and targeted drug release. SLN can be produced 
without using organic solvents, minimizing the toxicological risk and are easy to scale up 
and sterilize, thus fulfilling the requirements for an optimum particulate carrier system [7-
9]. Previous studies performed in our laboratories showed 
99m
Tc-radiolabelled SLN could 
be successfully aerosolized and delivered by inhalation. The authors proposed the same 
strategy for the treatment of lung cancer using SLN containing paclitaxel being 
demonstrated that this system provides a target administration, which is expected to avoid 
a high concentration of the drug at non-target tissues, reducing toxicity and increasing the 
drug’s therapeutic index [10].  
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In fact, the concept of delivering antitubercular drug through the aerosol route is not new. 
In earlier studies, microparticles encapsulating rifampicin or rifampicin plus isoniazid 
were used for this purpose [11, 12]. More recently, inhalable polymeric nanoparticles and 
liposomes were shown to be efficient antitubercular drug carriers. However, the 
advantage of using SLN over the use of liposomes is their long-term stability as well as 
superior drug incorporation efficiency. However, SLN have not yet been fully explored 
for the respiratory delivery of antitubercular drugs. In fact, the SLN nebulization is a new 
and upcoming area of research [2]. Therefore, the aim of this work was to encapsulate 
RFB in SLN formulations and demonstrate its suitability for pulmonary administration. 
The study involved a full SLN physicochemical characterization, as well as the stability 
studies of SLN in liquid suspension and in freeze-dried form during 12 months. In vitro 
evaluation included cytotoxicity analysis using relevant lung cell lines and the uptake 
evaluation by human monocytes.  
 
2.2. Materials  
RFB was acquired from CHEMOS GmbH (Germany). Glyceryl dibehenate (m.p. 70°C) 
was a kind gift from Gattefossé (France). Glyceryl tristearate (m.p. 72-75°C), 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), propidium iodide, 
dimethylsulfoxide (DMSO), phorbol 12-myristate 13-acetate (PMA) and 
paraformaldehyde were purchased from Sigma-Aldrich (USA). Tween 80 (polysorbate 
80) was obtained from Merck (Kenilworth, USA). Lung surfactant (Curosurf) was a 
generous gift from Angelini Farmacêutica, Lda. (Portugal). For the viability studies, three 
cell lines were used: A549 (human alveolar lung carcinoma cell line, ATCC CCL-185), 
Calu-3 (human lung adenocarcinoma from tracheobronchial epithelium cell line, ATCC 
HTB-55) and THP1 cells (human monocytic cell line, ATCC® TIB-202). DAPI, the 
culture medium and their supplements were acquired from Life Technologies (UK). 
Phosphate buffered saline (PBS, pH 7.4) was purchased from Invitrogen. Purified water 
was obtained by inverse osmosis (Millipore, Elix 3) with a 0.45 μm pore filter. All other 
reagents were of analytical grade and were used without further purification. 
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2.3. Methods  
2.3.1. RFB solubility studies 
In a first stage, the solubility of RFB in the molten lipids (glyceryl dibehenate and 
glyceryl tristearate) was determined using a slight modification of a previously described 
method [13]. Briefly, the solid lipids were melted at a temperature 10°C above their 
respective m.p. (glyceryl dibehenate has a m.p. of 70°C and glyceryl tristearate between 
72-75°C), in a controlled temperature water bath. Small amounts of RFB were then 
successively added until the saturation of the lipid was achieved. This occurred when 
excess of solid RFB persisted for more than 8 h. Each determination was carried out in 
triplicate (n=3). 
  
2.3.2. Formulation of SLN  
The preparation of SLN was made using glyceryl dibehenate or glyceryl tristearate as the 
lipid component and Tween 80 as a surfactant, using a modification of a previously 
described-hot high shear homogenization (HSH) method [14]. Briefly, the lipid phase was 
melted at a temperature 10°C above its m.p.. RFB was added to the melted lipid until 
complete dissolution. An aqueous phase was prepared by dissolving Tween 80 in 
purified water and heated to the same temperature of the oil phase. Then, the hot aqueous 
phase was added to lipid phase and homogenization was carried out using a high-shear 
laboratory mixer (Silverson SL2, UK) at 12300 rpm for 10 min, in a water bath to keep 
the melting temperature of the lipids. The SLN dispersions were finally obtained by 
allowing the hot nanoemulsion to cool in an ice bath, with gentle agitation for 5 min. 
Each formulation was carried out in triplicate (n=3). The final dispersions were packaged 
in sterile glass vials, closed with bromobutyl rubber stoppers, sealed with aluminium seal, 
and stored at 53°C until further use. 
 
2.3.3. Characterization of SLN 
2.3.3.1. Particle size, surface charge and physical stability 
The average particle size was analysed by photon correlation spectroscopy (PCS) using a 
Zetasizer Nano S (Malvern Instruments, UK). Samples were kept in polystyrene cuvettes 
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and the measurements were made at 25.00.1°C after appropriate dilution in 0.45 μm-
pore filtered purified water (1:100). Results were expressed as average particle size and 
polydispersity index (PI). Surface charge was determined through particle mobility in an 
electric field to calculate the zeta potential of SLN using a Zetasizer Nano Z (Malvern 
Instruments, UK). For this purpose, samples were placed in a specific cuvette where a 
potential of 150 mV was established after appropriate dilution of the samples in filtered 
purified water. For all the measurements, at least three replicate samples were 
determined. 
 
2.3.3.2. Encapsulation efficiency and drug loading 
After preparation, non-incorporated RFB was separated from the SLN dispersions by size 
exclusion chromatography on Sephadex G-25/PD-10 columns. The RFB incorporation in 
SLN was determined after dissolving the nanoparticles with acetonitrile, which promoted 
the precipitation of the lipid phase. The encapsulated RFB remained in the supernatant, 
which was separated by centrifugation. The amount of free drug in the aqueous phase was 
measured in the supernatant using UV-Visible spectrophotometry, at λmax of 320 nm, in a 
microplate spectrophotometer reader (FLUOstar Omega, BMGLabtech, Germany). The 
supernatant of unloaded nanoparticles was used as basic correction. This quantification 
method was actually validated based on the international guideline ICH Topic Q2(R1) 
(CPMP/ICH/381/95), Validation of Analytical Procedures, showing sensitivity and 
precision adequate to the concentration range used in this investigation. The linearity was 
established between 0.375 and 0.00037 mg/mL with a standard error of the method of 
0.0034 and a 5% relative standard deviation. Intraday precision for the standard controls 
prepared at 0.375 and 0.094 mg/mL was less than 5% relative standard deviation. The 
limit of quantification and detection were 0.034 mg/mL and 0.011 mg/mL, respectively, 
with 95% of confidence. 
The RFB EE and DL were calculated according to the following equations: 
      
           
            
                                                                                        (Eq. 2.1) 
      
           
      
                                                                                        (Eq. 2.2) 
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where Winitial drug is the weight of the drug used, Wloaded drug is the weight of encapsulated 
drug that was detected in the supernatant after SLN purification, solubilization and 
centrifugation and Wlipid represents the weight of the lipid vehicle. 
 
2.3.3.3. Stability studies  
Stability of SLN suspensions was evaluated in different conditions: the aqueous 
suspension of SLN at 53°C and its freeze-dried form at room temperature in a 
dessicator. For stability in suspension, SLN were stored at 53°C and mean particle 
diameter, PI and zeta potential were determined after 6 and 12 months of storage. The 
average particle size was analysed by PCS using a Zetasizer Nano S (Malvern 
Instruments, UK) as described in section 2.2.3.1. Besides, for detection of larger sized 
particles, i.e., outside the measuring range of PCS, laser diffractometry (LD) was 
employed using a Malvern Mastersizer 2000 (Malvern Instruments, UK). In this 
equipment, the size distribution measurements were achieved five times for individual 
samples and at least three replicate samples were done (n=3). Stability evaluation was 
also performed in terms of EE and DL after separation of non-incorporated RFB by size 
exclusion chromatography, as described above. 
The effect of freeze-drying was also assessed. For that, after preparation, SLN 
formulations were divided into two aliquots of equal volume. One aliquot was frozen 
overnight and freeze-dried for 24 h (Christ Alfa 1-4, Osterode am Harz, Germany) while 
the other one (reference) was kept at 53°C for comparative evaluation of  the 
physicochemical properties (particle diameter, PI and surface charge as well as EE and 
DL). 
 
2.3.3.4. Transmission electron microscopy analysis (TEM)  
The morphological analysis of SLN was conducted by TEM. The samples were stained 
with phosphotungstic acid at 2% (w/v) during 2 min and fixed on racks of copper covered 
by a membrane of carbon for observation. Afterwards, they were analysed with a JEOL 
Microscopy (JEM 2010, Japan) at 120 kV, and the images were acquired through a Gatan 
Orius camera. 
Chapter 2 - Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy:                         
physicochemical and in vitro studies 
 
74 
 
2.3.3.5. Thermal analysis using dynamic light scattering (DLS) 
The influence of temperature on the physical stability of SLN suspensions was assessed 
using- DLS (Zetasizer Nano S; Malvern Instruments, UK). Samples were appropriately 
diluted with purified water (1:100) in a quartz cell and particle size analysis was 
performed while heating the sample from 25°C up to 90°C at a rate of 0.5°C/min and 
subsequently followed by cooling from 90°C to 25°C at a rate of 0.5°C/min. Particle size 
measurements were made every 0.5°C. For each sample, measurements were carried out 
in triplicate (n=3). Morphology of SLN after these thermal studies was assessed by TEM, 
as previously described. 
 
2.3.3.6. Differential scanning calorimetry (DSC) studies 
Measurements were performed on a calorimeter DSC Q200 (TA Instruments, DE, USA). 
The SLN dispersions (empty and loaded with RFB) and bulk materials (glyceryl 
dibehenate, glyceryl tristearate, Tween 80 and RFB) were accurately weighted into 
aluminium pans, which were hermetically sealed and measured against an empty 
reference pan. The pan was heated and the thermograms were recorded at temperature 
range from -20°C to 240°C at a heating rate of 10°C/min. The heat flow was measured. 
 
2.3.4. In vitro cell viability studies 
The cytotoxicity of SLN formulations was assessed using MTT reduction [7] and 
propidium iodide exclusion assays. MTT is a yellow, water-soluble tetrazolium dye that is 
converted by viable cells to a water-insoluble and purple compound, formazan [15]. Cell 
viability was assessed in A549 and Calu-3 after 24 h of incubation of the cell lines with 
the different formulations. The Calu-3 and A549 respiratory epithelial cell lines have 
been frequently used in this context to evaluate the behaviour of systems aimed at 
respiratory drug delivery, either nasal or pulmonary [16]. The day before the experiment, 
A549 and Calu-3 cell lines were seeded in sterile flat bottom 96 well tissue culture plates 
(Greiner, Germany), in RPMI 1640 culture medium, supplemented with 10% foetal serum 
bovine, 100 units/m of penicillin G (sodium salt), 100 μg/mL of streptomycin sulfate and 
2 mM L-glutamine, at a cell density of 1x10
5
 cells/mL, and 100 μL per well. Cells were 
incubated at 37ºC and 5% CO2. On the next day, the medium of the cell lines A549 and 
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Calu-3 cells was replaced by fresh medium containing the different samples to be 
analysed. Each sample was tested in six wells per plate. In negative control (K-), cells 
were incubated with culture medium and, in positive control (K+), sodium dodecyl 
sulphate (SDS) was added at 1 mg/mL in order to promote the cell lyses. After 24 h of 
incubation, medium was replaced by 0.3 mM propidium iodide in culture medium (stock 
solution 1.5 mM in DMSO, diluted with culture medium 1:5). Fluorescence was 
measured (excitation, 485 nm; emission, 590 nm) in microplate reader (FLUOstar 
Omega, BMGLabtech, Germany), and then, the MTT assay was performed. Medium was 
replaced by medium containing 0.25 mg/mL MTT. The cells were further incubated for 3 
h. On the plates that contain reduced MTT, the media was removed and the intracellular 
formazan crystals were solubilized and extracted with 100 µL DMSO. After 15 min at 
room temperature, the absorbance was measured at 570 nm in a microplate reader 
(FLUOstar Omega, BMGLabtech, Germany). The relative cell viability (%) compared to 
control cells was calculated for the MTT assay using the following equation: 
                              
         
          
                                                        (Eq. 2.3) 
where Abssample is the absorbance value obtained for cells treated with nanoparticles and 
Abscontrol is the absorbance value obtained for cells incubated with culture medium.  
And for propidium iodide by: 
                                     
                  
                   
                                         (Eq. 2.4) 
where Fluorescencesample is the relative fluorescence unit (URF) values obtained for cells 
treated with nanoparticles and Fluorescencecontrol is the URF values obtained for cells 
incubated with culture medium. 
 
2.3.5. Quantitative SLN uptake assessment  
To assess SLN-cell interactions, SLN were labelled by incorporating coumarin-6 after 
lipid melting. THP1 cell line was grown in 96 well plates at a cell density of 2.5x10
5
 
cells/mL. Cells were incubated at 37ºC and 5% CO2. Then, the THP1 cell line was 
differentiated to macrophages for 3 days with 200 nM of PMA before exposition to the 
samples. After 3 days, the culture medium was replaced by 100 µL of coumarin-6 loaded 
nanoparticles in the test wells, in order to obtain a final SLN concentration of 0.75 
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mg/mL. Fluorescence measurements were performed at excitation wavelength of 485 nm 
and emission 520 nm. These determinations were performed immediately after particles 
addition and after several incubation times (1 h and 24 h at 37°C, 5% CO2) after 3 
washing steps with 250 µL of PBS containing 20 mM glycine at pH 7.4 pre-warmed at 
37°C. The PBS solution was removed and the cells were disrupted with 100 µL of 1% 
Triton X-100 solution and the fluorescence was again measured to determine the 
internalized amount of particles. The particles internalized were determined as a 
percentage of the initial amount feed of cells. Using particle fluorescence as a function of 
their concentration, it was possible to determine the amount of particles internalized by 
cells. 
 
2.3.6. Fluorescence Microscopy 
Cell cultures were performed at same conditions as described in section 2.3.4, in terms of 
incubation times of particles tested and cell density. Cells grown on 12 multi-well plates 
containing sterile glass slides (Greiner, Germany). After the time of incubation with 
particles, cells were rinsed 3 times with 10 mM PBS containing 20 mM glycine at pH 7.4 
before and after being fixed for 15 min at room temperature in dark with a 4% (w/v) 
paraformaldehyde. After cell fixation, and, for actin staining with Rhodamine phalloidin, 
cells were permeabilized with 0.1% Triton X-100 for 4 min, then cells were rinsed 3 
times with 10 mM PBS containing 20 mM glycine at pH 7.4. The 6.6 µM phalloidin-
TRITC solution in 10 mM PBS was added to the cells for 30 min at room temperature. 
After cells rinsed 3 times with 10 mM PBS containing 20 mM glycine at pH 7.4, and air 
dried, cell slides were mounted in fluorescent mounting medium ProLong® Gold antifade 
reagent with DAPI and their fluorescence was observed and recorded on an Axioscop 40 
fluorescence microscope (Carl Zeiss, Germany) equipped with an Axiocam HRc (Carl 
Zeiss, Germany) camera. Images were processed with the software AxioVision Rel. 4.8.1 
(Carl Zeiss, Germany). 
 
2.3.7. In vitro RFB release studies  
Prior to the release studies, the nanodispersions were desalted on Sephadex G-25 medium 
pre-filled PD-10 columns (GE Healthcare Life Sciences). The release of RFB was carried 
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out by incubating the nanoparticles in a release medium comprising 10 mM PBS pH 7.4 
and 0.1% of pulmonary surfactant (Curosurf) (0.75 mg of nanoparticles in 1 mL of the 
release medium), with horizontal shaking (300 rpm) at 37°C. At appropriate time 
intervals, individual samples were centrifuged (Allegra 64R centrifuge, Beckman 
Coulter) at 30000g for 30 min at 4°C. The amount of released RFB was evaluated in the 
supernatants by spectrophotometry in a microplate reader (FLUOstar Omega, BMG 
Labtech, Germany) at 320 nm (n=3). 
In order to investigate the mechanism of RFB release from glyceryl dibehenate and 
glyceryl tristearate SLN, the obtained release data were analyzed with different models 
including: zero-order (Eq. 2.5), first-order (Eq. 2.6), Higuchi (Eq. 2.7) and Korsmeyer–
Peppas (Eq. 2.8) [17]: 
                                                                                                                  (Eq. 2.5) 
            
  
     
                                                                                          (Eq. 2.6) 
         
 
                                                                                                     (Eq. 2.7) 
       
                                                                                                               (Eq. 2.8) 
where M0 is the initial amount of RFB, Mt is the cumulative amount of drug release at 
time t, k0 is the zero-order release constant, k1 is the first-order release constant, kH is the 
Higuchi constant, kKP is the Korsmeyer–Peppas constant and n is an exponent 
characterizing the release mechanism. The model that best fits the experimental data was 
selected based on the highest determination coefficient (r
2
) values. The OriginPro8 
software was used to perform the data treatment. 
 
2.3.8. Statistical analysis 
Statistical analysis of the experimental data was performed using a one-way analysis of 
variance (one-way ANOVA) and differences between groups were tested by a one-way 
ANOVA with Dunnet’s post hoc test with GraphPad Prism version 6.0 (GraphPad 
Software, San Diego, CA). Data were expressed as meanSD or 95% confidence interval. 
A p<0.05 value was considered significant. All data are shown as meanSD. 
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2.4. Results and Discussion 
2.4.1. SLN characterization 
Delivery of antitubercular drugs by nanoparticles offers potential advantages over free 
drug, including the potential to target specifically the tissues and cells that are infected by 
M. tuberculosis, thereby increasing therapeutic efficacy and decreasing systemic toxicity, 
as well as the capacity for prolonged drug release, allowing less-frequent administration 
[3]. In this context, two different SLN compositions loaded with RFB were prepared 
using different lipids (glyceryl dibehenate and glyceryl tristearate), and Tween 80 as the 
surfactant component. The resultant SLN presented particle size distributions within the 
nanometre range with PI values < 0.2 (Table 1). Negative zeta potential values of -17 mV 
and -18 mV were observed for glyceryl dibehenate and glyceryl tristearate SLN, 
respectively. Although below the critical zeta potential for stability in terms of purely 
electrostatic repulsions, these values still indicate a good colloidal stability of the 
nanoparticles suspensions considering the sterically stabilizing effect of Tween 80 [18]. 
The RFB was incorporated in both lipid formulations at theoretical amounts of 10.0% and 
7.3% (w/w) relative to glyceryl dibehenate and glyceryl tristearate, respectively. These 
concentrations were selected based on preliminary solubility studies and correspond to 
the maximum solubility of RFB in the molten lipids. High RFB incorporation, as 
expressed by EE and DL, was obtained for both formulations, confirming similar results 
described in the literature for other lipids as hard fat suppository bases [19], tripalmitin 
[7] and glyceryl palmitostearate [20]. The EE values obtained for RFB were 89.9±5.1% 
for glyceryl dibehenate SLN and 81.0±9.6% for glyceryl tristearate SLN. 
Moreover, comparison of blank SLN with those loaded with RFB reveals drug 
incorporation into SLN led to an increase in zeta potential, which may be explained by 
the fact that RFB is a strong base with a dissociation constant (pKa) of 8.62 and, 
therefore, predominantly negative at the formulation pH value (pH 7-8). No significant 
variations on size and PI were observed after RFB inclusion in the formulations as 
compared to empty SLN. Again, the SLN suspensions remained fairly homogeneous with 
no significant aggregate formation. Microscopy studies by TEM confirmed the particle 
size distributions previously established from the PCS analysis. The spherical 
nanostructure of SLN is also evident in TEM micrographs as well as the compact 
appearance, which is similar to unloaded nanoparticles (Figure 2.1). 
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Figure 2.1: TEM micrographs of RFB-loaded SLN based on (A) glyceryl dibehenate and 
(B) glyceryl tristearate (scale bar: 200 nm). 
 
2.4.2. Stability studies 
When nanocarriers are formulated as aqueous suspensions, both physical (aggregation/ 
particle fusion) and chemical instability phenomena are known to appear at some point, 
limiting nanoparticles applications. Regarding the present work, it is important to recall 
that a pulmonary formulation of nanoparticles may involve the lyophilisation of the 
nanoparticles suspensions, which facilitates administration and can be beneficial for 
storage [21]. The ability of the SLN matrix to retain RFB and keep the physical properties 
during storage was assessed both on nanoparticles suspensions at 53°C and after 
lyophilisation after 6 and 12 months. The stability-indicating parameters were particle 
mean diameter, PI, surface charge and DL (Table 2.1). The physical properties (particle 
size, PI and surface charge) of the empty and RFB-loaded SLN suspensions stored at 
53°C remained almost unchanged for up to 12 months, indicating there was no tendency 
to form aggregates being then the dispersions stable. However, by LD analysis it was 
possible to observe the presence of some aggregates after 12 months (Figure 2.2B). On 
the other hand, over the time there was a considerable decrease in RFB content, which 
may be due to polymorphic transitions of the lipid matrices with subsequent drug 
expulsion, as described elsewhere [22, 23].  
Lyophilisation is being widely used to overcome physical instability of nanosuspensions 
by reducing the amount of water, which improves the physical and chemical stability of 
the nanosystems [21]. In the present work, SLN were lyophilised and then rehydrated, 
which can induce changes in particle size, although formulations remained within the 
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nano-range scale allowing their use in further studies (Table 2.1). This increase in particle 
size of lyophilised SLN may be due to the absence of a cryoprotectant during 
lyophilisation. However, LD analyses did not reveal the presence of aggregates after 12 
months of formulation (Figure 2.2D). Despite of this size increase, there was a lower 
decrease in RFB content when compared to that of SLN that were kept in suspension at 
53°C. Zeta potential and PI values did not evidence significant alterations after 
lyophilisation in any tested conditions. Previous stability studies from our laboratories 
also showed that SLN can be freeze-dried without significant variations in 
physicochemical properties or significant drug losses throughout the process [7]. 
Lyophilisation appears in this context as a very adequate choice for ensuring a mild 
drying procedure while preserving stability even without the use of cryoprotectants. 
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Figure 2.2: Particle size distribution of SLN after formulation (A) and 12 months of storage (B) at 53°C in suspension and in freeze-dried 
form after formulation (C) and 12 months of storage (D): (1) empty glyceryl dibehenate SLN, (2) empty glyceryl tristearate SLN, (3) RFB 
loaded-glyceryl dibehenate SLN and (4) RFB loaded-glyceryl tristearate SLN. 
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Table 2.1: Physicochemical properties of: (A) empty glyceryl dibehenate SLN, (B) RFB-loaded glyceryl dibehenate SLN, (C) empty glyceryl 
tristearate SLN and (D) RFB-loaded glyceryl tristearate SLN freshly prepared and after 6 and 12 months of storage in suspension at 53°C and in 
lyophilised form (meanSD, n=3).  
 SLN Suspension at 53°C Lyophilised SLN 
 A B C D A B C D 

 (
n
m
) 
Month 0 994 1085 2108 1917 1034 1212 21916 29910 
Month 6 921 1020 1871 1741 963 1872 2391 2914 
Month 12 1048 1065 2107 18612 23920 2235 26011 3136 
P
I 
Month 0 0.120.01 0.160.03 0.150.02 0.170.01 0.150.02 0.180.02 0.190.03 0.200.02 
Month 6 0.150.01 0.160.01 0.160.01 0.160.02 0.130.01 0.170.03 0.170.01 0.190.02 
Month 12 0.180.02 0.190.02 0.180.02 0.190.04 0.280.03 0.170.03 0.160.02 0.200.02 
Z
P
 (
m
V
) Month 0 -17.10.7 -24.00.5 -17.80.5 -24.60.4 -18.20.3 -27.60.2 -18.60.4 -21.60.4 
Month 6 -18.30.8 -27.40.4 -17.30.5 -20.00.4 -22.90.8 -30.51.3 -13.90.9 -24.80.7 
Month 12 -12.80.7 -24.62.2 -17.32.1 -19.70.7 -17.30.7 -25.51.3 -18.41.1 -24.80.3 
E
E
 (
%
) 
Month 0 - 89.95.1 - 81.09.6 - 70.44.5  56.72.1 
Month 6 - 36.20.3 - 19.90.1 - 62.83.2 - 53.64.3 
Month 12 - 36.31.7 - 21.83.1 - 68.43.2 - 55.91.5 
D
L
 (
%
) 
Month 0 - 9.00.5 - 6.00.7 - 6.80.2 - 4.20.4 
Month 6 - 4.00.3 - 1.60.1 - 6.20.9 - 3.90.3 
Month 12 - 2.80.2 - 2.40.2 - 7.20.4 - 4.80.1 
: mean particle size; PI: polydispersity index; EE: encapsulation efficiency; DL: drug loading. 
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2.4.3. DLS thermal analysis 
The effect of temperature on particle size of SLN formulations was assessed using DLS, 
applying a heating ramp from 25°C up to 90°C and then a cooling ramp to the initial 
temperature (Figure 2.3). This assay allowed to state the psychochemical properties 
(particle size and PI) when SLN were subjected to a temperature increase followed by a 
decrease. Nevertheless, DLS studies need to be performed whenever a formulation is 
intended for further temperature processing. Overall the heating and cooling process 
induced particle size changes in the SLN prepared with both solid lipids, which behaved 
in a different manner. In the case of glyceryl dibehenate SLN, a gradual particle size 
reduction was evident throughout the heating step (from 97 to 71 nm), and the initial 
particle size was not fully recovered after the cooling phase, in line with previous 
observations with tripalmitin-based SLN whereby particle size was recovered or even 
slightly decreased, with variations occurring during process [24]. On the other hand, 
glyceryl tristearate SLN suffered a slight decrease in particle size during heating followed 
by a marked increase after 75°C, suggesting some instability at these temperatures. This 
may occur because glyceryl tristearate is a mixture of mono, di- and triglycerides and not 
a pure lipid. During the cooling step, particle size stabilizes. The particle size variations 
were always within the nanosize range, indicating both SLN formulations based on 
glyceryl dibehenate and glyceryl tristearate may withstand the harsh formulation 
conditions such as moist-heat sterilization or spray-drying conditions used to prepare 
microparticles intended for pulmonary delivery, thus confirming previously published 
results [7, 24]. 
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Figure 2.3: DLS thermograms of (A) glyceryl dibehenate SLN and (B) glyceryl 
tristearate SLN: (■) from 25ºC to 90ºC and (●) from 90ºC to 25ºC (meanSD, n=3), with 
inset of TEM micrographs of SLN after thermal analysis (scale bar: 200 nm). 
 
2.4.4. DSC analysis 
DSC analysis is a powerful technique that was carried out with the aim to observe the 
physical thermodynamic variations of the samples related to morphological changes when 
they are submitted at a temperature ramp throughout time. In other words, thermal 
analysis determines the temperature and heat flow associated with material transitions as 
a function of time and temperature. It also allows viewing the crystalline state of the drug 
after being encapsulated in a ternary system (drug-surfactant-lipid). Figure 2.4 shows the 
thermograms of pure RFB, glyceryl dibehenate, glyceryl tristearate, Tween 80 and 
SLN, either empty or incorporating RFB. The thermograms of pure lipids showed melting 
peaks of 74°C and 60°C for glyceryl dibehenate and glyceryl tristearate, respectively. 
Pure RFB showed a melting endotherm at approximately 149°C. All these values are in 
agreement with those reported in the literature. Concerning RFB, the thermogram also 
showed complete degradation after the m.p. was reached. However, the thermograms of 
both freeze-dried RFB-SLN preparations did not show the melting peak of RFB, which 
can be ascribed to the amorphous or molecularly dispersed structure of the RFB in the 
lipid matrix. In the preparation method, RFB was dissolved in the molten lipids and, 
subsequently, the surfactant was added. This allowed the homogeneous dispersion of drug 
in the lipid. Furthermore, it has been reported that in the homogenization process, such as 
that herein used, the presence of surfactants and the rapid quenching of the 
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microemulsion may not allow the drug to crystallize [7, 23]. In all formulations, the m.p. 
of the lipids was depressed when compared to the m.p. of the bulk lipids (71°C for 
glyceryl dibehenate SLN, either empty or loaded with RFB and 59°C for glyceryl 
tristearate SLN, either empty and loaded with RFB). This was attributed to the creation of 
lattice defects onto the lipid matrices following a decrease in their crystallinity in 
comparison to their bulk counterparts. For less ordered crystals or amorphous solids, the 
melting of the substance requires much less energy than crystalline substances that need 
to overcome lattice forces. This m.p. depression might also be due to small particle size 
(nano) which significantly increases their surface area or to the presence of surfactants [7, 
25]. Despite the reduction on the lipid m.p. in the SLN formulations, no significant effect 
was observed on lipid matrix thermal behaviour pattern after incorporation of RFB. 
 
 
Figure 2.4: DSC thermograms of: (a) glyceryl dibehenate, (b) glyceryl tristearate, (c) 
Tween 80, (d) RFB, (e) empty glyceryl dibehenate SLN, (f) empty glyceryl tristearate 
SLN, (g) RFB-glyceryl dibehenate SLN and (h) RFB-glyceryl tristearate SLN. 
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2.4.5. In vitro cell viability studies 
Evaluating the biocompatibility of drug delivery formulations is nowadays a mandatory 
aspect to address. While an accurate determination of the toxicity of a formulation can 
only be determined in vivo, a variety of in vitro toxicological assays, performed in 
adequately selected cell lines, might provide very useful information and are widely 
accepted as first indicators. Current international guidelines require the evaluation to be 
contextualised with a specific route of administration and dose of the material [26].  
To address the above mentioned issues, the evaluation of the biocompatibility of SLN 
was performed by means of two different assays, i.e. the metabolic activity (MTT) and 
the cell membrane integrity through propidium iodide assay. The SLN were prepared 
from biocompatible lipids, so better tolerability with respect to polymeric nanoparticles 
can be hypothesized. In addition, triglycerides, fatty acids or waxes are known to release 
natural occurring degradation by products [27]. To investigate the potential cytotoxicity 
of glyceryl dibehenate and glyceryl tristearate SLN, empty and loaded with RFB, the cell 
viability when in contact with SLN was evaluated using selected lung cell lines (A549 
and Calu-3) as they are representative of the respiratory epithelia. Calu-3 is an 
immortalised cell line obtained from lung adenocarcinoma and has been extensively used 
in the study of formulations designed for either nasal or pulmonary drug delivery, as it is 
considered a model of the epithelium of both regions, whereas A549 is a cell line 
representative of the alveolar epithelium, obtained from human alveolar adenocarcinoma 
[21]. 
The MTT assay provides an evaluation of the cell metabolic activity upon exposure to the 
samples and has been used very frequently in the assessment of drug delivery carriers 
biocompatibility [28]. It evaluates the ability of the cells to reduce the MTT reagent to 
tetrazolium salts, an action that is dependent on mitochondrial metabolism. A reduction of 
cellular metabolic activity is generally accepted as an early indicator of cellular damage 
[29]. In this work, A549 and Calu-3 cells were cultured and exposed to SLN for a 
prolonged period (24 h). After this incubation period, no evidence of acute cytotoxicity 
was observed for the nanoparticles (with and without RFB) at the concentration used for 
transfection. Over 80% cell viability was observed in A549 and Calu-3 cell lines for both 
nanodispersions when compared to a negative control consisting of cells incubated only 
with fresh medium (Figure 2.5).  
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Figure 2.5: Relative cell viability of (A) A549 and (B) Calu-3 cell lines measured by the 
MTT reduction. (K-) negative control (culture medium); (K+) positive control (SDS, 1 
mg/mL); (1) Tween® 80; (2) empty glyceryl dibehenate SLN; (3) RFB loaded-glyceryl 
dibehenate SLN; (4) RFB solution at 75 µg/mL; (5) empty glyceryl tristearate SLN; (6) 
RFB loaded-glyceryl tristearate SLN and (7) RFB solution at 75 µg/mL. The 
nanoparticles concentration is 0.75 mg/mL in all samples. Results are expressed as 
mean±SD (n=6). Statistical analysis between the control group (K-) and other groups was 
performed using one-way ANOVA with Dunnet's post hoc test (*p˂0.05, **p˂0.01, 
***p˂0.001 and ****p˂0.0001). 
 
Moreover, the cells in contact with SLN had higher viability than that of the positive 
control, where cells were in contact with SDS, an anionic surfactant that promotes cell 
lysis. Therefore, as a cell viability of 70% is the threshold beyond which a cytotoxic 
effect is considered to occur according to ISO 10993-5, the observed effects are devoid of 
physiological relevance (ISO, 2009). This indicates that Calu-3 and A549 cells do not 
evidence a particular sensitivity to any of the tested samples, either pure RFB or 
nanoparticles-based formulations, at the tested concentrations. The decrease in cell 
viability (20%) was an expected finding, because SLN were formulated using Tween 
80 and surfactants are considered to be decisive in SLN toxicity [30]. These findings are 
also in good agreement with other studies reporting an increased cytotoxicity of Tween 
80 in combination with nanoparticles [31, 32]. Nevertheless, the SLN cytotoxicity is 
relatively low in general when compared to polymeric nanoparticles, particularly those 
produced with polyalkylcyanoacrylates or PLGA [33, 34]. Furthermore, the incorporation 
of RFB in SLN did not promote major differences in cell viability when compared to 
Chapter 2 - Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy:                             
physicochemical and in vitro studies 
 
88 
 
blank formulations. These findings, in both respiratory cell lines, are considered good 
indicators of biocompatibility. 
On the other hand, propidium iodide serves as a dead cell indicator since this dye 
monitors losses in membrane integrity [35]. Thus, the retention values of propidium 
iodide in positive control were high, since these cells were not viable, with a damaged 
cell membrane promoting dye uptake ( 2 URF for glyceryl dibehenate SLN and  1.5 
URF for glyceryl tristearate SLN). On the other hand, in the negative control, cells were 
only incubated with fresh medium, being viable, with intact cell membranes and 
consequently presented low values of propidium iodide uptake ( 1 URF) [36]. Moreover, 
Figure 2.6 also shows that the cell membranes that were in contact with the formulations 
were also intact because the values of propidium iodide assay are approximately equal to 
the negative control (1 URF for all formulations), concluding that these cells had not 
disrupted plasma membranes. 
 
 
Figure 2.6: Propidium iodide uptake by (A) A549 and (B) Calu-3 cell lines. (K-) negative 
control (culture medium); (K+) positive control (SDS, 1 mg/mL); (1) Tween 80; (2) 
empty glyceryl dibehenate SLN; (3) RFB loaded-glyceryl dibehenate SLN; (4) RFB 
solution at 75 µg/mL; (5) empty glyceryl tristearate SLN; (6) RFB loaded-glyceryl 
tristearate SLN and (7) RFB solution at 75 µg/mL. The nanoparticles concentration is 
0.75 mg/mL in all samples. Results are expressed as meanSD (n=6). Statistical analysis 
between the control group (K-) and other groups was performed using one-way ANOVA 
with Dunnet's post hoc test (**p˂0.01 and ****p˂0.0001). 
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The findings obtained in this work for all nanoparticles-based formulations in both 
respiratory cell lines are considered good indicators of biocompatibility. However, the 
evaluation of a biocompatibility profile demands the use of complementary assays to 
assess other aspects of cell response, which are certainly of importance to establish a final 
tendency. 
 
2.4.6. Intracellular SLN uptake studies 
It is well known that macrophages are predominantly involved in the uptake of 
nanoparticles, leading to their degradation. The rate of phagocytosis is largely determined 
by the physicochemical properties of the particle, such as size, surface modification, 
surface charge and hydrophobicity. Augmented particulate hydrophobicity is known to 
increase the uptake by forming hydrophobic interactions with the cell surface and, 
moreover, cationic surface charge is desirable as it promotes interaction of the 
nanoparticles with cells and, hence, increases the rate and extent of internalization [37, 
38]. When nanoparticles are administered in vivo, they are rapidly taken up by 
macrophages. This tendency of nanoparticles is an advantage in the treatment of 
intracellular infections involving this type of cells, such as TB. The main mechanism by 
which SLN are captured by phagocytic cells follows several steps: (i) stable adsorption 
onto the cell membrane, (ii) vesicle internalization through an energy-dependent 
mechanism, (iii) fusion of the endocytic vesicles with the particles and (iv) degradation of 
the nanoparticles by lysosomal enzymes, releasing the drug encapsulated within them 
[33]. In order to demonstrate that glyceryl dibehenate SLN and glyceryl tristearate SLN 
can be adopted as a platform for delivering anti-TB drugs in human macrophages, both 
formulations were incubated with PMA-differentiated human macrophage-like THP1 
cells. For this purpose, SLN containing the fluorescent label coumarin-6 were incubated 
with the previous cells at 0.75 mg/mL at 37ºC for 1 h and 24 h. Results showed SLN were 
efficiently internalized by these cells (Figure 2.7). Fluorescence microscopy was used to 
follow the intracellular trafficking of coumarin-6-labeled nanoparticles and their uptake 
by human THP1 cells. At 1 h after addition of the SLN to macrophages, 25.98.6% of 
RFB loaded-glyceryl dibehenate SLN and 6.30.9% of RFB loaded-glyceryl tristearate 
SLN were internalized in THP1 cells. As expected, this uptake was higher after 24 h of 
incubation, with 46.33.0% and 25.69.3% respectively for RFB loaded-SLN based 
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glyceryl dibehenate and glyceryl tristearate, indicating that nanoparticles are clearly taken 
up by macrophages. These uptake differences between glyceryl dibehenate and glyceryl 
tristearate SLN are related with particle sizes, since glyceryl dibehenate SLN (100 nm) 
have a smaller size than those of glyceryl tristearate (200 nm) and so they are more 
readily phagocytized [39]. Indeed, this high uptake is important, because, since M. 
tuberculosis is an intracellular parasite, the SLN formulations herein described are 
expected to be internalized by the macrophages where the acidic/enzymatic conditions 
inside the phagolysosome will be sufficient to release the drug from the nanoparticles and 
make it available to act upon the bacteria. 
 
 
Figure 2.7: Fluorescence micrographs of (A) glyceryl dibehenate and (B) glyceryl 
tristearate SLN uptake in macrophages. SLN were labeled with coumarin-6 (green, 
arrows), rhodamine phalloidin was used as a marker of actin (red) and nuclei were stained 
with DAPI dye (blue) (scale bar: 10 µm). 
 
2.4.7. In vitro RFB release studies from SLN 
To investigate the ability of the designed SLN to act as drug reservoirs, glyceryl 
dibehenate and glyceryl tristearate SLN were loaded with RFB, which is used for the 
treatment of mycobacterial infections caused by M. tuberculosis [40]. Release studies 
were performed using 0.1% of lung surfactant in the release medium with the purpose to 
mimic the lung environment as well as to increase RFB solubility in the release medium. 
Both in vitro RFB release profiles from SLN presented a drug release profile where 
almost all encapsulated RFB was released (97.41.3% for glyceryl dibehenate SLN and 
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95.61.7% for glyceryl tristearate SLN) over 24 h (Figure 2.8). The drug release from the 
nanoparticles appeared to have two components with an initial fast release of about 65% 
at the first sampling time of 30 min. This was followed by a slower exponential release of 
the remaining drug over the next 12 h. The rapid initial release of RFB was probably due 
to drug molecules which were adsorbed or close to the surface of SLN, as well as the 
large surface to volume ratio of the nanoparticles geometry [41]. Overall, upon addition 
of the nanosuspensions to the release medium, RFB partitioned rapidly into the release 
medium accounting for the “burst effect” observed. On the other hand, the exponential 
delayed release may be attributed to diffusion of the dissolved drug within the core of the 
nanoparticles into the dissolution medium. As all drug content was released within 12 h, 
these systems have great advantages for short-term drug release applications. 
 
 
Figure 2.8: Release profiles of RFB from (A) glyceryl dibehenate and (B) glyceryl 
tristearate SLN in 10 mM PBS pH 7.4 and 0.1% of lung surfactant, at 37°C (meanSD, 
n=3). 
 
The drug release kinetics was characterized by fitting the experimental data with the 
standard release equations (eq. 2.5–2.8). According to the r2 values in Table 2.2, the best 
fit for both types of SLN was with the Korsmeyer–Peppas model, which was applied as 
the mechanism of drug release and is used when more than one type of mechanism is 
involved. Both systems showed a n value smaller than 0.43 indicating that the release rate 
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was also significantly dependent on the rate of RFB diffusion (Fickian diffusion) through 
the crosslinked lipid networks. 
To tailor the release profiles to an appropriate efficiency for certain applications, it would 
be necessary to change the formulation of the liquid precursor (e.g. concentration of 
surfactants) to modify the structure of the particles in order to control drug release by 
increasing the structural complexity of the particles, namely, by the production of 
multilayer spherical systems where non-loaded layers may act as barriers to control the 
release of drugs immobilized in the inner layers. 
 
Table 2.2: Mathematical models and respective parameters (correlation coefficients and 
release constants) obtained from the fitting of the experimental data corresponding to a 
RFB release from: (A) glyceryl dibehenate SLN and (B) glyceryl tristearate SLN. 
 
Zero-order First-order Higuchi Korsmeyer-Peppas 
r
2
 
k0 
(µg/h) 
r
2
 k1 (h
-1
) r
2
 kH (h
-0.5
) r
2
 kKP (h
n
) n 
A 0.343 2.261 0.611 0.017 0.632 16.264 0.922 1.814 0.148 
B 0.196 1.716 0.363 0.009 0.434 13.074 0.759 1.895 0.082 
r
2
: determination coefficient;
 
k0: zero-order release constant; k1: first-order release 
constant; kH: Higuchi constant; kKP: Korsmeyer–Peppas constant; n: release mechanism 
exponent  
 
2.5. Conclusions 
Stable SLN formulations prepared with two different lipid compositions were optimized 
revealing high entrapment efficiencies of RFB close to the drug solubility in the molten 
lipids were obtained. The drug RFB was dissolved in the lipid matrix of the nanoparticles 
as shown by DSC analysis, while the formulations presented a remarkable physical 
stability, being able to endure temperature changes up to 90ºC, recovering their particle 
size and morphology. The nanoparticles were easily internalized by human monocytes, 
which is an important feature because M. tuberculosis is an intracellular parasite. After 
SLN incubation with lung cells, no evidence of acute cytotoxicity was observed, thus 
confirming that lipid nanoparticles are potential carrier systems for pulmonary delivery of 
anti-TB drugs. 
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Abstract 
Solid lipid nanoparticles (SLN) containing rifabutin (RFB), with pulmonary 
administration purposes, were developed through a technique that avoids the use of 
organic solvents or sonication. In order to facilitate their pulmonary delivery, the RFB-
loaded SLN were included in microspheres of appropriate size using suitable excipients 
(mannitol and trehalose) through a spray-drying technique. Confocal analysis microscopy 
showed that microspheres are spherical and that SLN were efficiently microencapsulated 
and homogenously distributed throughout the microsphere matrices. The aerodynamic 
diameters observed an optimal distribution for reaching the alveolar region. The dry 
powder’s performance during aerosolization and the in vitro drug deposition were tested 
using a twin-impinger approach, which confirmed that the microspheres can reach the 
deep lung. Isothermal titration calorimetry revealed that SLN had higher affinity for 
mannitol than for trehalose. Upon microsphere dissolution in aqueous media, SLN were 
readily recovered, maintaining their physicochemical properties. When these dry powders 
reach the deep lung, microspheres are expected to readily dissolve, delivering the SLN 
which, in turn, will release RFB. The in vivo biodistribution of microencapsulated RFB-
SLN demonstrated that the antibiotic achieved the tested organs 15 and 30 min post 
pulmonary administration. Their antimycobacterial activity was also evaluated in a 
murine model of infection with a Mycobacterium tuberculosis strain H37Rv resulting in 
an enhancement of activity against M. tuberculosis infection compared to non-treated 
animals. These results suggest that RFB-SLN microencapsulation is a promising 
approach for the treatment of tuberculosis.  
 
Graphical abstract 
 
Chapter 3 - Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery 
 
102 
 
This page was intentionally left blank. 
 
  
Chapter 3 - Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery 
 
103 
 
3.1. Introduction 
The lung is an attractive target for the treatment of respiratory diseases due to easy self-
administration of inhalable aerosols and direct delivery to the site of action [1]. 
Pulmonary administration is very interesting for locally treating pulmonary TB, which is 
the most common form of TB, since the alveolar macrophages host a large number of the 
bacilli [2]. Effective chemotherapy of TB involves daily oral administration of two or 
more drugs for a period of six months or longer [3]. Moreover, most orally delivered anti-
TB drugs currently in use fail to reach high drug concentrations in the lung, since drugs 
can be degraded before reaching their target site [4]. Hence, targeting drugs to the 
alveolar macrophages by inhalation may offer the advantage that the drug is administered 
directly to the site of action and, as a result, the lag time before onset of action is shorter. 
In addition, direct drug delivery to the lung could potentially lead to a reduction in the 
therapeutic dose, which could further reduce systemic concentrations and the incidence of 
adverse events and drug interactions [5]. 
Nanoparticles of different compositions have been proposed to deliver drugs to the lung 
epithelium, having marginal side effects compared to the free drug [2, 6, 7]. Among 
these, SLN can be produced without using organic solvents and can incorporate 
hydrophobic or hydrophilic drugs, thus fulfilling the requirements for an optimum 
particulate drug carrier system for the pulmonary route [8]. Although SLN have already 
been efficiently aerosolized, reaching the deep lung region [9], some instability 
phenomena common to nanosized systems, such as particle-particle interactions and poor 
delivery efficiency due to exhalation of low-inertia nanoparticles, could not be precluded. 
In previous studies dealing with polymeric nanoparticles intended for inhalation, their 
microencapsulation in micron-sized powder carriers using suitable spray-drying 
techniques has been proposed [6, 10]. This has resulted in improved handling and 
aerosolization of nanoparticles through enhanced powder stability and acquisition of 
aerodynamic properties that lead to an efficient lung delivery. In addition, inhalable 
powders have also demonstrated to be superior over their liquid counterparts with regard 
to enhanced absorption and bioavailability of active ingredients [11]. The so formed 
microparticles present a suitable daer, relating to particle aerodynamic behaviour and lung 
deposition. Aerosols with optimal properties must contain particles that are neither too 
small, risking exhalation, nor too large, which are likely to deposit in the upper airways. 
The optimal daer for reaching the alveolar region has been intended to be between 1 and 5 
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μm. [12]. Besides, the nanoparticle-containing microparticles must readily deliver the 
primary nanoparticles upon depositing in the lung interstitial fluid, which should retain 
their benefits as highly potent carriers for biopharmaceuticals [13, 14]. For this purpose, 
the spray-drying process typically employs a wide range of inert pharmaceutical 
excipients, which are approved by the regulatory authorities and act as drying adjuvants 
that protect the structural integrity of the nanoparticles, avoiding coalescence upon 
exposure to high temperature during the spray-drying process and during subsequent 
storage [14]. 
The aim of this study was to obtain microencapsulated SLN powders adequate for the 
pulmonary administration of the anti-TB drug RFB. Herein we report the preparation of 
two types of RFB-loaded SLN based on glyceryl dibehenate and glyceryl tristearate 
(biocompatible and biodegradable solid lipids exhibiting high m.p.). Thereafter, these 
SLN were microencapsulated in mannitol and trehalose microspheres by spray-drying to 
acquire adequate morphological and aerodynamic properties for lung deposition. 
Structural and aerodynamic characterization of these micro-powders loaded with SLN 
were performed using scanning electron microscopy (SEM), confocal laser scanning 
microscopy (CLSM) and aerodynamic sampling using a twin-impinger. Physical 
characterization of the powders was performed by isothermal titration calorimetry (ITC). 
SLN recovery from microspheres and RFB release from microencapsulated SLN were 
also assessed. In vitro antimycobacterial activity of RFB formulations was evaluated by a 
(3- (4,5-dimethylthiazol-2-yl) - 5 - (3-carboxymethoxyphenyl) - 2 - (4-sulfophenyl) - 2H -
tetrazolium) (MTS) reduction assay. The in vivo biodistribution profile of 
microencapsulated RFB-SLN was analyzed following 15 and 30 min post pulmonary 
administration. Their antimycobacterial activity was also evaluated in a murine model of 
infection with a M. tuberculosis strain H37Rv. 
 
3.2. Materials  
3.2.1. Chemicals 
RFB was acquired from CHEMOS GmbH (Germany). Glyceryl dibehenate was a kind 
gift from Gattefossé (France). Glyceryl tristearate, mannitol and D-(+)-trehalose 
dihydrate were purchased from Sigma-Aldrich (Spain). Tween 80 (polysorbate 80) was 
obtained from J. Vaz Pereira, S.A. (Portugal). Lung surfactant (Curosurf) was a 
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generous gift from Angelini Farmacêutica, Lda. (Portugal). PBS, pH 7.4 was acquired 
from Invitrogen. Bodipy 630/650-X was obtained from Molecular Probes 
(Netherlands). Purified water was obtained by inverse osmosis (Millipore, Elix 3) with a 
0.45 μm pore filter. Middlebrook 7H9 broth and 7H11 agar, BACTO Middlebrook and 
albumin-dextrose-catalase enrichments were obtained from Difco Laboratories (Detroit, 
USA). Reagents for the MTS assay were purchased from Promega (WI, USA). All other 
reagents were of analytical grade and were used without further purification. 
 
3.2.2. Animals 
BALB/c mice (6–8 weeks old, 25-30 g) were obtained from the Gulbenkian Institute of 
Science (Oeiras, Portugal). The animals were kept under standard hygiene conditions, fed 
commercial chow and given acidified drinking water ad libitum. All animal experiments 
were carried out with the permission of the local ethical committees of the Faculty of 
Pharmacy and of the Institute of Molecular Medicine in accordance with the EU Directive 
(2010/63/UE) and Portuguese laws (DR 113/2013, 2880/2015 and 260/2016).  
 
3.2.3. Mycobacterial strains 
For in vitro studies, the M. avium strain DSMZ 44157 from Leibniz-Institute, Germany 
was used. For in vivo studies, the M. tuberculosis strain H37Rv was used. Quantification 
of inocula was performed as described previously by Gaspar et al. [15].  
 
3.3. Methods 
3.3.1. Preparation of RFB-loaded SLN 
RFB-loaded glyceryl dibehenate and glyceryl tristearate SLN were prepared using a hot 
HSH, as previously described in Chapter 2, section 2.3.2..  
 
3.3.2. Characterization of RFB-loaded SLN 
Size and zeta potential of RFB-loaded SLN were characterized by PCS using a Zetasizer 
Nano S and Z (Malvern Instruments, UK) respectively, as reported in Chapter 2, section 
2.3.3.1.. Briefly, samples were kept in polystyrene cuvettes and the measurements were 
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made at 25.00.1°C after their appropriate dilutions (1:100) with filtered (0.45 μm) 
purified water and, then, they were analyzed at a 173° scattering angle. Surface charge 
was determined through particle mobility in an electric field to calculate the zeta potential 
of SLN. For that, samples were placed in a specific cuvette where a potential of 150 mV 
was established after their appropriate dilution with filtered purified water. Particle size 
distribution and morphology were also confirmed by atomic force microscopy (AFM). 
Noncontact AFM in air was performed with a XEI-100 instrument from Park Systems, 
operating with decoupled XY (50 Å ~50 μm2) and Z-scanners (12 μm). SLN formulations 
were diluted (1:250) in Milli-Q water and deposited on freshly cleaved muscovite mica 
for 20 min. After subsequent washes, the samples were allowed to air dry at room 
conditions. Samples were mounted on top of magnetic discs and imaged by using 
microfabricated crystal silicon probes with a spring constant of 40 N/m and a resonant 
frequency of 300 kHz (ACTA, AppNano). The XYZ-accuracy was checked once a day 
by means of a silicon grating (TGXYZ02, from Mikromasch), ensuring a nominal height 
deviation lower than 2% at the highest scan size. To eliminate imaging artifacts, the scan 
direction was varied, ensuring a true image. The images were obtained from at least three 
macroscopically separated areas on each sample. All images were processed using 
procedures for plane-fit and flatten in the WSxM 4.0 Develop 11.4 software50 without 
any filtering. Surface topography and roughness were determined from 10 Å ~10 µm
2
 
images. All experiments were carried out at room temperature. 
 
3.3.3. Determination of association efficiency and drug loading of RFB 
The EE and DL of RFB were also determined, as previously reported in Chapter 2, 
section 2.3.3.2.. Briefly, non-associated RFB was separated from the SLN by size 
exclusion chromatography on Sephadex G-25/PD-10 columns. The amount of RFB 
associated to SLN was determined after dissolving the nanoparticles with acetonitrile, 
which promoted the precipitation of the lipid phase. The encapsulated RFB remained in 
the supernatant, which was separated by centrifugation (30 min at 12300 rpm). The 
amount of drug was measured by UV-Visible spectrophotometry, at λmax of 320 nm, in a 
microplate spectrophotometer reader (FLUOstar Omega, BMGLabtech, Germany). The 
supernatant of unloaded nanoparticles was used as basic correction. All experiments were 
carried out in triplicate (n=3). The RFB EE and DL were calculated according to the 
following equations: 
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                                                                                        (Eq. 3.1) 
      
           
      
                                                                                        (Eq. 3.2) 
where Winitial drug is the weight of the drug used, Wloaded drug is the weight of encapsulated 
drug that was detected in the supernatant after SLN purification, solubilization and 
centrifugation and Wlipid represents the weight of the lipid vehicle. 
 
3.3.4. Preparation of dry powders containing SLN 
The RFB-SLN dispersions were suspended in aqueous spray-drying excipient solutions, 
at a 1:3 SLN:excipient mass ratio, containing 20% and 22% w/v of mannitol and 15% and 
17% w/v of trehalose for glyceryl dibehenate and glyceryl tristearate SLN, respectively. 
Dry powders were obtained by spray-drying the suspensions using a laboratory-scale 
spray-dryer (Büchi Mini spray-dryer, B-290, Switzerland). The spray-drying conditions 
were: two fluids external 0.7 mm nozzle, feed rate varied from 2.3 to 8.5 mL/min 
(depending on the spray-dried suspension), air flow of 400 L/h and Tinlet of 1032°C, 
resulting in an Toutlet between 63°C and 70°C. The aspirator rates were kept constant at 
100% and 70% for SLN suspensions in mannitol and trehalose, respectively. The 
produced spray-dried powders were collected and stored in a dessicator at room 
temperature until further use. For CLSM studies, the SLN and excipients were previously 
stained with fluorescent labels to allow visualization by confocal microscopy. SLN were 
labeled with coumarin-6 during their formulation (40 μL of a coumarin-6 solution was 
added to the melted lipid). Mannitol and trehalose were stained with the fluorophore 
Bodipy, which was added to the spray-drying excipient solution (500 μL of a 1 mg/mL 
solution of Bodipy in DMSO) and kept under magnetic stirring for 2 h before spray-
drying. The spray-drying production yields (PY) were calculated by gravimetry, 
comparing the initial total solids amount with the resultant powder amount after spray-
drying, as follows: 
       
                                                         
                                                           
                       Eq. (3.3) 
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3.3.5. Characterization of microspheres size, morphology and moisture content 
Particle size and morphology of the spray-dried powders were assayed using SEM. The 
dry powder samples were mounted on an aluminium stub using a double-side adhesive 
tape, covered with a 200 nm thick gold-palladium film using an Emitech K550 (London, 
UK) sputter coater and analyzed using a Zeiss Evo LS15 (UK) microscope, working at an 
accelerating voltage of 20 kV and at various amplifications. The SEM micrographs were 
used to calculate the mean particle size, which was estimated as the Feret’s diameter and 
measured as the mean of 300 particle measurements (n=300) [6]. 
The moisture content of the spray-dried powders was determined by calculating the loss 
of weight upon drying from 25°C to 105°C, using an electronic moisture balance 
(Shimadzu, EB-280 MOC, Japan), according to the Ph. Eur. (2.2.32. Loss on drying). The 
percentage of the initial weight that was lost during the heating process was ascribed to 
the moisture content of the powders. Measurements were carried out in triplicate. 
 
3.3.6. Structural characterization of SLN-loaded microspheres using CLSM 
The internal structures of SLN-loaded microspheres were observed using CLSM with an 
AOBS SP5X microscope (Leica GmbH, Germany), which collects images using different 
detectors for fluorescent signals upon irradiation with a white light laser. Small aliquots 
of the dry powders comprised of coumarin-6-labelled SLN encapsulated in Bodipy-
labelled excipient microspheres (mannitol and trehalose) were placed on a glass slide, and 
a drop of immersion oil was added to avoid particle displacement during viewing. Laser 
excitation wavelengths of 470 and 633 nm were used to scan the powder, and fluorescent 
emissions from coumarin-6 (emission =480-555 nm) and Bodipy (emission =650-700 
nm) were collected using separate channels. Images were acquired with a magnification 
of 63X, using an oil immersion objective (HCX PL APO CS). The gray scale images 
obtained from each scan were pseudo-coloured green (coumarin-6) and red (Bodipy) 
and overlapped afterwards (LAS AF, Leica Confocal Software, Leica GmbH, Germany) 
to obtain a multicoloured image. 
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3.3.7. Determination of the dry powders flow properties  
The real density (real ) of the dry powders was measured using a helium pycnometer 
(AccuPyc 1330, Micrometrics Ltd, Dunstable, UK) at room temperature (n=3). The 
apparent density or tapped density (apparent ) was determined under defined conditions 
of the apparent volumes, before and after settling (Stav 2003, JEF Germany). The latter 
was obtained by measuring the volume of a known weight of the dry powder in a 10 mL 
test-tube after mechanical tapping (1250 taps), according to the Ph. Eur. (2.9.34. Bulk 
density and tapped density of powders) (n=3). Using density measurements, it was 
possible to calculate the Carr's index and Hausner ratio, which are considered as 
appropriate methods of evaluating flow properties of solids. The daer, Carr’s index and 
Hausner ratio of spray-dried particles were calculated based on the following equations 
3.4, 3.5 and 3.6, respectively: 
              
  
   
                                                                                             (Eq. 3.4) 
where dgeo is the particle geometric diameter, ρs is 1 g/cm
3
, ρe is the effective particle 
density in the same unit as ρs and λ is the dynamic shape factor of the particle. This shape 
factor is theoretically defined as 1 for spherical particles. 
                 
            
  
                                                                             (Eq. 3.5) 
              
  
  
                                                                                                  (Eq. 3.6) 
where Vo is the unsettled apparent volume and Vf is the final tapped volume. 
 
3.3.8. Isothermal titration calorimetry of SLN and spray-drying excipients 
Binding studies between SLN and spray-drying excipients were performed using a VP-
ITC titration microcalorimeter from MicroCal Inc., (Northampton, MA) with a cell 
volume of 1.436 mL at 25°C. Samples were degassed in a ThermoVac system (MicroCal) 
prior to use. The sample cell was filled with the sugar solution containing either mannitol 
(1160 or 1280 mM when injecting glyceryl dibehenate and glyceryl tristearate SLN, 
respectively) or trehalose (397 or 450 mM) and the reference cell with a buffer solution. 
The SLN solution (64.7 and 31.4 mM for glyceryl dibehenate and glyceryl tristearate, 
respectively) was introduced into the thermostated cell by means of a syringe and stirred 
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at 286 rpm, which ensured rapid agitation without foaming on solutions. Each titration 
consisted of an initial 2 μL injection (neglected in the analysis) followed by 55 
subsequent 5 μL injections programmed to occur at 400 s intervals, sufficient for the heat 
signal to return to the baseline. The results of the ITC experiments, in terms of the heat of 
injection normalized by the SLN concentration added per each injection (Q*), were 
presented as a function of the SLN to excipient molar ratio. The heats of dilution from 
titrations of SLN suspension into buffer were subtracted from the heats obtained from 
titrations of the SLN suspensions into the sugar solution to obtain the net binding heats. 
All experiments were carried out at least in duplicate and the reproducibility was within 
3%. Raw data of binding were analyzed as described previously [16] on the basis of a 
set of two identical binding sites model by using the Affinimiter software. The two 
identical binding sites model employs the following fitting equation that incorporates 
Langmuir isotherm binding equilibria for two independent types of association, where Q* 
is the heat per injection, ni the binding stoichiometry, Θi the fractional sites of 
macromolecule occupied by ligand, M the macromolecule concentration, ΔHi the enthalpy 
of interaction and V the cell volume. 
                                                                                                 Eq. (3.7) 
where the sub-indices 1 and 2 stand for the two sets of sites. 
One can solve for Θ1 and Θ2 using the equilibria equations for binding constants K1 and 
K2, with X being the total concentration of ligand and [X] the concentration of unbound 
ligand: 
    
  
         
    and       
  
         
   with                             Eq. (3.8) 
To reach an accurate fit of all floating parameters to these data, multiple assays were 
performed starting from random initial parameters. The same values were reached at the 
minimum χ2 regardless of the values of initialization. Finally, changes in free energy 
ΔGi and entropy of binding ΔSi for each site were calculated from the fitted parameter 
values according to the following standard, thermodynamic relations: 
                                                                                              Eq. (3.9) 
where Rg is the universal gas constant. 
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3.3.9. In vitro deposition of dry powders using a twin-stage liquid impinger 
Hard capsule shells made of hydroxypropyl methylcellulose (HPMC) were manually 
filled up with 40.00.2 mg of each dry powder and introduced in a Rotahaler device. 
The aerodynamic characteristics of inhalable complexes were assessed through a TSLI 
(TSI, Copley Instruments, UK). Briefly, the TSLI equipment was divided in four 
compartments, corresponding to: (i) device+capsules (D+C); (ii) mouth+throat (M+T); 
(iii) medium compartment (MC) and (iv) lung. According to the Ph. Eur. (2.9.18. 
Preparations for inhalation: aerodynamic assessment of fine particles, Aparatus A – glass 
impinger), 7 and 30 mL of ethanol were added to MC and lung compartments, 
respectively. The content of each capsule was discharged through a flow rate of 605 
L/min during 15 s (5 s3). The lower impingement chamber of the apparatus is so 
designed at an air flow rate of 60 L/min and an effective mean daer particle cut-off size of 
6.4 μm. Indeed, drug deposition in this chamber, which simulates the alveoli, was of 
interest to us. The TSLI was disassembled and all the compartments were carefully 
washed with ethanol and separately collected to conical flasks up to final volume of 50 
mL. Samples were filtered and RFB content in each compartment determined by 
spectrophotometry in a microplate reader (FLUOstar Omega, BMG Labtech, Germany) at 
320 nm (n=3).  
 
3.3.10. SLN recovery from microspheres  
The spray-dried powders were incubated in 10 mM isotonic PBS pH 7.4 with 0.1% of 
lung surfactant (Curosurf) under mild magnetic stirring at 37°C for 90 min. After this 
time, the mean particle size and zeta potential of the recovered SLN were analyzed using 
a Zetasizer Nano S and Z (Malvern Instruments, UK), respectively. The morphology was 
observed by TEM. The average particle size was analyzed by PCS and the surface charge 
was determined through particle mobility in an electric field to calculate the zeta potential 
of SLN, as described in detail in section 3.3.2.. On the other hand, the morphological 
analysis of SLN after being recovered from microspheres was conducted by TEM. 
Briefly, the samples were stained with phosphotungstic acid at 2% (w/v) during 2 min 
and fixed on racks of copper covered by a membrane of carbon for observation. 
Afterwards, the samples were analyzed on a JEOL Microscopy (JEM 2010, Japan) at 120 
kV and the images were acquired through a Gatan Orius camera. 
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3.3.11. In vitro RFB release from microencapsulated RFB-loaded SLN 
The release of RFB was carried out by incubating the SLN (0.75 mg) and the dry 
powders (1005 mg) in 1 mL of a medium comprised by 10 mM isotonic PBS pH 7.4 
with 0.1% of lung surfactant (Curosurf), under horizontal shaking (300 rpm) at 37°C. 
At appropriate time intervals, individual samples were taken and centrifuged in a high 
speed centrifuge (Allegra 64R centrifuge, Beckman Coulter) at 30000g for 30 min at 
4°C. The amount of released RFB was evaluated in the supernatants by 
spectrophotometry in a microplate reader (FLUOstar Omega, BMG Labtech, Germany) at 
320 nm (n=3).  
 
3.3.12. In vitro activity of RFB formulations against M. avium strain DSMZ 44157 by 
MTS assay  
The susceptibility of M. avium strain to RFB formulations was assessed by adding 10 µL 
of inocula at a concentration of 10
9
 colony-forming units (CFU)/mL to 96 well plates 
containing the formulations diluted in 7H9 broth with albumin-dextrose-catalase 
supplement (six replicate samples). RFB formulations under study, at a concentration of 
10 µg/mL, were added to the first well making serial two-fold dilutions up to 12 wells 
with 7H9 broth supplemented. Wells only with the supplemented 7H9 broth were used as 
negative controls. After inoculation, the plates were incubated for 10 days at 37ºC and 5% 
CO2 in a humidified atmosphere. After the incubation period, 20 µL of the MTS was 
added to all wells, plates were incubated at 37ºC for 3 h and the absorbances were 
measured at 490 nm in a microplate reader Model 680 (Bio-Rad, CA, USA).  
 
3.3.13. In vivo fate of RFB formulations 
3.3.13.1. Biodistribution studies 
Mice received inhaled RFB formulations using a simple apparatus based on a 15 mL 
centrifuge tube where the dry powder was inserted. A small hole was done in the bottom 
of the tube allowing the powder delivery to mouse. A manual pump connected to the 
upper part of the tube allowed the production of a turbulent air stream for fluidizing the 
powder. Each mouse was restrained in a 50 mL tube where a small hole in the bottom was 
done. This lower part of the 50 mL tube was connected to the 15 mL tube using a baby 
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bottle teat. The tested formulation was RFB-glyceryl dibehenate SLN microencapsulated 
in mannitol and RFB-mannitol microspheres as control. Forty mg of each dry powder 
were put in the device and each animal received the formulation by inhalation during 2 
min. Fifteen and 30 min following administration (four animals per time point), mice 
were anaesthetised with isoflurane, blood was collected from the retinal blood vessels 
into heparinised tubes and stored at -30°C. Animals were then, sacrificed by cervical 
dislocation and lung, spleen and liver were removed and stored at -70°C. 
 
3.3.13.2. RFB extraction from blood and tissues 
RFB levels in blood and tissues were determined by high-performance liquid 
chromatography (HPLC) after an extraction procedure described in Gaspar et al. [17]. 
This quantification method was validated showing sensitivity and precision adequate to 
the concentration range used in this study. The linearity was established between 5.60 and 
0.25 µg/mL with a 5% relative standard deviation. The quantification and detection limits 
were 0.380 and 0.125 µg/mL, respectively, with 95% of confidence. Briefly, 500 µL of 
blood were mixed with 250 µL of potassium dihydrogen phosphate buffer 0.05 M and 
sodium acetate 0.05 M (pH adjusted to 4.0 with acetic acid) and extracted twice with 1 
mL of a dichloromethane:isooctane mixture (2:3, v/v) under stirring at room temperature 
(15 min), followed by a centrifugation step at 1200×g for 10 min (Beckman Instruments, 
Inc.). Liver, lung and spleen tissues were thawed and aliquots of ca. 100 mg were 
weighed out for each sample and extracted twice with 2300 µL of 
dichloromethane:isooctane mixture by mechanical shaking for 30 min at room 
temperature, followed by a centrifugation step at 1200×g for 10 min in a centrifuge. The 
organic extracts were pooled and evaporated to dryness under nitrogen. The residue was 
dissolved in 500 µL of mobile phase, filtered and then injected into the HPLC system. To 
determine the efficiency of the extraction procedures, a known amount of RFB was added 
to blood and solid tissues removed from mice that had not received RFB administration 
and then submitted to the same above-mentioned extraction protocol. 
 
3.3.13.3. Determination of RFB by HPLC 
Plasma and tissue levels of RFB were determined by HPLC according to Gaspar et al. 
[17]. Briefly, the HPLC system consisted of a System Gold (Beckman Instruments, Inc.), 
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a Midas Spark 1.1 autoinjector and a Diode-Array 168 detector (Beckman Instruments, 
Inc.). The wavelength of this detector was set to 275 nm. The analytical column was a 
LiChroCART® (250-4.6), Purospher® Star RP-8 (5 µm) (Merck, Darmstadt, Germany). 
The mobile phase consisted of potassium dihydrogen phosphate 0.05 M and sodium 
acetate 0.05 M (pH adjusted to 4.0 with acetic acid)-acetonitrile (53:47, v/v) with a flow 
rate of 1 mL/min at 25°C. 
 
3.3.13.4. Preparation of standard solutions for HPLC 
Standard solutions of RFB (100 µg/mL) were prepared by weighing the appropriate 
amount of bulk RFB and dissolving it in mobile phase. Further stock solutions were made 
by diluting the initial stock standard solutions with mobile phase. Calibration curves, 
ranging from 0.25 to 5.0 µg/mL with a loop of 100 µL, were used for the quantification of 
RFB in plasma and tissues. A stock solution of 1.0 µg/mL was stored at -30°C and a 
sample of this stock solution was always injected together with the analyzed samples to 
verify the precision of the obtained concentrations of RFB in samples and controls from 
their peak area concentration response. 
 
3.3.14. Biological evaluation in a M. tuberculosis infection model: experimental 
infection, treatment and bacterial counts 
BALB/c mice were injected intravenously with 5×10
4 
CFU of M. tuberculosis H37Rv. 
Treatment started 2 weeks after infection induction and mice received the tested 
formulation (RFB-glyceryl dibehenate SLN microencapsulated in mannitol) using the 
same simple apparatus described in section 3.3.13.1.. Forty mg of dry powder were put in 
the device and each mice received the formulation by inhalation during 2 min. 
Administrations were performed in a total number of 10 for two weeks. Two days after 
the last administration, mice were sacrificed, liver, spleen and lung were aseptically 
removed, homogenized, serially diluted in 0.04% Tween 80 and plated onto 
Middlebrook 7H11 agar medium supplemented with OADC for CFU countings. One 
group of mice infected and non-treated was sacrificed at the beginning of treatment and 
another one at the end. The CFU counts in liver, spleen and lung were analyzed. Colonies 
were counted after 21 days of incubation at 37ºC with 5% CO2. From CFU counts, the 
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growth index was calculated using the difference between the log10 CFU at the end of 
treatment and the log10 CFU at the beginning of treatment [18]. 
 
3.3.15. Statistical analysis  
Statistical analysis of the experimental data was performed using a one-way analysis of 
variance (one-way ANOVA) and differences between groups were tested by a one-way 
ANOVA with Dunnet’s post hoc test with GraphPad Prism version 6.0 (GraphPad 
Software, San Diego, CA). Data were expressed as meanSD or 95% confidence interval. 
A p<0.05 value was considered significant. All data are shown as meanSD. 
 
3.4. Results and Discussion 
3.4.1. SLN formulation and characterization 
SLN have emerged as an alternative to liposomes and polymeric nanoparticles mainly due 
to their easy scale-up, good stability and biocompatibility, while providing drug 
protection and sustained release [8]. Herein, two different SLN formulations loaded with 
RFB were prepared using different lipids (glyceryl dibehenate and glyceryl tristearate), 
and Tween 80 as the surfactant component, using a hot HSH technique, as previously 
described in Chapter 2. Both SLN formulations presented particle size distributions 
within the nanometer range (1085 nm for RFB-glyceryl dibehenate SLN and 1917 nm 
for RFB-glyceryl tristearate SLN) with suitable polydispersity index values (< 0.2). 
Furthermore, negative zeta potential values (ca. -18 mV) and high EE were obtained for 
both formulations (89.95.1% and 81.09.6% for glyceryl dibehenate and glyceryl 
tristearate SLN, respectively). Regarding DL results, the obtained values were 9.00.5% 
for glyceryl dibehenate SLN and 6.00.7 for glyceryl tristearate SLN.  
Concerning AFM analysis of RFB-loaded SLN, the microphotographs showed isolated 
discoid structures, revealing a spherical appearance of both types of SLN. A detailed 
inspection of the cross-section profiles (Figure 3.1A) showed the diameter of the RFB-
SLN corresponds to the width of the peak at the base of the graphic. The regular trace of 
the graphs indicates that particles present low surface roughness. After measuring the 
width from each cross-section, a width frequency count histogram (Figure 3.1B) was 
built. The results acquired from the width histogram, after applying the Gaussian model, 
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showed that RFB-SLN are homogenous formulations, with similar size distinguishable 
subpopulations with similar average cross-sectional widths. Overall, particle sizes 
obtained using AFM images are similar to those established from the PCS analysis. The 
full characterization of these SLN had been reported in Chapter 2. 
 
 
Figure 3.1: AFM images of the optimized RFB-glyceryl dibehenate and RFB-glyceryl 
tristearate SLN: (A) cross-section height profiles and (B) histograms of width frequency 
counts performed to quantitatively measuring the width of the particles. 
 
3.4.2. Dry powder preparation and characterization 
Pulmonary administration of therapeutic SLN is an attractive concept. However, their 
direct aerosolization may result in poor delivery efficiency due to exhalation of the low-
inertia nanoparticles [19-21]. The inclusion of nanoparticles in a microparticulated system 
became a promising alternative to deliver them to the  deep lung [6, 10], while avoiding 
the stability problems of liquid formulations. In this context, previously optimized RFB-
Chapter 3 - Microencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery 
 
117 
 
loaded SLN were microencapsulated using a spray-drying process with two different inert 
and FDA-approved excipients, the polyol mannitol and the disaccharide trehalose, at a 1:3 
SLN:excipient ratio. The used excipients are known to enhance aerosolization 
performance, as well as to reduce moisture content. The SLN microencapsulation process 
was performed in a one-step spray-drying process after an initial screening of different 
SLN/excipient mass ratios, excipient concentrations and spray-drying conditions, seeking 
for the production of dry powders with the most suitable characteristics for pulmonary 
delivery. Hence, Tinlet, which in turn determines Toutlet, needs to be higher than the boiling 
point of water to evaporate the excipient drops but it cannot be too high in order to avoid 
SLN melting. So, Tinlet was established to be 103°C. In addition, a screening of spray-
drying conditions (e.g., aspirator and pump) using several mannitol and trehalose 
concentrations indicated that the optimum excipient concentration for glyceryl tristearate 
SLN (22% and 17% w/w for mannitol and trehalose, respectively) was higher than those 
used for glyceryl dibehenate SLN (20% and 15% w/w for mannitol and trehalose, 
respectively). This is due to the fact that glyceryl tristearate is a lipid that presents a lower 
m.p. than glyceryl dibehenate and thus, SLN based on glyceryl tristearate require a larger 
quantity of excipient to protect them from the high temperatures during the spray-drying 
process. 
The spray-drying processes presented acceptable PY values (approximately 50%, Table 
3.1) for both SLN, in line with data reported elsewhere for spray-drying using similar 
excipients [6, 11]. It should be emphasised that lab-scale spray-drying processes typically 
present lower PY values – in comparison to large-scale spray-drying processes – due to 
higher wall deposits, since air residence times and radial distances from the atomiser to 
the drying chamber wall are shorter [22].  
Successful delivery of inhaled particles is governed by the deposition pattern. This is 
mainly controlled by particle size and density that strongly influence the dispersion and 
sedimentation properties of the powder [23, 24]. The daer along with the densities (real  
and apparent ) and Feret's diameters of the dry powders are depicted in Table 3.1. The 
microspheres’ daer (between 4.33 and 5.16 m) and densities (real  of approximately 1.5 
g/cm
3
 and tap  < 0.6 g/cm3) are within the optimal particle range for deposition in the 
deep lung. Similar results were obtained by Grenha et al. [6] and Al-qadi et al. [25] for 
systems consisting in microencapsulated chitosan nanoparticles for pulmonary 
administration of insulin.  
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The Carr’s index and the Hausner ratio, which can be used as indirect measures of the 
interparticulate forces within each powder, were calculated from the poured and apparent 
 using equations 3.5 and 3.6 (above), and are also listed in Table 3.1. According to the 
results, all formulations presented high Carr’s index (≥20) and Hausner ratio (≥1.35) 
values, predicting poor flowability of powders according to Ph. Eur. (2.9.36. Powder 
Flow). However, despite being extensively used to predict the quality of powders 
regarding flowability and deposition, precaution must be taken during the interpretation 
of Carr’s index and Hausner ratio because it has been reported that microcapsules 
prepared by spray- and freeze-drying may have poor or very poor flowability, probably 
due to some residual moisture content and their small size [26, 27].  
 
Table 3.1: Physical and aerodynamic properties of SLN-loaded dry powders: glyceryl 
dibehenate SLN microencapsulated in mannitol (A), glyceryl tristearate SLN 
microencapsulated in mannitol (B), glyceryl dibehenate SLN microencapsulated in 
trehalose (C) and glyceryl tristearate SLN microencapsulated in trehalose (D) (meanSD, 
n=3). 
Dry 
Powders 
Process 
yield 
(%) 
Feret’s 
diameter 
(μm, n=300) 
Real 
density 
(g/cm
3
) 
Apparent 
density 
(g/cm
3
) 
Aerodynamic 
diameter 
(μm) 
Carr’s 
index 
(%) 
Hausner 
ratio 
Moisture 
residual 
content 
(%) 
A 60.52.5 4.871.61 1.470.00 0.620.01 4.750.52 38.74.6 1.60.1 0.570.02 
B 47.01.1 5.541.79 1.460.00 0.590.01 5.160.88 38.30.6 1.60.0 0.010.01 
C 52.47.0 4.751.10 1.460.00 0.480.02 4.560.75 40.31.5 1.70.0 1.670.04 
D 56.42.5 4.501.60 1.500.00 0.450.04 4.330.81 36.03.0 1.60.1 1.660.05 
 
Regarding the moisture content of the powders, a factor that has a major impact on it is 
the Toutlet during spray-drying, whereby a lower moisture content is associated to a higher 
Toutlet value [28]. In this study, the obtained Toutlet values were ca. 61°C and 56°C for the 
microencapsulation process of glyceryl dibehenate and glyceryl tristearate SLN in 
mannitol and 65°C and 67°C for the spray-drying of glyceryl dibehenate and glyceryl 
tristearate SLN in trehalose microspheres. However, a correlation between the residual 
moisture content and the Toutlet was not found. The differences in moisture contents of the 
spray-dried powder can be related to the excipient properties, as reported elsewhere [28]. 
The low moisture content of the spray-dried mannitol particles was explained by their 
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crystalline state. In addition, this compound possesses a low MW and a good drying 
aptitude contrarily to trehalose which is characterized by a high MW [28]. 
The shape and morphology of particles produced by spray-drying are mainly determined 
by the rate of droplet evaporation and the composition [28]. Figure 3.2 shows the 
morphology of SLN-loaded mannitol and trehalose microspheres. In general, 
microspheres had a spherical shape with well-defined limits, although some mannitol 
microspheres showed a slightly convoluted morphology (Figure 3.2A and B).  
 
 
3.4.3. Structural characterization of SLN-loaded microspheres using CLSM  
The application of CLSM permitted elucidating the microsphere structure and the SLN 
distribution within the microspheres, using double fluorescent labelling (i.e. green 
coumarin-6 for SLN and red Bodipy for the spray-drying excipient). According to the 
images depicted in Figure 3.3, glyceryl dibehenate and glyceryl tristearate SLN 
 
Figure 3.2: SEM micrographs of dry powders: mannitol microspheres containing (A) 
glyceryl dibehenate SLN and (B) glyceryl tristearate SLN, and trehalose microspheres 
containing (C) glyceryl dibehenate SLN and (D) glyceryl tristearate SLN (scale bar: 20 
µm).  
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formulations stained with coumarin-6 were efficiently incorporated into the mannitol and 
trehalose microspheres obtained by spray-drying process, being homogenously 
distributed throughout the matrix of both types of microspheres. 
  
 
Figure 3.3: Confocal imaging of dry powders: mannitol microspheres containing (A) 
glyceryl dibehenate SLN and (B) glyceryl tristearate SLN and trehalose microspheres 
containing (C) glyceryl dibehenate SLN and (D) glyceryl tristearate SLN. SLN were 
labeled with coumarin-6 (green channel) and excipients were stained with Bodipy (red 
channel) (scale bar: 5 µm). 
 
These matrix type structures are different from those obtained by Grenha et al. [29] and 
Al-qadi et al. [25] after the incorporation of chitosan nanoparticles in mannitol 
microparticles, which resulted in microcapsule-like structure consisting of a mannitol 
matrix containing the nanoparticles, which is surrounded by an outer mannitol shell. This 
shell around the matrix was not observed in the present study. It may be hypothesized that 
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these structural differences may happen due to two factors. First, Tinlet was different in 
both studies, in the current work it was 103°C, while in Grenha et al. and Al-qadi et al. 
studies was 170°C. So, this high Tinlet allowed a high drying ratio of mannitol molecules 
in microspheres’ shell. On the other hand, the used excipient concentrations were also 
different in both studies, being higher in the present work and, consequently, with a 
higher viscosity solution. Thus, water molecules had more difficult to diffuse during the 
drying step, while in Grenha et al., the excipient solution was less concentrated and 
excipient molecules had a high trend to follow the water diffusion to out of the particles, 
remaining at the microspheres’ shell after drying process. 
 
3.4.4. Determination of SLN binding affinity to microspheres by ITC 
As commented previously, the spray-drying process of SLN with the two excipients, 
mannitol and trehalose, led to the formation of microspheres with distinct morphological 
particularities. Hence, to gain further knowledge about the origin of such differences, the 
nature of the interactions established between SLN and the excipients used in the spray-
drying process was investigated using ITC. This technique enables to probe the 
thermodynamics of nanocarrier-excipient interactions, which are quantitatively measured 
as a change in the system energy triggered by molecule binding/dissociation, 
perturbations of the solvent around the binding site, by structural changes in the target 
binding site and/or ligand binding mode. All alterations in the system’s thermodynamic 
parameters, including the binding affinity/dissociation constants at a given temperature, 
reaction stoichiometry, as well as enthalpic and entropic contributions to the binding are 
evaluated [30]. The association of SLN mannitol and trehalose was studied by titration of 
SLN suspensions onto each excipient solution at the same concentrations used in the 
spray-drying process. Figure 3.4 shows the net enthalpy of injection of SLN into the 
excipient solution (after subtraction of the heat evolved after the titration of SLN 
suspension into water) as a function of the SLN/excipient molar ratio for both types of 
SLN. The inset in Figure 3.4C shows the raw enthalpies of titration of glyceryl tristearate 
onto mannitol and water. 
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Figure 3.4: Heats of interaction of glyceryl dibehenate SLN with (A) mannitol and (B) 
trehalose and glyceryl tristearate SLN with (C) mannitol and (D) trehalose solutions. Each 
dot on the curve corresponds to the heat of reaction following 2 µL injection every 400 s 
at 25°C (cell volume=1.436 mL). The solid lines represent the fitting to experimental 
data. 
 
In the case of mannitol (Figures 3.4A and C), the enthalpy of interaction (Hi
i
, the 
superscript denoting the binding site) with SLN is rather more negative than that of 
trehalose (Figures 3.4B and D), and hence the complexation process is exothermic and 
becomes progressively less negative as the SLN/mannitol molar ratio increases, as 
observed for other systems such as protein-drug and polyelectrolyte-polyelectrolyte 
systems [31]. The negative Hi
i
 values can be originated from extensive hydrogen 
bonding network formation between fatty acids comprising both types of SLN and 
hydroxyl groups of mannitol. Increase in SLN concentration leads to a progressive 
increase of Hi
i
 (less exothermic) due to surface dehydration of SLN and excipient 
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molecules upon mutual interaction, although contributions from a certain SLN charge 
shielding and excipient’s molecular rearrangements upon excipient adsorption onto SLN 
surfaces could not be neglected. Finally, a plateau region is reached which corresponds to 
simple SLN dilution effects at molar ratios ca. 0.0025 and 0.005 for glyceryl tristearate 
and glyceryl dibehenate SLN, respectively.  
On the other hand, titrations of SLN into trehalose solution (Figures 3.4B and D) led to a 
different profile. There exists firstly a progressive exothermic decrease in Hi
i
 at low 
SLN/trehalose molar ratios until reaching an exothermic minimum (at ca. 0.0055 for both 
types of SLN) followed by an additional averaged endothermic event leading to less 
negative Hi
i
 values. In this case, a plateau region is not observed probably because this 
would take place at larger SLN/trehalose molar ratios exceeding those here analyzed 
which reproduce the concentrations used in the spray-drying process, as mentioned 
above. The first exothermic decrease and subsequent minimum can be associated to 
dipole-dipole interactions between water molecules oriented favourable on adjacent SLN 
thanks to the presence of trehalose molecules at low SLN concentrations, as also 
suggested for other systems [32]. In contrast, subsequent addition of SLN would lead to 
an enhancement of trehalose and SLN dehydration to promote extensive trehalose binding 
to all injected SLN favouring mutual interactions, giving to progressive larger Hi
i
 
values. The potential contribution of hydrophobic interactions between disaccharide rings 
and conformational rearrangements of trehalose molecules onto SLN surface might play 
an additional role and can contribute to Hi
i
 values.  
Regarding the thermodynamic characterization, Table 3.2 summarizes the enthalpy, 
entropy, binding constant and the stoichiometry of SLN-excipients interaction derived on 
the basis of the two-binding-site model. As observed, binding of glyceryl tristearate SLN 
with both excipients involved binding constants in the order of 10
5
 and 10
3 
M
-1
 for the 
first and second class of binding sites, respectively, two orders of magnitude larger than 
those observed for glyceryl dibehenate ones (10
3
-10
4
 and 10
1
-10
2
 M
-1
). Such differences 
may probably arise from the relatively lower hydrophobic character and some steric 
restrictions of the former lipid which facilitates the interaction with the excipients via 
dipole-dipole interactions. Nevertheless, the magnitude of binding constants and their 
variability is rather similar to those previously obtained when analyzing, for example, the 
interactions between saccharides with proteins, such as lectins [33] and functionalized 
latex nanoparticles [34].  
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Table 3.2: Enthalpy (Hi
i
), entropy (Si
i
), binding constant (K
i
) and stoichiometry (n
i
) of 
the interaction of glyceryl dibehenate and glyceryl tristearate SLN with mannitol and 
trehalose at 25°C (meanSD, n=3).  
Spray-drying 
excipient 
Type of SLN 
Hi
i 
(cal/mol) 
Si
i
 
(cal/mol) 
10
-3
 K
i
 
(M
-1
)
 10
2
 n
i 
Mannitol 
Glyceryl 
dibehenate 
-4234 
-2432 
943 
292 
935 
00 
00 
20 
Glyceryl 
tristearate 
-8526 
-2903 
1098 
703 
66416 
50 
00 
00 
Trehalose 
Glyceryl 
dibehenate  
-1301 
-1999 
723 
234 
60 
00 
00 
30 
Glyceryl 
tristearate  
-35145 
-3581 
1037 
582 
27820 
10 
00 
20 
Values in each column from top to bottom correspond to the first and second class of binding sites (i=1, 2). 
 
In addition, the stoichiometry of binding is fractional, corresponding to the interaction of 
multivalent substrate/ligands, such as SLN, for which 1/n
i
 would provide the functional 
valence of the nanocarriers to the excipients [35]. Concerning the enthalpy of interaction, 
their relatively small exothermic values agree with the potential predominance of 
hydrogen bonding between excipients and nanoparticles. Moreover, some electrostatic 
repulsion between SLN and small dispersion forces of attraction occurring in solution 
(such as dehydration processes and molecular rearrangements) leads to Hi
i
 values 
slightly larger for glyceryl tristearate than for glyceryl dibehenate SLN in both excipients. 
In spite of the negative values Hi
i
, SLN-excipients complexation was proven to be 
entropically driven as observed from the relatively large and positive entropy changes, in 
agreement with strong changes in solvation. In particular, release of water molecules to 
the solvent either hydrogen bonded to polar groups of the excipient molecules and SLN 
surfaces or ordered at the interface of SLN apolar groups upon intermolecular interaction 
[36]. 
In summary, it can be deduced from thermodynamic data that interactions of both kinds 
of SLN with mannitol are more energetic (more exothermic) and with higher affinity than 
for trehalose, in agreement with a larger hydration shell and interaction strength with 
water of the latter saccharide. This behaviour could imply a greater ability of trehalose to 
encapsulate SLN in more rigid and packed structures requiring lower concentrations than 
other excipients, as corroborated by SEM and spray-drying experimental data. 
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3.4.5. In vitro deposition studies 
The TSLI, that simulates the respiratory tract, was used to evaluate the in vitro 
performance during aerosolization and drug deposition of each formulation. It has an 
aerodynamic particle cut-off of 6.4 μm for the lower impingement chamber, which 
mimics the alveoli. Thus, the drug deposited in this chamber correlates to the amount of 
drug which will probably get deposited in the terminal lung units. A Rotahaler device 
was chosen for these experiments due to its simple construction, allowing comparison of 
the dispersibility of loaded powders. Mass deposition of the spray-dried formulation in 
the DPI and on each stage of the TSLI were measured by spectrophotometry following 
their dissolution in ethanol and expressed as a percentage of the total RFB mass 
recovered. In general, the percentage of each component deposited on a specific TSLI 
stage or in the DPI device varied with respect to particle size of the sample. The 
aerodynamic behaviour of the different evaluated powder formulations is shown in Figure 
3.5. Overall, approximately 30% of RFB percentage was retained in the D+C for all 
tested dry powders. A possible explanation for this result might be the inadequacy of the 
device or capsule used or/and the cohesive/adhesive properties of the powders, which can 
limit the process. A small fraction of RFB ( 15%) was retained in the upper (M+T) and 
medium chamber (MC). Regarding the RFB contents that reached the lung compartment, 
 50% of the total administered drug per dry powder can be detected in the lower 
compartment of the TSLI equipment. This can indicate that when these RFB-SLN-loaded 
microspheres are administered in vivo, 51.68.0% and 51.32.9% of the RFB loaded in 
glyceryl tristearate SLN microencapsulated in mannitol and in trehalose, respectively, 
could reach the deep lung. These amounts are higher than those corresponding to the 
same antibiotic loaded in glyceryl dibehenate SLN microencapsulated in mannitol and in 
trehalose (44.12.1% and 45.40.4%, respectively). 
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Figure 3.5: In vitro deposition of the spray-dried microsphere powders:  (a) mannitol 
microspheres containing glyceryl dibehenate SLN; (b) mannitol microspheres containing 
glyceryl tristearate SLN; (c) trehalose microspheres containing glyceryl dibehenate SLN; 
(d) trehalose microspheres containing glyceryl tristearate SLN. () device+capsules 
(D+C); () mouth+throat (M+T); () medium compartment (MC) and () lung 
compartment (meanSD, n=3).  
 
3.4.6. SLN recovery from microspheres  
To preserve their advantages as colloidal carriers after microencapsulation, SLN must be 
readily delivered from microspheres following their in vivo pulmonary administration, 
maintaining their original size and zeta potential. The excipient molecules are expected to 
protect the SLN from spray-drying, not only from the heat but also preventing 
particle/particle interactions that might be able to involve their aggregation and avoid 
their deposition and delivery in the deep lung [6, 28]. Since the excipients used in the 
microencapsulation process are freely soluble in aqueous medium, it is possible to easily 
recover the microencapsulated SLN in aqueous media [6]. Recovery studies were 
performed by incubating the dry powders in isotonic PBS pH 7.4 with 0.1% lung 
surfactant in order to mimic the lung environment. The mean particle size and surface 
charge of SLN, before spray-drying and after recovery from dry powders, were 
compared. It is possible to state that there was a change in the size of the recovered 
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glyceryl dibehenate SLN when compared with initial records (Table 3.3), since it was 
observed a size increase of 2.3-fold for recovery from trehalose microspheres compared 
to 1.7-fold for mannitol microspheres. On the other hand, glyceryl tristearate SLN 
maintained their initial sizes. In addition, it is also possible to observe that, in some cases, 
there was an inefficient dissolution process of the carrier particles (mainly in trehalose 
microspheres) (Figure 3.6) at the assayed incubation time (90 min); the presence of some 
“excipient bridges” can still be observed, similar to that described elsewhere [14]. 
Nevertheless, in spite of the enlargement presented by glyceryl dibehenate nanoparticles, 
they are still in the nano-range, being the increase irrelevant for our purposes. The 
enlargement of nanoparticle size after spray-drying has also been reported for powders 
prepared with chitosan [6] and gelatin [13] nanoparticles and was attributed to eventual 
changes in conformation due to the thermal conditions of the spray-drying process. 
Furthermore, a lower zeta potential was observed for the reconstituted SLN as compared 
to the fresh ones probably due to the fact that the release medium was composed by PBS 
with lung surfactant. This surfactant is constituted by proteins that when adhered to the 
surface of the SLN promoted this reduction in the zeta potential. Consequently, from this 
assay, we could expect that after reaching the deep lung, mannitol and trehalose 
microspheres will be quickly dissolved in the lung aqueous covered epithelium and 
release the RFB-loaded SLN.  
 
Table 3.3: Mean size () and zeta potential (ZP) of SLN after recovery from dry 
powders in isotonic PBS pH 7.4 with 0.1% lung surfactant (meanSD, n=3). 
Microspheres 
SLN 
Glyceryl dibehenate  SLN Glyceryl tristearate  SLN 
 (nm) ZP (mV)  (nm) ZP (mV) 
Fresh 994 -181 2108 -181 
Mannitol 
Recovered 1682 -123 1967 -101 
Mean 1 1.7 0.7 0.9 0.6 
Trehalose 
Recovered 22913 -91 22412 -91 
Mean 2 2.3 0.5 1.1 0.5 
1: size or zeta potential of recovered nanoparticles from mannitol microspheres / size or zeta potential of 
fresh nanoparticles 
2: size or zeta potential of recovered nanoparticles from trehalose microspheres / size or zeta potential of 
fresh nanoparticles 
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Figure 3.6: TEM micrographs of: (A) glyceryl dibehenate SLN and (B) glyceryl 
tristearate SLN after recovery from mannitol microspheres; and (C) glyceryl dibehenate 
SLN and (D) glyceryl tristearate SLN after recovery from trehalose microspheres. 
 
3.4.7. In vitro RFB release studies 
The employed excipients (mannitol and trehalose) are soluble in aqueous medium and 
allowed nanoparticle easy delivery as discussed in the previous section, resulting in a 
nanoparticle suspension with the native characteristics. Thus, results suggest that after 
reaching the deep lung, microspheres will be quickly dissolved in the lung aqueous 
covered epithelium, releasing the nanoparticles [6, 11]. Figure 3.7 depicts the release 
profile of RFB from SLN and dry powders in PBS pH 7.4 and 0.1% lung surfactant at 
37°C as previously described. Indeed, the RFB release profile from SLN and from SLN 
microencapsulated in mannitol and trehalose revealed a fast drug release within the first 
hour for both particulate systems followed by a controlled and more sustained release 
over a prolonged period of time (24 h). However, the RFB release from trehalose 
microspheres for both SLN formulations was incomplete probably due to the fact that 
trehalose microspheres did not dissolve totally, as discussed before (Figure 3.6C and D), 
thus hampering the RFB release (80.4±1.2% for RFB release from glyceryl dibehenate 
microencapsulated in trehalose and 86.60.0% for RFB release from glyceryl tristearate 
microencapsulated in trehalose).  
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Figure 3.7: Release profiles of RFB from (A): (■) glyceryl dibehenate SLN, (●) 
glyceryl dibehenate SLN microencapsulated in mannitol and (▼) glyceryl dibehenate 
SLN microencapsulated in trehalose; and (B): (■) glyceryl tristearate SLN, (●) glyceryl 
tristearate SLN microencapsulated in mannitol and (▼) glyceryl tristearate SLN 
microencapsulated in trehalose. These release studies were performed in 10 mM 
isotonic PBS pH 7.4 and 0.1% of lung surfactant at 37°C (meanSD, n=3). 
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3.4.8. In vitro antimycobacterial activity of RFB formulations by MTS assay  
A high number of biological assays are currently in use for evaluating the susceptibility of 
mycobacteria to formulations of interest, ranging from classical disk diffusion and broth 
dilution assays to radiorespirometric (BACTEC), dye-based and fluorescent/luminescence 
methodologies. In particular, the use of oxidation/reduction indicator dyes such as Alamar 
Blue, MTT or MTS, allowing the fluorimetric or spectrophotometric quantification of the 
respective reduced forms constitute accurate and reproducible methods for mycobacterial 
viability evaluation without the need of radioisotopes or costly materials and equipment 
[37]. In the present work, the susceptibility of M. avium strain to different RFB 
formulations was evaluated by the MTS assay. The intention was to validate if RFB 
antimycobacterial activity was preserved after incorporation in glyceryl dibehenate SLN 
or following their encapsulation in mannitol microparticles. As the previous experiments 
allowed to anticipate similar characteristics of the SLN prepared with both lipids as well 
as both kind of microspheres, for further studies only the microencapsulated RFB-
glyceryl dibehenate SLN in mannitol were analyzed. RFB formulations were tested at 
concentrations ranging from 0.005 to 10 µg/mL in the free form, loaded in glyceryl 
dibehenate SLN and loaded in glyceryl dibehenate SLN microencapsulated in mannitol. 
Moreover, the influence of mannitol, present in the microspheres, on mycobacterial 
growth was also evaluated constituting the empty mannitol microspheres. Figure 3.8 
shows the viability of the M. avium inoculum 10 days after incubation with the selected 
formulations. For all tested RFB formulations, the increase on the antibiotic concentration 
resulted in a reduction on the mycobacterial viability. In addition, for the same 
concentration no statistically significant differences were observed for the three types of 
RFB formulations and empty mannitol microspheres did not display any 
antimycobacterial effect as viability was always superior to 100%. Taking into account 
the obtained results, the antimycobacterial activity is due to RFB and not from the raw 
materials that formed the formulations (i.e. from mannitol). Moreover, RFB was able to 
keep its antimycobacterial effect after being encapsulated in SLN and followed by 
microencapsulation through spray-drying technique. Indeed, RFB withstands the harsh 
physical conditions present in both production techniques, i.e. HSH and spray-drying. 
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Figure 3.8: In vitro antimycobacterial activity of RFB formulations by MTS assay: () 
RFB in free form, () RFB-loaded glyceryl dibehenate SLN, () RFB-loaded glyceryl 
dibehenate SLN microencapsulated in mannitol and () empty mannitol microspheres 
(meanSD, n=6).  
 
3.4.9. In vivo fate of RFB formulations: biodistribution studies 
Biodistribution studies of microencapsulated RFB-glyceryl dibehenate SLN in mannitol 
following pulmonary administration were performed and the amount of non-metabolized 
antibiotic in the spleen, liver, lung and blood was determined by HPLC after an extraction 
procedure previously described (Figure 3.9). RFB microencapsulated in mannitol was 
used as a control. 
For both formulations under study, the pulmonary administration allowed an 
accumulation of the antibiotic mainly in lung, spleen and blood. Higher amounts of RFB 
incorporated in mannitol microencapsulated SLN were observed in lung when compared 
with RFB in mannitol microspheres. In addition, RFB amounts increased after 30 min of 
pulmonary administration, from 0.870.23 µg/g to 1.370.47 µg/g of lung regarding 
RFB-loaded glyceryl dibehenate SLN microencapsulated in mannitol and from 0.290.14 
µg/g to 0.490.21 µg/g of lung concerning RFB in mannitol microspheres. The same 
profile was obtained for RFB levels in blood. An increase was observed for both 
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formulations with time, from 0.970.09 µg/g to 1.390.09 µg/g of blood for RFB-loaded 
glyceryl dibehenate SLN microencapsulated in mannitol and from 0.700.47 µg/g to 
1.050.32 µg/g of blood for RFB in mannitol microspheres. The liver constituted the 
organ where low RFB levels were achieved for both dry powder formulations. The 
obtained results are in accordance with literature as inhaled microparticles were able to 
reach systemic circulation [38, 39]. Overall, regarding the amount of the antibiotic, low 
levels of non-metabolized RFB were obtained in the studied organs. However the RFB 
loading in SLN and, subsequently, in microspheres was very low and so other strategies 
to enhance the DL should be addressed.  
 
 
Figure 3.9: Biodistribution of (A) RFB-glyceryl dibehenate SLN microencapsulated in 
mannitol and (B) RFB microencapsulated in mannitol as measured by non-metabolised 
RFB in BALB/c mice in () lung, () liver, () spleen and () total blood following 
pulmonary administration. Mice were sacrificed after 15 and 30 min of administration 
(mean±SD, n=4 mice per selected time).  
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3.4.10. Biological evaluation of RFB-SLN in mannitol microparticles in a murine 
model of M. tuberculosis  
In spite of the low levels of RFB achieved after pulmonary administration, the biological 
evaluation in a M. tuberculosis murine model of infection was performed. The therapeutic 
activity of RFB-glyceryl dibehenate SLN microencapsulated in mannitol was evaluated in 
mice infected intravenously with 4.7 log10 CFU of M. tuberculosis and compared with 
infected and non-treated mice (control group). From CFU counts in liver, spleen and lung, 
the growth index was calculated as previously described. At the beginning of treatment, 
bacillary burdens had increased in all organs and a group of infected mice was sacrificed 
and the log10 CFU average in liver, spleen and lung was 5.1, 5.2 and 3.9, respectively. 
Figure 3.10 shows the growth index values for control and treated groups.  
 
 
Figure 3.10: Influence of pulmonary administration of RFB-glyceryl dibehenate SLN 
microencapsulated in mannitol on the growth index of M. tuberculosis in () liver, () 
spleen and () lung of BALB/c mice. The M. tuberculosis strain used in this animal 
model was the H37Rv. Each mouse was intravenously infected with 5x10
4
 CFU of the 
inoculum. Treatment started two weeks after infection induction. Mice received the 
formulation under study five times a week for two weeks (meanSD, n=5). Statistical 
analysis between the control (infected and non-treated) and treated groups, for each organ 
was performed using one-way ANOVA with Dunnet’s post hoc test (*p<0.05). 
*
*
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The displayed results showed relevant decrease on the growth index values in the liver 
(from 0.960.28 to 0.260.24), spleen (from 0.750.10 to 0.210.20) and lung (from 
1.950.16 to 1.250.19) to control group and treated mice, respectively. The values 
indicated that RFB formulation was able to reduce the bacterial loads in all analyzed 
organs. Overall, conjugating these results with biodistribution data, it is possible to 
sustain that, despite the low non-metabolized RFB levels observed after pulmonary 
administration, these microencapsulated SLN were able to reduce the bacterial loads in 
liver, spleen and lung. 
 
3.5. Conclusions 
In this work, RFB-loaded glyceryl dibehenate and glyceryl tristearate SLN were 
successfully incorporated in mannitol and trehalose microspheres by means of a spray-
drying process, resulting in dry powders with suitable properties for pulmonary 
administration. This method allows to overcome stability issues of liquid nanoparticle 
formulations, as well as to reach deep lung deposition upon inhalation. The inert 
excipients, mannitol and trehalose, serve as thermoprotectants, resulting in dry powders 
consisting in microencapsulated SLN, with adequate morphological and aerodynamic 
properties. The structural examination by SEM and CLSM indicated that microspheres 
are spherical with well-defined limits and that SLN were efficiently encapsulated in the 
microspheres, being homogeneously distributed within the whole microparticles. These 
observations confirm the efficiency of the microencapsulation method, according to the 
formulation and process conditions employed in this work. Physical characterization by 
ITC demonstrated that SLN have higher affinity for mannitol than for trehalose during the 
spray-drying process, favouring the interactions between SLN and mannitol. Through in 
vitro deposition studies, it was demonstrated that a considerable portion of dry powders 
can reach the lung. Mannitol and trehalose microspheres were readily dissolved and the 
SLN redispersion was immediate, providing a high in vitro RFB release (>95% for SLN 
and SLN-mannitol microspheres and ca. 80% for SLN microencapsulated in trehalose 
over 24 h). In vitro results confirmed that the micro-nanoformulations kept the 
antimycobacterial activity of RFB. In vivo studies demonstrated that the dry powder was 
an effective formulation to deliver RFB to the lung, although relevant quantities were also 
detected in liver and spleen. The RFB in microencapsulated-glyceryl dibehenate SLN 
reduced the growth index of the M. tuberculosis infection in all studied organs compared 
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to non-treated animals. Thereby, it was confirmed that these microencapsulated SLN are a 
promising platform for pulmonary delivery of therapeutic antibiotics for the treatment of 
mycobacterial infections in the lung, contributing to improved chemotherapy of TB. 
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Abstract 
Associating protein with nanoparticles is an interesting strategy to improve their 
bioavailability and biological activity. Solid lipid nanoparticles (SLN) have been sought 
as carriers for therapeutic proteins transport to the lung epithelium. Nevertheless, because 
of their low inertia, nanoparticles intended for pulmonary application usually escape from 
lung deposition. To overcome this problem, the production of spray-dried powders 
containing nanoparticles has been recently reported. Herein we developed new hybrid 
microencapsulated SLN for pulmonary administration, containing a model protein 
(papain, PAP). PAP was adsorbed onto glyceryl dibehenate and glyceryl tristearate SLN. 
Physical characterization using transmission electron microscopy, Fourier transform 
infrared spectroscopy and differential scanning calorimetry confirmed the interaction 
between PAP and SLN corroborating that the protein was efficiently adsorbed at SLN’s 
surface. PAP adsorption onto SLN (PAP-SLN) slightly increased particle size, while 
decreasing the SLN negative surface charge. The adsorption process followed a 
Freundlich type of adsorption isotherm. Nanoformulations were then spray-dried, 
originating spherical microparticles with suitable aerodynamic characteristics. Full 
characterization of microparticles was performed using scanning electron microscopy, X-
ray photoelectron spectroscopy and isothermal titration calorimetry. PAP was released 
from dry powders in a higher extent when compared with non spray-dried SLN. 
Nevertheless, protein stability was kept throughout microsphere production, as assessed 
by SDS-PAGE. 
 
Graphical abstract 
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4.1. Introduction 
Being highly vulnerable molecules, proteins usually present short in vivo half-lives either 
at the site of administration or in every anatomical location on their way to the site of 
pharmacological action. Regardless the administration route, many therapeutic proteins 
do not possess the required physicochemical properties to be absorbed and reach or enter 
target cells, needing delivery and targeting systems to overcome these limitations and 
improve drug performance [1].  
Soon after their first description by the research groups of R.H. Müller and M.R. Gasco, 
SLN have been sought as alternative carriers for therapeutic peptides, proteins and 
antigens [1]. These molecules may be incorporated in SLN and further administered by 
parenteral routes or by alternative routes such as oral, nasal and pulmonary. However, the 
smaller the particle diameter, the more difficult it becomes to achieve high drug 
encapsulation efficiency and a good sustained release effect. To circumvent this problem, 
the proteins can be adsorbed onto the particle surface rather than encapsulated within. 
Due to their amphipathic nature, proteins are known to adsorb, accumulating at solid-
liquid interfaces where the rate and extent of protein adsorption are influenced by the 
properties of the protein and its concentration in solution, by the characteristics of the 
adsorption matrix [2]. Adsorption of proteins onto particles often comprises various steps 
or stages: (i) transport of the protein from the bulk solution into the interfacial region, (ii) 
attachment of the protein at the sorbent surface and (iii) the relaxation of the protein on 
the surface, i.e., optimization of the protein-surface interaction [3, 4]. In protein 
adsorption studies, particle properties such as electrical charge density and 
hydrophobicity as well as environmental conditions like pH, temperature and ionic 
strength are often taken as experimental variables [5]. However, loss of activity of protein 
molecules during adsorption and release from particle surfaces is often mentioned as an 
example of the change in the structure of adsorbed proteins [1].  
Although nanoparticles have been proposed as valuable vehicles for efficient drug 
transport to the lung epithelium, their utility for pulmonary application is severely 
hindered because of their low inertia due to their excessively small dimensions and mass, 
which causes them to escape from lung deposition and be predominantly exhaled. 
Furthermore, their small size often leads to aggregation, making physical handling of 
nanoparticles difficult in liquid and dry powder forms. To solve these limitations, 
nanoparticles may be microencapsulated using spray-drying techniques thus forming 
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powders suitable for inhalation, which will quickly dissolve in the lung epithelium [6, 7]. 
This process has the advantages of being simple, continuous, easily up scaled and cost-
effective. Moreover, it has been shown that spray-dried heat sensitive molecules are 
exposed to high temperatures for only a few milliseconds to seconds in the spray-drying 
chamber, thus minimizing temperature-related stability problems [8]. During the spraying 
process, stability issues may also arise as a result of shear forces, which increase the 
kinetic energy of the system, leading to an intensification of particle collisions. These 
phenomena can be decreased by the addition of protectants, excipients generally 
recognized as safe, inert and non-toxic, for example sugars such as lactose and mannitol, 
or polymers that are located between the particles, or by decreasing the particle 
concentration in the sprayed liquid [6, 7]. Microencapsulation improved nanoparticles 
handling and aerosolization performance, enhanced stability and acquisition of 
aerodynamic properties, which resulted in an efficient lung delivery [6]. 
In the previous chapters, we described the development of SLN intended for anti-TB drug 
pulmonary administration, formulated with glyceryl dibehenate and glyceryl tristearate 
and prepared, using a hot HSH, which were successfully microencapsulated in mannitol 
and trehalose microparticles. The purpose of the present work was to explore the 
application of such procedure to protein drugs, producing powders for inhalation based on 
the microencapsulation of protein-containing SLN. A model protein was loaded onto 
previously prepared SLN using adsorption to avoid the harsh conditions involved in SLN 
preparation. The nanoparticles were then suitably microencapsulated in mannitol and 
trehalose microspheres using spray-drying and evaluated throughout the procedure. The 
effects of production parameters as well as the effects of excipients on the integrity of the 
protein were assessed. Papain (PAP), a commonly used and well characterized protease, 
was selected as a model protein, allowing the assessment of changes in the molecule 
integrity and stability [9]. The studies included the full physicochemical, pharmaceutical 
and in vitro biological characterization of PAP-SLN and dry powders. 
 
4.2. Materials 
Glyceryl dibehenate, m.p. 70°C, was a gift from Gattefossé (France). Tween 80 
(polysorbate 80) was obtained from J. Vaz Pereira, S.A. (Portugal). Glyceryl tristearate 
(m.p. 72-75°C), mannitol, D-(+)-trehalose dihydrate, SDS and PBS were purchased from 
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Sigma-Aldrich (USA). PAP from Carica papaya (MW 23 kDa; ≥3 units/mg protein) 
was acquired from Fluka (Sigma-Aldrich). Lung surfactant (Curosurf) was a generous 
gift from Angelini Farmacêutica, Lda. (Portugal). Purified water was obtained by inverse 
osmosis (Millipore, Elix 3) with a 0.45 μm pore filter. All other reagents were of 
analytical grade and were used without further purification. 
 
4.3. Methods 
4.3.1. Nanoparticle preparation 
Glyceryl dibehenate and glyceryl tristearate SLN were prepared using a hot HSH, as 
described previously in Chapter 2, section 2.3.2.. Briefly, the lipid phase was melted at a 
temperature 10°C above its m.p.. A hot aqueous phase consisting of Tween 80 in 
purified water was added to lipid phase and homogenized using a high-shear laboratory 
mixer (Silverson SL2, UK) at 12300 rpm for 10 min. The SLN dispersions were allowed 
to cool in an ice bath, with gentle agitation during 5 min. The final dispersions were 
stored at 53°C until further use. Each formulation was carried out in triplicate (n=3).  
 
4.3.2. Protein adsorption 
PAP adsorption onto SLN was carried out as described elsewhere [10, 11]. Briefly, the 
SLN (30 mg) were incubated overnight with a protein solution (0.197 mg/mL to 1.083 
mg/mL) in PBS pH 7.4, at 37ºC, with gentle horizontal shaking. SLN incubated with 
PBS, without PAP, were used as a control. After incubation, unadsorbed protein was 
separated from SLN using ultrafiltration membranes (Sartorius AG, Germany; cut-off of 
100 kDa,) at 15000g for 30 min at 4°C in a high-speed centrifuge (Allegra 64R 
centrifuge, Beckman Coulter). The degree of adsorption was calculated indirectly by 
determining the amount of protein remaining in the supernatant by the BCA protein assay 
(Pierce, USA), using a microplate reader (FLUOstar Omega, BMG Labtech, Germany), at 
562 nm (n=3).  
Protein adsorption kinetics of PAP was evaluated using the Langmuir and Freundlich 
models, as previously described [11]. Briefly, the Langmuir model can be expressed by: 
  
  
 
  
  
 
 
    
                                                                                                        (Eq. 4.1) 
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where Ce is the concentration in equilibrium (μg/mL), Qe is the amount of protein 
adsorbed (μg/mg) and Qm is the maximum adsorption capacity (μg/mg), which is the 
plateau surface concentration. KL is a Langmuir constant related to the adsorption 
capacity. This theory refers that the adsorbed protein layer is confined to a monolayer, 
where the adsorbate solution is very dilute and all sites available for adsorption are 
energetically equivalent and there are no lateral interactions between adsorbate 
molecules. Usually the deviations from this hypothesis are attributed to the formation of 
multilayers and are treated by the Freundlich equation, which does not predict a limiting 
value for adsorption and can be expressed by: 
            
 
 
                                                                                            (Eq. 4.2) 
where KF is the Freundlich constant for the system, whose index n is usually < 1, so that 
the amount adsorbed increases less rapidly than the concentration. This model predicts 
infinite adsorption at infinite concentration. The main assumptions are: the adsorbed layer 
is not confined to a monolayer and lateral interactions between adsorbate molecules may 
be possible. 
 
4.3.3. Nanoparticle size and surface charge  
The average particle size of SLN before and after PAP adsorption was analyzed by PCS 
using a Zetasizer Nano S (Malvern Instruments, UK). Zeta potential determination was 
performed by anemometry using a Zetasizer Nano Z (Malvern Instruments, UK). Both 
procedures were previously described in Chapter 2, section 2.3.3.1.. 
 
4.3.4. Transmission electron microscopy 
The morphological analysis of nanoparticles was performed by TEM, following the same 
specifications as detailed in Chapter 2, section 2.3.3.4.. 
 
4.3.5. Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of PAP, glyceryl dibehenate, glyceryl tristearate and PAP-adsorbed SLN 
were obtained using a Fourier transform infrared spectrometer (IRAffinity-1, Shimadzu, 
Kyoto, Japan). Samples equivalent to 2 mg were mixed with KBr (about 30 mg) and 
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ground into a fine powder using an agate mortar, before compressing into the KBr disk 
under a press at 10,000 psi. Baseline was corrected and the samples were scanned against 
a blank KBr pellet background at a wave number ranging from 4000 to 400 cm
-1 
with a 
resolution of 2.0 cm
-1
, with 30 scans. The characteristic peaks were recorded. 
 
4.3.6. Thermal analysis 
4.3.6.1. Differential scanning calorimetry 
Measurements were performed on a calorimeter DSC Q200 (TA Instruments, DE, USA). 
The SLN dispersions (both blank and PAP-adsorbed nanoparticles) and bulk materials 
(glyceryl dibehenate, glyceryl tristearate, Tween 80 and PAP) were accurately weighted 
into aluminium pans (ca. 2 mg), which were hermetically sealed and measured against an 
empty reference pan. The pan was heated and the thermograms were recorded at 
temperature range from -20°C to 240°C, at a heating rate of 10°C/min. The heat flow was 
measured. 
 
4.3.6.2. Dynamic light scattering 
The influence of temperature on the physical stability of PAP-SLN suspensions was 
assessed using-DLS (Zetasizer Nano S; Malvern Instruments, UK) as previously reported 
in Chapter 2, section 2.3.3.5.. A PAP solution in PBS was kept at 37°C for 2 h and 
analyzed by DLS as a control of PAP stability during the adsorption process. For each 
sample, measurements were carried out in triplicate. 
 
4.3.7. Spray-drying process of SLN 
The PAP-SLN formulations were incubated with aqueous spray-drying excipients 
solutions containing 20 and 22% w/v of mannitol and 15 and 17% w/v of trehalose for 
SLN based on glyceryl dibehenate and glyceryl tristearate respectively, selected 
according to previous studies, and using the same SLN:excipient mass ratio (1:3). The 
suspensions were spray-dried (Büchi Mini spray-dryer, B-290, Switzerland) to produce 
dry powders in the same conditions that detailed in Chapter 3, section 3.3.4..  
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The spray-drying PY was calculated by gravimetry, comparing the initial amount of total 
solids with the amount of resultant powder after spray-drying, through the following 
equation: 
       
                                                 
                       
                                    (Eq. 4.3) 
 
4.3.8. Microsphere size, shape and moisture content 
Particle morphology and residual moisture content of the spray-dried powders were 
evaluated using SEM and an electronic moisture balance respectively, as previously 
described in Chapter 3, section 3.3.5.. 
 
4.3.9. Isothermal titration calorimetry  
Binding studies were performed using a VP-ITC titration microcalorimeter from 
MicroCal Inc., (Northampton, MA) with a cell volume of 1.436 mL at 25°C. Samples 
were degassed in a ThermoVac system (MicroCal) prior to use. The sample cell was 
filled with the sugar solution containing either mannitol (1160 or 1280 mM when 
injecting glyceryl dibehenate and glyceryl tristearate SLN, respectively) or trehalose (397 
or 450 mM) and the reference cell with buffer solution only. The PAP-SLN solution (64.7 
and 31.4 mM for glyceryl dibehenate and glyceryl tristearate, respectively) was 
introduced into the thermostated cell by means of a syringe and stirred at 286 rpm, which 
ensured rapid mixing but did not cause foaming on solutions. The following procedure 
was fully described in Chapter 3, section 3.3.8.. 
 
4.3.10. X-ray photoelectron spectroscopy (XPS) 
The surfaces of microencapsulated glyceryl dibehenate nanoparticles in mannitol and 
trehalose, and blank microspheres were analyzed by XPS. Raw material glyceryl 
dibehenate was also analyzed as a control. XPS analysis was performed using a Thermo 
Scientific K-Alpha ESCA instrument (VG Escalab 250 iXL ESCA, VG Scientific, UK), 
equipped with aluminium Ka monochromatized radiation at 1486.6 eV X-ray source. The 
X-ray monochromatic spots were 400 μm in diameter and the correspondingly sampling 
area was 0.35 mm
2
. Due to the non-conductor nature of samples, it was necessary to use 
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an electron flood gun to minimize surface charging. Neutralization of the surface charge 
was performed using both a low energy flood gun (electrons in the range 0 to 14 eV) and 
a low energy argon ions gun. The XPS measurements were carried out using 
monochromatic Al-K radiation (λν = 1486.6 eV). Photoelectrons were collected from a 
take-off angle of 90° relative to the sample surface. The measurement was carried out in a 
Constant Analyzer Energy mode with a 100 eV pass energy for survey spectra and 20 eV 
pass energy for high resolution spectra. Charge referencing was achieved by setting the 
lower binding energy C1s photopeak at 285.0 eV C1s hydrocarbon peak. Residual 
vacuum in the analysis chamber was maintained at around 6x10
-9
 mbar. Surface 
elemental composition was determined using the standard scofield photoemission cross 
sections. 
 
4.3.11. Powder flow properties 
The real  of the dry powders was measured using a helium pycnometer (AccuPyc 1330, 
Micrometrics Ltd, Dunstable, UK) at room temperature (n=3). The apparent  was 
determined before and after settling the samples (1250 taps) using a stampf volumeter 
(Stav 2003, JEF Germany). The daer, Carr’s index and Hausner ratio of spray-dried 
particles were also calculated based on the equations 3.4, 3.5 and 3.6 respectively, 
depicted in Chapter 3, section 3.3.7.. 
 
4.3.12. Aerodynamic assessment of fine particles  
The aerodynamic characteristics of inhaled complexes were assessed through a TSLI 
(TSI, Copley Instruments, UK), corresponding to the Ph. Eur. (2.9.18. Preparations for 
inhalation: aerodynamic assessment of fine particles, Apparatus A - glass impinger), 
according to the procedure reported in Chapter 3, section 3.3.9.. After that, the TSLI was 
disassembled and all the compartments were carefully washed with 10 mM PBS pH 7.4 
and separately collected to conical flasks up to final volume of 50 mL. Samples were 
filtered and PAP content in each compartment was determined by the MicroBCA protein 
assay (Pierce, USA) measuring the absorbances by spectrophotometry in a microplate 
reader (FLUOstar Omega, BMG Labtech, Germany) at 562 nm (n=6). 
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4.3.13. SLN recovery from microspheres  
Since the excipients used for microsphere preparation are freely soluble in aqueous 
media, it is possible to recover the microencapsulated SLN, mimicking what happens 
when the dry powders reach the deep lung. For that purpose, the spray-dried powders 
were incubated in 10 mM PBS pH 7.4 with 0.1% of lung surfactant (Curosurf) under 
mild magnetic stirring at 37°C for 90 min. After that time, the physicochemical properties 
and morphology of the recovered SLN were analyzed by PCS and TEM as above 
described. 
 
4.3.14. In vitro release studies 
Release was determined by incubating the nanoparticles (0.3 mg SLN/mL) or the dry 
powders (2 mg microspheres/mL) in 1 mL of isotonic PBS, as reported elsewhere [7], 
with horizontal shaking (300 rpm), at 37°C. At pre-established periods of time, aliquots 
of 500 µL of the supernatant were taken out and replaced with equal volume of fresh 
medium to maintain the volume constant during the release study. The amount of released 
protein was evaluated in the supernatants by the MicroBCA protein assay (Pierce, USA) 
measuring the absorbances by spectrophotometry in a microplate reader (FLUOstar 
Omega, BMG Labtech, Germany) at 562 nm (n=3). 
 
4.3.15. Assessment of PAP integrity 
Structural integrity of PAP throughout the adsorption process and after release from SLN 
and dry powders was assessed by SDS-PAGE [12]. In brief, suitable volumes of samples, 
in order to obtain a PAP quantity of 7.5 µg per sample, were denatured for 5 min in 
sample buffer (NuPAGE® Technical Guide, Life Technologies, USA). Afterwards, 
samples were loaded into each well and analyzed by SDS-PAGE on a NuPAGE® Novex 
12% Bis-Tris Gel (Life Technologies, USA) on NuPAGE® MES SDS Running Buffer 
for 1 h at 135 mA. Proteins were visualized by Coomassie blue staining (SimplyBlue 
SafeStain solution, Life Technologies, USA). 
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4.3.16. Proteinase assays with fluorogenic peptide substrates 
Assays were carried out in 200 μL assay buffer (10 mM PBS, pH 7.4, 5 mM DTT) 
containing 20 μL of PAP activated in assay buffer at 5 μg/mL [13]. Reactions were 
initiated by the addition of 50 μM fluorogenic substrate (Z-Leu-Leu-Arg-AMC, from 
Bachem, Germany) and activity was monitored (excitation 355 nm; emission 460 nm) for 
30 min, at 37°C on a Fluorescence Microplate Reader (FLUOstar Omega, BMGLabtech, 
Germany). For all assays, saturated substrate concentration was used, throughout, in order 
to obtain linear fluorescence curves. The assays were performed in triplicate. 
 
4.4. Results and Discussion 
4.4.1. PAP-SLN characterization 
Therapeutic protein formulation is highly dependent on protein stability. Preventing 
degradation, denaturation and aggregation is critical to ensure the maintenance of 
physicochemical and biological properties of protein drugs [1]. Loading nanoparticulate 
carriers with proteins using adsorption has become an important formulation tool in the 
biomedical field. It is also an alternative to common encapsulation procedures, avoiding 
harsh formulation conditions, such as the use of organic solvents, high shear agitation, or 
high-pressure homogenization [1]. In the present work, the model protein drug (PAP) was 
adsorbed onto SLN to avoid its possible degradation caused by the high temperatures 
involved in the glyceryl dibehenate and glyceryl tristearate SLN formulation, which 
occurs at 80°C for the lipid melting. PAP contains 345 amino acid residues, and consists 
of a signal sequence (1-18), a propeptide (19-133) and a mature peptide (134-345). It is a 
cysteine protease with strong biological activity, which is isolated from the latex of the 
Carica papaya fruit. The enzyme has a large spectrum of action, being involved in the 
degradation of myofibrillar proteins and collagen [9]. 
As a first formulation step, the stability of PAP in solution was studied by DLS for 2 h at 
37°C to mimic the adsorption process. These results predict that PAP is stable in PBS at 
37°C, since its initial mean size (3.7±0.2 nm) did not change during the 2 h period 
(4.1±0.5 nm after 2 h). 
The adsorption of increasing amounts of PAP onto SLN led to an increase of mean 
particle diameter in both formulations but the PI remained within the optimal range for 
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SLN, suggesting the nanoparticle populations remained fairly homogeneous (Figure 4.1A 
and B). For the SLN prepared with glyceryl tristearate, there was an abrupt size increase 
at higher PAP concentrations, which may indicate the formation of aggregates favored by 
protein binding between different particles. TEM analysis confirmed the sizes established 
from the PCS analysis and showed fairly round particles with a dynamic layer of proteins 
adsorbed into nanoparticles surface (inset of Figure 4.1A and B).  
 
 
Figure 4.1: Mean size and PI of glyceryl dibehenate (A) and glyceryl tristearate (B) SLN 
containing different concentrations of PAP adsorbed onto the SLN surface. The bars 
represent the mean size and the symbols () correspond to the PI. Charge of glyceryl 
dibehenate (C) and glyceryl tristearate (D) SLN containing different concentrations of 
PAP adsorbed onto the surface. (a) blank SLN; SLN incubated with (b) 0.197 mg/mL; (c) 
0.361 mg/mL; (d) 0.619 mg/mL; (e) 0.722 mg/mL; (f) 0.812 mg/mL; (g) 0.963 mg/mL; 
(h) 1.026 mg/mL and (i) 1.083 mg/mL of PAP (SLN weight30 mg) (meanSD, n=3). 
TEM micrographs of PAP-SLN prepared using: (A) glyceryl dibehenate and (B) glyceryl 
tristearate. The arrows correspond to the layer of proteins around SLN (scale bar: 200 
µm). 
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Not surprisingly, PAP adsorption onto SLN resulted in a decrease of zeta potential when 
compared to the respective blank controls (Figure 4.1C and D). Protein adsorption at 
interfaces is generally considered as being through hydrophobic interactions and 
hydrogen bonds between the molecules of the adsorbate and the adsorbent [2]. In this 
study, some electrostatic interactions may not be precluded since the isoelectric point of 
PAP is 8.8 so, at physiological pH value, it is positively charged while the SLN have a 
negative surface charge (-24.20.3 mV for blank glyceryl dibehenate SLN and -16.80.8 
mV for blank glyceryl tristearate SLN). When all the SLN surface is covered with protein 
molecules, the potential zeta stabilizes around -6.70.3 mV for glyceryl dibehenate SLN 
(Figure 4.1C) and -5.90.2 mV for glyceryl tristearate SLN (Figure 4.1D), confirming the 
previous findings [11], where similar findings were obtained with other nanoparticulate 
systems and proteins. 
 
4.4.2. Characterization of the adsorption process  
As adsorption from solution depends on solute concentration, the final composition of the 
formulation will also depend on the concentration of protein added to the nanoparticles 
(Table 4.1). Results from PAP adsorption onto SLN show adsorbed amounts were up to 
51% (w/w) and 41% (w/w) of the initial amount, for glyceryl dibehenate SLN and 
glyceryl tristearate SLN, respectively, corresponding to maximum adsorption efficiencies 
of 3.690.39% and 2.940.08% (w/w). So, PAP seems to have a high affinity for both 
triacylglycerols. 
 
Table 4.1: Adsorption efficiency of PAP onto SLN. 
PAP (mg/mL) 
Amount adsorbed (% w/w) in final spheres composition 
Glyceryl dibehenate SLN  Glyceryl tristearate SLN  
0.197 0.100.03 0.210.04 
0.361 0.390.08 0.340.08 
0.619 1.420.11 0.980.11 
0.722 1.610.22 1.350.04 
0.812 2.170.17 1.700.18 
0.963 2.900.24 2.450.10 
1.026 2.940.45 2.480.11 
1.083 3.690.39 2.940.08 
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The protein effectively adsorbed from solution onto particle surface can be described by 
several models, including those of Langmuir and Freundlich, providing information on 
how molecules bind to the surface. The PAP adsorption followed the empirical 
Freundlich type of isotherm for both SLN compositions (r
2≥ 0.982), over the 
concentration range studied (Table 4.2), corroborating our previous results whereby a 
complex protein mixtures was adsorbed onto nanoparticles [11]. In such cases adsorption 
results from the competition of many different protein molecules to the particles’ surface. 
In addition, the interactions protein–protein, which are likely to occur with complex 
protein mixtures, are not considered by the Langmuir monolayer theory. In fact, the 
enzyme used in the present study is not a pure protein (supplier’s specifications). In 
addition, the SLN size increased with the increase of PAP amounts in both formulations 
(Figure 4.1A, B), as well as the gradual increase of adsorption efficiency (Table 4.1), also 
supports this theory of multilayer PAP adsorption. Apparently the adsorption occurs as a 
result of three phenomena: (i) protein-lipid interaction, i.e., adsorption of protein onto the 
lipid surface; (ii) protein-protein interaction on the lipid surface, in which adsorption of 
protein onto lipid was followed by adsorption onto previously adsorbed protein layer, this 
resulted in formation of multilayer, and (iii) adsorption onto lipid at high protein 
concentrations wherein self-association of PAP molecules (protein-protein interaction) 
preceded adsorption onto the lipid resulting in multilayer formation [14]. Further studies 
were performed using PAP-adsorbed SLN obtained at PAP concentrations of 1.026 
mg/mL for glyceryl dibehenate and 0.812 mg/mL for glyceryl tristearate. These 
concentrations were chosen taking into account the amount of protein adsorbed and 
nanoparticle size. Since the adsorption process follows the equation of Freundlich, the 
isotherms do not reach a clear plateau and the mathematical model does not predict a 
limiting value for adsorption. So these concentrations make a balance between the 
amount of PAP adsorbed and the other physicochemical properties resulted from the 
interaction, such as size, PI and surface charge. 
 
 
 
 
 
Chapter 4 - Microencapsulated SLN: an innovative strategy for pulmonary protein delivery 
 
157 
 
Table 4.2: Langmuir and Freundlich parameters for PAP adsorption onto SLN. 
 
Langmuir isotherm Freundlich isotherm 
 
r
2
 KL Qm r
2
 KF n 
Glyceryl dibehenate SLN 0.871 2.8710-4 14.49 0.985 4.7810-5 0.52 
Glyceryl tristearate SLN 0.917 1.0710-3 8.08 0.982 10.0310-5 0.56 
r
2
: correlation coefficient; KL: Langmuir constant related to the adsorption capacity; Qm: maximum 
adsorption capacity; KF: Freundlich constant and n: is the slope of the straight line. 
 
4.4.3. Fourier transform infrared spectroscopy analysis 
The Fourier transform infrared spectra of raw materials (glyceryl dibehenate, glyceryl 
tristearate and PAP) and optimized blank and PAP-adsorbed glyceryl dibehenate and 
glyceryl tristearate SLN are shown in Figure 4.2. Both lipids showed peaks corresponding 
to C=O stretching (1635 cm
−1
) and aliphatic C–H stretching (near of 2800 cm−1). The 
reduction (in case of glyceryl dibehenate SLN) or disappearance (regarding glyceryl 
tristearate SLN) of these lipids absorption bands on SLN spectra could be attributed to the 
smaller amounts of lipid used. PAP also showed a predominant band, as a hump, at 3750-
2350 cm
−1
. In literature it is described that raw PAP must have a peak at 3300 cm
−1
 due to 
the N–H stretch of a secondary N–substituted amide, p-substituted aromatic out of plane 
C–H deformation of an aromatic residue of tryptophan or tyrosine at 868 cm−1 and 850 
cm
−1
, with C=O stretch of a carboxylate anion and an amide group at 1654.2 cm
−1
 and 
strong peaks between 1150–1050 cm−1 and 705-570 cm−1 due to C–S stretch of sulfides 
and disulfides. However, this peak was not observed, probably due to residual moisture 
content in the sample. The spectra of the PAP-adsorbed nanoparticles showed slight 
peaks at 3380 cm
−1
 for the substituted secondary amide, 875 cm
−1
 due to the substituted 
aromatic ring, and 1145 cm
−1
 and 600 cm
−1
 due to C–S stretch of sulfides and disulfides, 
confirming the adsorption of the enzyme. However, further physical characterization of 
the surface of PAP-adsorbed nanoparticles is still needed to confirm these observations. 
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Figure 4.2: The FTIR spectra of: (a) PAP powder; (b) glyceryl dibehenate; (c) glyceryl 
tristearate; (d) optimized formulations of blank glyceryl dibehenate and (e) glyceryl 
tristearate SLN and optimized formulations of PAP adsorbed on (f) glyceryl dibehenate 
and (g) glyceryl tristearate SLN. 
 
4.4.4. Differential scanning calorimetry 
The DSC thermograms of PAP, glyceryl dibehenate, glyceryl tristearate, Tween 80 and 
blank and PAP-adsorbed SLN of glyceryl dibehenate and glyceryl tristearate are shown in 
Figure 4.3. The thermograms obtained with the three excipients (glyceryl dibehenate, 
glyceryl tristearate and Tween 80) matched their normal thermal behavior as previously 
described in Chapter 2, section 2.4.4., particularly the broad endotherm peak at 74°C and 
60°C for the triacylglycerols, glyceryl dibehenate and glyceryl tristearate respectively 
(Figure 4.3a, b and c). The native protein showed two endothermic peaks, at 90.49°C and 
198.97°C (Figure 4.3d). It has been reported that the DSC profile of PAP is characterized 
by a peak at 83°C and another peak at 89°C, corresponding to unfolding of two 
domains [15]. Although some differences can be due to the presence of impurities (as 
shown by SDS-PAGE analysis), only the second endothermic could be detected, while 
the peak at 198.97°C is probably due to thermal protein degradation. The DSC 
thermograms of PAP-adsorbed SLN were similar to those of the respective lipids, but the 
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melting peaks were shifted to lower temperatures due to the presence of PAP. No thermal 
events similar to those of pure PAP were detected, suggesting the adsorbed enzyme is in 
an amorphous state. 
 
 
Figure 4.3: DSC thermograms of: (a) glyceryl dibehenate; (b) glyceryl tristearate; (c) 
Tween 80; (d) PAP; (e) blank glyceryl dibehenate SLN; (f) PAP-glyceryl dibehenate 
SLN; (g) blank glyceryl tristearate SLN and (h) PAP-glyceryl tristearate SLN. 
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4.4.5. Dynamic light scattering  
The effect of temperature on particle size of PAP-SLN was assessed throughout a heating 
ramp from 25°C up to 90°C and then a cooling ramp to the initial temperature (Figure 
4.4). This study allowed studying the physicochemical properties when SLN suspensions 
were subjected to severe temperature variations, being useful whenever a formulation is 
intended for further temperature processing. Firstly, a 0.06 mg/mL PAP solution was 
subjected a heating ramp from 25°C up to 90°C and then a cooling ramp to 25°C. The 
respective data are depicted in Figure 4.4A showing protein aggregation above 80°C, 
which was not reversed upon cooling.  The heating process induced particle size changes 
in the SLN prepared with both solid lipids, although the particle size variations were 
always within the nanosize range. In the case of glyceryl dibehenate SLN, a gradual 
particle size increase was observed after 70°C reaching 556 nm, demonstrating the 
formation of protein aggregates (Figure 4.4B). The PAP aggregation masked the glyceryl 
dibehenate m.p. (70°C). Moreover, the initial particle size was not fully recovered after 
the cooling phase, in line with previous studies conducted with SLN of similar 
composition in Chapter 2, section 2.4.3.. On the other hand, glyceryl tristearate SLN 
suffered a slight decrease in particle size during heating, at a temperature close to the 
lipid’s m.p.. However, after 80°C, there was a slight increase, suggesting some instability 
above this temperature, which can be due to protein aggregation as happened with 
glyceryl dibehenate SLN (Figure 4.4C). During the cooling step, particle size stabilizes 
reaching the initial particle size (291 nm), indicating a protein stabilizing effect of both 
SLN formulations. 
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Figure 4.4: DLS thermograms of (A) PAP, (B) glyceryl dibehenate and (C) glyceryl 
tristearate SLN with PAP adsorbed: (■) from 25°C to 90°C and (●) from 90°C to 25°C 
(meanSD, n=3). 
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4.4.6. SLN microencapsulation by spray-drying 
The delivery of nanoparticles to the lung is difficult, if not impractical, due to their 
reduced size and low inertia [7]. To overcome these limitations, PAP-SLN were 
encapsulated within microspheres made of mannitol or trehalose, as an attempt to 
improve aerosolization, by conferring adequate aerodynamic properties for suitable 
particle deposition and drug delivery in the lung. In addition, it was expected these 
excipients would have a general stabilizing effect on PAP-SLN formulations. Mannitol 
and trehalose are FDA and EMA approved excipients for pulmonary delivery used in 
osmotic adjustment in injectable preparations, as well as bulking agents in freeze-drying 
and various dry powder formulations contributing to the enhanced aerosolization 
performance [16]. In addition, as polyols they also play an important role on the 
stabilization of relevant therapeutic proteins throughout pharmaceutical processing [17], 
including spray-drying [7, 18].  
Spray-drying is an evaporation technique where the aqueous solvent is removed very 
quickly due to heat energy provided in the spray-drier. Both SLN formulations were 
spray-dried with the two excipients in a one-step spray-drying process with acceptable 
yields around 45-55% (w/w). The enzyme PAP was associated to the SLN before spray-
drying and it was expected that PAP bioactivity would be retained at the spray-drying 
conditions used in this experiment [18]. In a similar work, an antibody (IgG1) was co-
spray-dried with mannitol as a stabilizer and a subsequent analysis of the protein 
secondary structure concluded that protein bioactivity was retained since the secondary 
structure was not significantly altered by the procedure [19]. The resulting nanostructured 
microparticles were observed using SEM evidencing spherical morphology with well-
defined limits (Figure 4.5).  
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Figure 4.5: SEM micrographs of dry powders: mannitol microspheres containing (A) 
PAP-glyceryl dibehenate SLN and (B) PAP-glyceryl tristearate SLN; trehalose 
microspheres containing (C) PAP-glyceryl dibehenate SLN and (D) PAP-glyceryl 
tristearate SLN (scale bar: 30 μm). 
 
Morphology is an important parameter when formulating powders for inhalation, 
essentially because particle shape and aggregation, which may interfere in the flow 
properties. However, the aerodynamic characteristics are the limiting parameters to 
succeed in pulmonary delivery. Generally, the daer, which is a combination of the particle 
size and density, influences the dispersion and sedimentation patterns, and should vary 
between 1 and 5, to allow an optimal alveolar deposition [20]. In this study, PAP-SLN-
loaded mannitol and trehalose microspheres exhibited a real  between 1.43-1.81 g/cm3, 
corresponding to an daer around 5-6 µm (Table 4.3), which confers suitable characteristics 
to achieve deep lung deposition.  
As density influences flowability, the Hausner ratio and Carr’s index were calculated as 
measures of the flow properties of the powders (Table 4.3). A Hausner ratio of < 1.25 
indicates a free flowing powder, whereas > 1.25 indicates poor flow ability. On the other 
hand, the smaller the Carr’s Index the better the flow properties. The Carr's index and the 
A B
C D
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Hausner ratio of all dry powders were greater than 23% and 1.25, respectively, suggesting 
the developed powders possessed extremely poor flow property according to Ph. Eur. 
(2.9.36. Powder Flow), but further data revealed that the microspheres were able to 
aerosolize suitably. Despite being extensively used to predict the quality of powders 
regarding flowability and deposition, precaution must be taken when analyzing the Carr’s 
index and the Hausner ratio, since for some powders a direct correlation between these 
parameters and higher fine particle fraction was not observed [21]. Furthermore, it has 
been reported that microspheres prepared by spray- and freeze-drying have poor or very 
poor flowability, probably due to some residual moisture content and, as verified in the 
present study.   
 
Table 4.3: Physical and aerodynamic properties of: (A) PAP-glyceryl dibehenate SLN 
and (B) PAP-glyceryl tristearate SLN microencapsulated in mannitol; (C) PAP-glyceryl 
dibehenate SLN and (D) PAP-glyceryl tristearate SLN microencapsulated in trehalose 
(meanSD, n=3). 
Dry 
Powders 
Process 
yield 
(%) 
Feret’s 
diameter 
(μm, 
n=300) 
Real 
density 
(g/cm
3
) 
Apparent 
density 
(g/cm
3
) 
Aerodynamic 
diameter 
(μm) 
Carr’s 
index 
(%) 
Hausner 
ratio 
Moisture 
residual 
content 
(%) 
A 50.75.1 5.340.94 1.470.00 0.590.01 6.471.14 42.02.0 1.70.1 0.580.03 
B 54.35.9 5.461.16 1.640.00 0.570.05 6.991.48 41.33.8 1.70.1 0.420.03 
C 47.14.6 4.451.57 1.810.00 0.440.03 5.992.11 29.37.6 1.40.2 1.780.02 
D 46.70.9 4.401.23 1.430.00 0.400.02 5.271.47 36.05.0 1.60.1 1.740.01 
 
4.4.7. Analysis of excipients and PAP-SLN binding affinity and their influence in 
microspheres formation by ITC 
The spray-drying of PAP-SLN with the two excipients led to the formation of 
nanostructured microspheres. Hence, ITC assays were performed with PAP-SLN and 
mannitol and trehalose to get further knowledge about the microspheres structure and the 
nature of the interactions established between PAP-SLN and both excipients during the 
spray-drying process. This is an extremely sensitive technique that probes the 
thermodynamics of PAP-SLN-spray-drying excipients (mannitol and trehalose) 
interactions, which are quantitatively measured as a change in the system energy. Figure 
4.6 shows the heat of injection normalized by the PAP-SLN amount added per injection, 
Hi
i
, as a function of the PAP-SLN to excipients molar ratio after subtraction of the heat 
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evolved after the titration of PAP-SLN suspension into water. The thermodynamic 
parameters (enthalpies, entropies, binding constants and stoichiometries) obtained from 
the fitting are shown in Table 4.4. For all combinations of PAP-SLN and excipients, 
deviations from SLN titration curve into water denote that the interaction between the 
excipient and SLN occurs even at the lowest concentration tested.    
Titrations of PAP-glyceryl dibehenate SLN into mannitol solution led to a biphasic 
profile (Figure 4.6A). Firstly, there was a progressive exothermic decrease in Hi
i
 at low 
PAP-SLN/mannitol molar ratios until reaches an exothermic minimum ( 0.002). In a 
second stage, further addition of PAP-SLN drew a progressively increase in the heat 
absorbed leading to less negative Hi
i
 values. The exothermic decrease and subsequent 
minimum at low PAP-SLN/mannitol molar ratios can be related to the establishment of 
strong dipole-dipole interactions between water molecules that were oriented favourable 
on adjacent PAP-SLN, as also suggested for polymer-protein [22], and hydrogen bonding 
formation between hydroxyl groups of fatty acids and protein molecules with those of 
mannitol. Moreover, a potential exothermic contribution stemming from some PAP 
release from the surface of PAP-SLN cannot be excluded. In fact, exothermic heats are 
diminished upon titration PAP-SLN onto a mannitol with PAP solution mixture (data not 
shown), with the shape profile largely maintained. Additional titrations (>0.002) of PAP-
glyceryl dibehenate SLN onto mannitol led to a progressive increase of Hi
i
 (less 
exothermic) thanks to an enhancement of mannitol and PAP-SLN dehydration to support 
the excipient binding to all PAP-SLN, favoring mutual interactions. Nevertheless, the 
potential contributions of hydrophobic interactions between mannitol molecules and/or 
with PAP/SLN, charge shielding effects and/or excipient’s molecular rearrangements 
upon excipient adsorption onto SLN surfaces could not be neglected. 
On the other hand, titrations of PAP-adsorbed glyceryl dibehenate SLN onto trehalose 
(Figure 4.6B) led to a similar profile as PAP-SLN/mannitol titrations except for the 
absence of the initial exothermic decrease and subsequent minimum. Instead, an 
exothermic plateau is observed up to a PAP-SLN/trehalose molar ratio of  0.012. This 
exothermic plateau region might be originated from, on one hand, fewer or at least less 
energetic interactions between this saccharide and PAP-SLN than mannitol ones, as 
observed from Figure 4.6A. The non-reducing character of trehalose would hinder direct 
binding of aldehyde or ketone end groups to the lysine or arginine residues of the protein. 
On the other hand, the flexible nature of the disaccharide molecule would enable the 
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rotation of the monosaccharide moieties around the glycosidic oxygen, which would 
favor the formation of a stable hydration layer, providing a further stabilization of PAP 
onto the SLN surface and decreasing their potential release. After the plateau region, the 
potential contribution of hydrophobic interactions between the disaccharide rings and 
conformational rearrangements of trehalose molecules, in particular, to give small 
aggregates onto SLN surface might play an additional role and could contribute to the 
observed less exothermic Hi
i
 values in the presence of PAP-adsorbed SLN. For both 
interactions of mannitol and trehalose with PAP-glyceryl dibehenate SLN, a final plateau 
region is not observed probably because this would take place at larger PAP-
SLN/trehalose molar ratios exceeding those here analyzed, which reproduce the 
concentrations used in the spray-drying process. 
The interaction between PAP-adsorbed glyceryl tristearate SLN and the two saccharides 
led to rather different titration profiles than those observed for PAP-glyceryl dibehenate 
ones. In particular, for both PAP-glyceryl tristearate SLN titrated onto mannitol (Figure 
4.6C) and trehalose (Figure 4.6D), positive Hi
i
 values are observed in the whole 
concentration range analyzed. In particular, at very low PAP-SLN/saccharide molar ratios 
(0.00034 and 0.0012 for mannitol and trehalose, respectively), an abrupt decrease in the 
endothermic Hi
i
 values is observed, which is followed by a more sustained one. In fact, 
for trehalose a quasi-plateau region can be envisaged at high PAP-glyceryl tristearate 
SLN/saccharide molar ratios. These endothermic values suggest that the interaction 
between PAP-glyceryl tristearate SLN and saccharides are entropically driven denoting 
the rupture of water solvation upon complex formation, which became progressively less 
important as more PAP-adsorbed SLN are present in the concentrated saccharide solution 
thanks to the establishment of extensive hydrogen bonding with the latter molecules being 
predominant. This is specially observed for the PAP-adsorbed glyceryl tristearate 
SLN/mannitol system, from which an additional contribution through some hydrophobic 
interactions between mannitol, with long hydrocarbon radicals in their molecular 
structure and PAP-glyceryl tristearate SLN may be present. On the other hand, the lower 
(less endothermic) Hi
i
 values for trehalose might arise from the certain stabilization of 
PAP on the SLN surfaces impeding their release, and hence contributing less to the 
overall thermodynamic process, as mentioned previously.  
The experimental data were fitted to a three-independent sites binding model, except for 
the PAP-glyceryl dibehenate SLN/trehalose system, which was fitted to a two-biding site 
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model. Binding of PAP-glyceryl dibehenate SLN with both excipients involved binding 
constants of up to ca. 10
8
 M
-1
,
 
one order of magnitude larger than those observed for 
glyceryl tristearate ones. Protein release may be the reason which impedes the fitting of 
experimental data to a less complex model as in the case of pure SLN onto excipients 
which was modeled by a two-binding site model. Also the presence of the protein on the 
SLN surface modified the heat profiles (from endothermic to exothermic) for the PAP-
adsorbed glyceryl tristearate SLN upon interaction with both excipients if compared to 
those SLN without surface-adsorbed protein. Moreover, the magnitude of binding 
constants and their variability are also larger than those of bare SLN.  
Concerning the enthalpy of interaction, the relatively small exothermic values found for 
PAP-glyceryl dibehenate SLN agrees with the potential predominance of hydrogen 
bonding upon interaction with both excipients. In contrast, interactions of PAP-glyceryl 
tristearate SLN with excipients involve positive Hi
i
 values indicating a predominance of 
the rupture of water solvation layer and dispersion forces upon interaction. Nevertheless, 
SLN-excipients complexation was proven to be enthalpic drive at most driven as 
observed from the relatively large and negative entropy changes (except for PAP-
adsorbed glyceryl tristearate SLN first binding site interacting with mannitol), in 
agreement with strong hydrogen bonding, and probably, protein release to the solution. In 
fact, the present behavior is opposite to that observed for the titration of bare SLN onto 
the excipients, in which the complexation process was exclusively entropy-driven. 
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Figure 4.6: Isothermal titration calorimetry of PAP-adsorbed onto glyceryl dibehenate 
SLN into (A) mannitol and (B) trehalose; PAP-adsorbed onto glyceryl tristearate SLN 
into (C) mannitol and (D) trehalose. Each dot on the curve corresponds to the heat of 
reaction following 5 µL injection every 400 s at 25°C (cell volume = 1.436 mL).  
 
Table 4.4: Enthalpy (Hi
i
), entropy (Si
i
), binding constant (K
i
) and stoichiometry (n
i
) of 
the interaction of PAP-adsorbed onto glyceryl dibehenate and glyceryl tristearate SLN 
with spray-drying excipients, mannitol and trehalose, at 25°C (meanSD, n=3).  
Excipient PAP-SLN 
10
-2
 Hi
i 
(cal/mol) 
Si
i
 
(cal/mol) 
10
-5
 K
i
 
(M
-1
)
 10
2
 n
i 
Mannitol 
Glyceryl 
dibehenate 
-7.30.2 
-1.5318.0 
-1.924.0 
-168.037.0 
-183.049.0 
-89.022.0 
8140.02865.0 
37419.01410.0 
0.50.1 
1.80.5 
0.00.0 
0.00.0 
Glyceryl 
tristearate 
1589.0111.0 
-536.050.0 
43.03.0 
408.091.0 
-245.066.0 
-57.023.0 
33.010.0 
0.00.0 
0.10.0 
0.00.0 
12.10.1 
97.10.1 
Trehalose 
Glyceryl 
dibehenate  
-2.50.3 
-2.50.3 
-158.045.0 
-134.061.0 
1724.0895.0 
96.05.0 
1.20.0 
2.40.0 
Glyceryl 
tristearate  
5.60.2 
1.40.6 
2.50.4 
-144.038.0 
-64.013.0 
-100.021.0 
445.056.0 
0.00.0 
1.80.2 
0.10.0 
17.71.2 
1.20.1 
Values in each column from top to bottom correspond to the first, second and third class of binding sites 
(i=1, 2, 3). In the case of PAP-glyceryl dibehenate SLN microencapsulated in trehalose, we only have the 
first and second class of binding sites, because it generally used the lowest amount of fitting parameters. 
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4.4.8. Microspheres surface analysis using XPS 
The application of XPS in the characterization of drug delivery systems arises from the 
ability of this technique to provide quantitative and qualitative information of surface 
composition. Upon exposure of the sample to a X-ray beam, the binding energies of 
characteristically emitted photoelectrons are measured, providing information on the 
elements from which they originate, as well as their chemical bonding. This is 
particularly relevant for the interpretation of drug location in the formulation, release and 
stability [6]. As the previous experiments, particularly ITC, allow anticipating a similar 
behavior during spray-drying of the SLN prepared with both lipids, only the microspheres 
containing glyceryl dibehenate SLN were analyzed by XPS. Table 4.5 displays the 
percentage of each chemical element present in the samples of controls (glyceryl 
dibehenate and PAP), nanoparticles and dry powders. The analysis of controls revealed 
the expected elements, such as carbon (C), oxigen (O), nitrogen (N) and sulfur (S). 
 
Table 4.5: Surface elemental composition of mannitol and trehalose microspheres 
containing glyceryl dibehenate-SLN, as determined by XPS. 
Samples 
Element (atomic percentage, %) 
C O N S Si O/C Ratio N/C Ratio 
Glyceryl dibehenate 92.80 7.20 0 0 0 0.08 0 
PAP 63.98 22.63 11.95 1.44 0 0.35 0.19 
Mannitol 54.60 45.40 0 0 0 0.83 0 
Trehalose 54.39 45.61 0 0 0 0.84 0 
Blank SLN 91.26 8.37 0 0 0 0.10 0 
PAP-SLN 89.66 9.35 0.99 0 0 0.10 0.11 
Mannitol microspheres 59.10 39.69 0 0 1.10 0.67 0 
Blank SLN microencapsulated 
in mannitol 
68.12 31.88 0 0 0 0.47 0 
PAP-SLN microencapsulated 
in mannitol 
66.31 32.88 0.47 0.23 0.33 0.49 0 
Trehalose microspheres 58.76 40.39 0 0 0.85 0.69 0 
Blank SLN microencapsulated 
in trehalose 
67.12 32.88 0 0 0 0.49 0 
PAP-SLN microencapsulated 
in trehalose 
70.59 28.66 0.76 0 0 0.41 0.01 
 
Glyceryl dibehenate presents a high atomic percentage of C and a low O percentage. On 
the other hand, PAP is the only compound that contains N in a considerable amount 
(11%) and S in its composition. Regarding the glyceryl dibehenate SLN, there was a 
variation when compared with the respective lipid raw material (control), with a slight 
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increase in the O percentage (from 7.20% to 8.37%), probably due to the presence of 
Tween 80 as surfactant in formulation. In contrast, the N signal in the PAP-
nanoparticles spectrum persisted after the sputter cycle with a relatively high value, 
suggesting that it is chemically bonded and could be ascribed to PAP adsorption at SLN 
surface. Concerning mannitol microspheres containing blank glyceryl dibehenate SLN, a 
modification in chemistry composition was noticed, with an increase in C percentage. An 
explanation for this feature is the presence of SLN at microspheres surface and the 
possibility of measurement of some photoelectrons from glyceryl dibehenate SLN. Our 
assumption of efficient nanoparticle microencapsulation can be further reinforced by the 
presence of N at the surface of microspheres loaded with PAP-SLN, which effectively 
indicated that there were PAP-SLN at the microspheres surface. It should be noticed that 
a signal for Si was identified in some spectra, which could be originated from the silicon 
wafer used as a sample support during the analysis. 
These results were also confirmed by deconvolution analysis of the spectra in which the 
high resolution spectra of carbon (C1s) signals, showing an envelope, were curve fitted 
using the Gaussian distribution into a series of peaks corresponding to different functional 
groups. The reference peak at the lowest binding energy (285.0 eV) was assigned to 
carbon atoms linked to other carbon and hydrogen atoms. Table 4.6 summarizes the 
relative peak area of each carbon environment. The peak areas (%) and relative intensities 
of C–C (285 eV), C–O (286.4 eV) and C=O (288 eV) were nearly similar in mannitol and 
trehalose microspheres and microencapsulated nanoparticles. More importantly, the peak 
of O–C=O (289 eV), unique for glyceryl dibehenate, was detected in the spectra of SLN 
and SLN-trehalose microspheres but not in the SLN-mannitol microspheres, probably due 
to a phenomenon that occurred during spray-drying. The analysis of deconvoluted C1s 
high resolution spectra confirmed that SLN are entirely encapsulated in mannitol and 
trehalose microspheres.  
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Table 4.6: The relative peak area (%) of each carbon environment for blank and PAP-
adsorbed glyceryl dibehenate SLN, mannitol and trehalose microspheres and 
microencapsulated SLN. 
Samples 
C–C/C–H 
285 (eV) 
C–O 
286.4 (eV) 
C=O 
288 (eV) 
O–C=O 
289 (eV) 
Glyceryl dibehenate 88.52 7.27 0 4.20 
PAP 47.48 26.27 26.25 0 
Mannitol 12.90 80.82 6.26 0 
Trehalose 7.27 71.48 20.94 0 
Blank SLN 78.94 17.46 0 3.60 
PAP-SLN 74.09 17.29 0 3.67 
Mannitol microspheres 26.66 67.98 5.36 0 
Blank SLN microencapsulated 
in mannitol 
41.38 53.51 5.11 0 
PAP-SLN microencapsulated in 
mannitol 
35.96 60.05 3.99 0 
Trehalose microspheres 23.64 57.36 17.29 1.71 
Blank SLN microencapsulated 
in trehalose 
25.61 31.35 8.97 1.21 
PAP-SLN microencapsulated in 
trehalose 
45.74 41.31 11.53 1.42 
 
4.4.9. In vitro deposition studies 
The performance during aerosolization and drug deposition of each formulation were 
evaluated using the TSLI apparatus, with an aerodynamic particle cut off of 6.4 μm for 
the lower impingement chamber, which mimics the terminal lung units (i.e., the alveoli). 
Thus, the drug deposited in this chamber correlates to the amount of drug which will 
probably get deposited in the terminal lung units, whereas the drug deposited in the upper 
chamber represents the amount of drug deposited in the tracheo-bronchial tree and the 
oropharynx. A Rotahaler device was chosen for these experiments due to its simple 
structure. Mass deposition of the spray-dried formulation in the inhaler and on each stage 
of the TSLI were measured and expressed as a percentage of the total PAP mass 
recovered. In general, the percentage of either component deposited on a specific TSLI 
stage or in the DPI device varied with respect to particle size of the sample. For all tested 
formulations >90% of the protein was delivered from the capsules. As illustrated (Figure 
4.7), all formulations showed higher mouth deposition when compared to the other 
compartments, probably due to the fact of the higher Feret’s diameter of microparticles 
calculated previously using SEM (Figure 4.5) and confirmed by daer measurement (Table 
4.3). However, for all dry powders, a significantly higher percentage of PAP was 
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deposited in the lower chamber (lung compartment), which demonstrated PAP-SLN dry 
powders could be distributed in the deep lung.  
 
 
Figure 4.7: In vitro deposition of the spray-dried microsphere powders containing PAP-
SLN. (1) Mannitol microspheres containing glyceryl dibehenate SLN; (2) mannitol 
microspheres containing glyceryl tristearate SLN; (3) trehalose microspheres containing 
glyceryl dibehenate SLN, and (4) trehalose microspheres containing glyceryl tristearate 
SLN. () device+capsules (D+C); () mouth+throat (M+T); () medium compartment 
(MC) and () lung compartment (meanSD, n=6). 
 
4.4.10. SLN recovery from microspheres  
In order to maintain the advantages of the nanoparticulate formulation, the SLN should be 
recovered immediately after microsphere dissolution in an adequate medium, while 
preserving their original properties. The used excipients are expected to protect the SLN 
during spray-drying, not only from the heat during spray-drying process but also against 
nanoparticles aggregation. Thus, after SLN reconstitution, they should keep their innate 
physicochemical characteristics, such as mean particle size, PI and surface charge. In this 
context, recovery studies should also mimic the in vivo conditions that dry powders will 
meet when administered by the pulmonary route. For this purpose, the experiments were 
performed using 10 mM PBS pH 7.4 with 0.1% of lung surfactant. The SLN main 
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characteristics after recovery from dry powders were then compared with those 
determined before spray-drying (Table 4.7). The recovered particles had similar diameters 
and PI when compared to those obtained with freshly prepared ones. This fact confirmed 
the hypothesis that both mannitol and trehalose protect SLN from some harsh conditions 
involved in the microencapsulation process, preventing, for example, particle melting or 
aggregation. The stabilizing effect of the excipients was further proved by TEM analysis 
of SLN recovered from the dry powders, which showed no aspect or particle size changes 
(Figure 4.8). Nevertheless, zeta potential increased in both SLN formulations, particularly 
in the glyceryl tristearate nanoparticles, probably due to some PAP release during the 
assay.  
 
Table 4.7: Mean SLN size (), polydispersity index (PI) and zeta potential (ZP) after 
recovery from dry powders (meanSD, n=3). 
Microspheres 
SLN 
Glyceryl dibehenate SLN Glyceryl tristearate SLN 
 (nm) PI ZP (mV)  (nm) PI ZP (mV) 
Fresh 1747 0.1670.004 -7.50.3 50816 0.2300.029 -5.80.0 
Mannitol 
Recovered 1636 0.2090.027 -10.71.1 5414 0.2370.001 -19.30.4 
Mean 1 0.9 1.3 1.4 1.1 1.0 3.3 
Trehalose 
Recovered 1828 0.2290.031 -12.81.2 4787 0.3190.085 -17.31.4 
Mean 2 1.0 1.4 1.7 0.9 1.4 3.0 
1: size or zeta potential of recovered nanoparticles from mannitol microspheres / size or zeta potential of 
fresh nanoparticles 
2: size or zeta potential of recovered nanoparticles from trehalose microspheres / size or zeta potential of 
fresh nanoparticles 
 
 
Figure 4.8: TEM micrographs of (A) glyceryl dibehenate SLN and (B) glyceryl 
tristearate SLN after recovery from mannitol microspheres; (C) glyceryl dibehenate SLN 
and (D) glyceryl tristearate SLN after recovery from trehalose microspheres. 
A B C D
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4.4.11. In vitro release studies  
The PAP in vitro release profiles from both SLN formulations (Figure 4.9) indicated a 
relatively slow and incomplete release, which could be explain by the interactions 
between the protein and the surface, because in some cases the presence of strong enough 
hydrophobic interactions and hydrogen bonds would result in some irreversible 
adsorption taking place. Furthermore, as protein molecules are attached to the adsorbent 
at several contact points, release would imply the simultaneous detachment of all these 
bonds, which is statistically improbable [2]. As mannitol and trehalose are freely soluble 
in aqueous media, the SLN are immediately delivered. Therefore, it was expected that the 
release profiles of PAP from dry powders were similar to those obtained from non-
microencapsulated SLN, as reported elsewhere for insulin-loaded chitosan nanoparticles 
microencapsulated in mannitol [7]. However, it did not occur in the present study because 
PAP release from the several dry powders was higher when compared the release from 
non-microencapsulated SLN. These studies clearly showed that PAP could withstand 
spray-drying conditions, which are usually harsh for protein molecules, either by its 
association with the SLN, or by the protective effect of mannitol or trehalose [17, 23]. 
The increase in protein release may be due to a solubilising effect of the polyols 
(mannitol or trehalose) used as microencapsulation excipients. Interestingly, the protein 
was adsorbed onto the glyceryl dibehenate SLN’s surface, it presented a higher release 
rate from trehalose microspheres than from mannitol microspheres. In turn, when the 
protein adsorbed onto the glyceryl tristearate SLN’s surface, it presented a higher release 
rate from mannitol microspheres than from trehalose microspheres. This phenomenon is 
explained by the binding constants (K
i
) determined during the ITC analyses (Table 4.4). 
Higher values were obtained for glyceryl dibehenate SLN microencapsulated in mannitol 
and glyceryl tristearate SLN in trehalose. So, as PAP release is mainly due to a desorption 
mechanism, it will be more delayed in the formulations presenting higher binding 
constants. 
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Figure 4.9: Release profiles of PAP from (A) glyceryl dibehenate SLN and (B) glyceryl 
tristearate SLN, in isotonic PBS pH 7.4/37°C (meanSD, n=3). (■) SLN; (●) SLN 
microencapsulated in mannitol; (▲) SLN microencapsulated in trehalose.  
 
4.4.12. Protein stability 
Adsorption of proteins at solid-liquid interfaces may affect their secondary and tertiary 
structures and, consequently, disturbing the biological function. There is consequently 
concern about the possibility of irreversibly damaging the protein during the formulation 
procedures. Although adsorption was used to associate proteins to nanocarriers in order to 
avoid protein exposition to harsh thermal conditions in SLN formulation, structural 
changes and loss of activity during adsorption and release may also occur. The stability of 
the enzyme was investigated by SDS-PAGE after adsorption onto nanoparticles and after 
release from SLN and microencapsulated SLN. No changes in the migration of the 
protein could be detected (Figure 4.10) when compared with the native protein. However, 
the additional bands seen in all wells confirm presence of impurities in the original PAP. 
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Figure 4.10: SDS-PAGE of PAP before and after adsorption and release (NuPAGE® 
Novex 12% Bis-Tris Gel). Lanes: (a) Native PAP; (b) PAP solution after adsorption onto 
glyceryl dibehenate SLN; (c) PAP solution after adsorption onto glyceryl tristearate SLN; 
PAP released from glyceryl dibehenate SLN after: (d) 1 h; (e) 2 h; (f) 6 h and (g) 9 h; 
PAP released from glyceryl dibehenate SLN microencapsulated in mannitol after: (h) 1 h 
and (i) 9 h and microencapsulated in trehalose after: (j) 1 h and (k) 9 h; PAP released 
from glyceryl tristearate SLN after: (l) 1 h; (m) 2 h; (n) 6 h and (o) 9 h; PAP released 
from glyceryl tristearate SLN microencapsulated in mannitol after: (p) 1 h and (q) 9 h and 
microencapsulated in trehalose after: (r) 1 h and (s) 9 h. 
 
Therefore, according to this method, the adsorption procedure appears not to affect the 
whole structure of PAP. However, such observation does not necessarily indicate that the 
PAP molecule retains its biological activity. So, with the aim to evaluate PAP activity 
after release from SLN and dry powders, the protein was analyzed by a fluorometric 
assay using a specific substrate. For this purpose, non-microencapsulated SLN and both 
dry powders were incubated in the release medium in the same conditions that previously 
described. After 12h of incubation, samples were centrifuged and the activity of released 
PAP was determined (Table 4.8). Results show that >90% of PAP was active in all 
glyceryl tristearate-based formulations, and >80% in all glyceryl dibehenate-based 
formulations, allowing to conclude that PAP formulation in SLN using an adsorption 
procedure and the subsequent microencapsulation of SLN in polyols matrix by a spray-
a           b             c           d           e          f           g          h           i           j          k     l             m          n          o          p           q           r           s           
Marker
(kDa)
181.8
115.5
82.2
64.2
48.8
37.1
25.9
19.4
14.8
6.0
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drying technique contribute to preserving protein stability throughout harsh 
pharmaceutical procedures. 
 
Table 4.8: Enzymatic activity of PAP from SLN, mannitol microspheres and trehalose 
microspheres after incubation with a specific fluorogenic substrate (Z-Leu-Leu-Arg-
AMC) (meanSD, n=3). 
Samples 
Total PAP 
concentration (µg/mL) 
Enzymatically active 
PAP (µg/mL) 
Activity 
(%) 
PAP-glyceryl 
dibehenate SLN 
SLN 152.6  7.4 128.6  11.0 84.2±13.3 
SLN microencapsulated 
in mannitol 
182.5  9.3 171.0  10.4 
 
93.6±14.0 
SLN microencapsulated 
in trehalose 
235.8  15.7 183.3  9.0 
 
77.7±18.1 
PAP-glyceryl 
tristearate SLN 
SLN 34.9  1.8 31.2  1.9 89.4±2.6 
SLN microencapsulated 
in mannitol 
73.1  10.2 64.9  3.4 
 
88.8±10.8 
SLN microencapsulated 
in trehalose 
48.7  0.9 48.8  2.0 
 
100.2±2.2 
 
4.5. Conclusions 
This study demonstrates the suitability of glyceryl dibehenate and glyceryl tristearate 
SLN as carriers for an application in pulmonary protein delivery. A model protein (PAP) 
was suitably adsorbed onto SLN, following a Freundlich type of adsorption isotherm over 
the concentration range studied, suggesting protein multilayers on the SLN surface 
through the electrostatic interaction between amino groups of PAP and the negative 
charged sites of SLN, as confirmed by FTIR, DSC and XPS. PAP-containing SLN were 
successfully incorporated in mannitol and trehalose microspheres by means of a spray-
drying process, resulting in dry powders with acceptable characteristics for lung 
deposition. The protein released from dry powders retained its enzymatic activity. 
Altogether, these results are an encouraging indicator of the utility of microencapsulated 
SLN as protein carriers for pulmonary delivery, making them suitable candidates for this 
application. 
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Abstract 
Plasmid DNA (pDNA) is a powerful tool for gene therapy but it is rapidly eliminated 
from the circulation following administration. Therefore, optimized DNA delivery 
systems are necessary for successful clinical use. Herein, the suitability of cationically 
modified solid lipid nanoparticles (SLN) as a novel pDNA carrier for the pulmonary 
route, as well as a transfection agent was investigated. Modified SLN were produced 
using glyceryl dibehenate or glyceryl tristearate as matrix lipid, Tween 80 as surfactant 
and chitosan as surface charge modifier. The SLN were loaded with the model plasmid 
pEGFP-C1 resulting in nanoparticles of approximately 200 nm, showing zeta potential 
values around +15mV. Electrophoretic analysis confirmed the stability, integrity and 
functionality of the loaded pEGFP-C1. The formulations were able to transfect the 
relevant pulmonary cell lines A549 and Calu-3, while showing low cytotoxicity. Further 
SLN encapsulation in mannitol and trehalose microspheres, obtained by spray-drying, 
yielded dry powders suitable for inhalation that protected pDNA against premature 
degradation.  
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5.1. Introduction 
Pulmonary delivery provides a non-invasive route for the administration of 
biomacromolecules like therapeutic genes, siRNA and proteins. It is therefore a 
promising approach for new treatments of genetic disorders like cystic fibrosis and other 
diseases such as asthma, chronic obstructive pulmonary disease, emphysema and lung 
cancer. The potential of pulmonary gene delivery is reflected in a large number of reports 
in the literature [1-3]. Theoretically pDNA is a powerful tool for gene therapy because of 
its easy preparation, great safety and stability. However, DNA is rapidly eliminated from 
the circulation due to the digestion by nucleases. Consequently, the therapeutic 
application of these pharmaceuticals is seriously limited. Therefore, the development of 
optimized delivery systems that can protect pDNA is critical for its success and 
conventional clinical use [2, 4]. 
Colloidal carriers seem to be the right choice for gene therapy since they have similar 
sizes compared to certain viruses, which are the natural but pathogenic gene delivery 
systems [5, 6]. A number of cationic polymers have been investigated as gene carriers, 
including polylysine [7], polyethyleneimine [8], polyamidoamine [9], poly (α-(4-
aminobutyl)-L-glycolic acid) [10], among others. Nevertheless, an ideal gene carrier has 
yet to emerge with high efficacy of gene transfer, targeting ability and good 
biocompatibility [11]. In this context, SLN are an alternative drug delivery system to 
emulsions, liposomes and polymeric nanoparticles since they can be produced without the 
use of toxic solvents and large-scale production is possible [12, 13]. Their solid matrix 
protects active biopharmaceuticals against chemical degradation and allows modulation 
of drug release profiles [14, 15]. These properties make them a suitable pulmonary drug 
carrier system [16]. Moreover, SLN of suitable composition have been shown to be well 
tolerated in vitro [17], as well as in vivo [18, 19]. In addition, the potential of CS as a 
polycationic gene carrier has been explored in recent years by several research groups 
[20-24]. CS is a biodegradable polysaccharide extracted from crustacean shells that has 
been shown to be non-toxic in a range of toxicity tests, both in experimental animals and 
humans [22]. It has also been shown to bind effectively DNA and partially protect it from 
nuclease degradation until it reaches its target, facilitating intracytoplasmatic trafficking 
to the nucleus by escaping the endosomal and lysosomal systems [11, 25]. 
Herein, we propose, as a proof of concept, systems for delivery of genetic material by 
pulmonary route. These systems are composed by hybrid nanocarriers with a core formed 
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by glyceryl dibehenate and glyceryl tristearate SLN, previously optimized and 
characterized in Chapter 2, and a shell produced by a CS coating. The genetic material 
association is done between the positively charged CS with the negatively charged 
plasmid by electrostatic interaction. It is expected that these systems maintain the plasmid 
integrity when in contact with nucleases. Afterwards, in order to investigate the potential 
of these polycationic SLN as a gene delivery system in the form of an inhaled powder, 
they were subjected to microencapsulation in mannitol or trehalose microspheres in a 
subsequent spray-drying process. The physicochemical properties of the carriers were 
characterized and the pDNA integrity tested when incubated with a specific 
endonuclease. The expression efficiency of pDNA was studied in vitro on A549 and 
Calu-3 pulmonary cell lines. Finally, the aerodynamic properties of the produced 
microsphere-based dry powders were characterized and an in-depth thermodynamic 
analysis was also performed using ITC. 
 
5.2. Materials 
Glyceryl dibehenate was a kind gift from Gattefossé (France). Tween 80 (polysorbate 
80) was obtained from Merck (Kenilworth, USA). Glyceryl tristearate, CS (low MW), 
chitosanase from Streptomyces griseus, mannitol, D-(+)-trehalose dihydrate, PBS, MTT, 
propidium iodide, DMSO and paraformaldehyde were purchased from Sigma-Aldrich 
(USA). BstBI (20000 U/mL), DNase I (2000 U/mL), 1 kb DNA molecular weight marker 
and CutSmart® buffer were from New England Biolabs Inc. (USA). Agarose L (low 
electroendosmosis) was from Amersham Biosciences (Uppsala, Sweden). pDNA 
(pEGFP-C1, GenBank U55763) was a generous gift from Institute of Biopathology and 
Regenerative Medicine (IBIMER), University of Granada, Spain. Lung surfactant 
(Curosurf) was a gift from Angelini Farmacêutica, Lda. (Portugal). For the viability 
studies, two cell lines were used: A549 (human alveolar lung carcinoma cell line, ATCC 
CCL-185) and Calu-3 (human lung adenocarcinoma from tracheobronchial epithelium 
cell line, ATCC HTB-55). The RPMI 1640 culture medium and their supplements 
(foetal serum bovine, penicillin G, streptomycin sulphate and L-glutamine) were acquired 
from Life Technologies (UK). Lipofectamine 2000 was purchased from Invitrogen 
(Scotland, UK). Purified water was obtained by reverse osmosis and electrodeionisation 
(Millipore, Elix 3) being afterwards filtered (pore 0.45 µm). Reagents used in DNA 
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isolation and analysis were of molecular biology grade. All other reagents were of 
analytical grade and were used without further purification. 
 
5.3. Methods 
5.3.1. Bacteria transformation and plasmid purification 
NEB® 5-alpha competent Escherichia coli DH5α™ was thawed on ice and 0.5 µg of 
pEGFP-C1 was gently mixed with E. coli. After 30 min on ice, E. coli was incubated at 
42°C for 30 s and then incubated on ice for 5 min. After heat shock, E. coli was cultured 
in Super Optimal broth with Catabolite repression (SOC) medium for 1 h at 37°C and 
100 μL was spread on the Lysogeny broth (LB) agar containing 30 μg/mL kanamycin and 
incubated at 37°C overnight. One colony was incubated in 500 mL of LB with kanamycin 
and incubated overnight at 37°C. The cells were isolated by centrifugation, the cell pellet 
was washed with pre-chilled 10 mM PBS pH 7.4 and was frozen until further use. 
Plasmid purification was performed according the procedure of Maxi Quialfilter Kit 
(Quiagen, Germany) and confirmed by 0.7% agarose gel containing 0.5 µg/mL ethidium 
bromide at 175 V for 50 min (Electrophoresis Power Supply, EPS 301, Amersham 
Pharmacia Biotech). DNA extracts were stored at -20°C for further molecular analyses. 
The quantification of the extracted DNA was measured using a Nanodrop ND-1000 
v3.3.0 spectrophotometer (Nanodrop Technology, Cambridge, UK) at 260 nm.  
 
5.3.2. Preparation of pDNA-polycationic SLN 
Empty glyceryl dibehenate and glyceryl tristearate SLN were prepared with Tween 80 
as a surfactant using a hot HSH technique, as described previously in Chapter 2, section 
2.3.2.. Briefly, a hot aqueous phase was added to a melted lipid phase and then 
homogenized using a high-shear laboratory mixer (Silverson SL2, UK). The SLN were 
obtained by cooling the dispersions in an ice bath. Afterwards, the SLN were coated with 
a CS solution 0.25% (w/v) in 1% acetic acid (v/v) at a CS:SLN ratio of 1:4 for 1 h at 
room temperature with a gentle stirring. The pEGFP-C1 (stock solution 5.07 µg/µL) was 
added to the nanosuspensions after CS coating. Loading capacity was determined by 
adding increasing amounts of pEGFP-C1 to the CS-coated SLN (from 0% to 100% of 
pEGFP-C1, where 100% (w:w) of pEGFP-C1 correspond to the total mass of CS in the 
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system). In other words, 100% (w:w) of pEGFP-C1 corresponds to a mass of 2.5 µg of 
plasmid. Nanoadsorption of pEGFP-C1 onto the CS-coated SLN (SLN:CS:pDNA) was 
investigated by gel electrophoresis (0.7% agarose containing 0.5 µg/mL ethidium 
bromide, at 175 V, 50 min) (Electrophoresis Power Supply, EPS 301, Amersham 
Pharmacia Biotech), using a 1 kb DNA molecular weight marker. The gel was visualized 
under an UV Transilluminator 2000 (Bio-Rad Laboratories). The SLN:CS:pDNA were 
further coated with an external CS layer (SLN:CS:pDNA:CS) in order to improve 
pEGFP-C1 integrity (Figure 5.1). The final nanodispersions were stored at 53°C until 
further use. Each formulation was carried out in triplicate (n=3). 
 
 
Figure 5.1: Preparation of DNA-containing SLN:CS hybrid nanoparticles. 
 
5.3.3. Nanoparticle characterization  
5.3.3.1. Particle size and surface charge 
The pDNA-polycationic SLN mean diameter and PI were determined by quasi-elastic 
laser light scattering in a Malvern Zetasizer Nano S (Malvern Instruments, UK). The zeta 
potential (surface charge) was determined using laser Doppler anemometry in a Nano Z 
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(Malvern Instruments, UK). Samples were appropriately diluted in filtered purified water 
for the measurements. For the measurements, at least three replicate samples were 
determined. 
 
5.3.3.2. Transmission electron microscopy analysis 
The shape and surface morphology of the pDNA-polycationic SLN were observed by 
TEM. The samples were prepared by fixing a drop of the dispersion onto copper grids 
with a carbon layer for examination. Subsequently, it was dried with paper filter and 
treated with 2% (w/v) phosphotungstic acid for 2 min. The grids were then observed in a 
JEOL Microscopy (JEM 2010, Japan) at 120 kV, coupled to a Gatan Orius camera. 
 
5.3.3.3. Thermal analysis using dynamic light scattering 
The influence of temperature on the physical stability of pDNA-loaded polycationic SLN 
either coated with a single or a double CS layer was assessed using DLS (Zetasizer Nano 
S; Malvern Instruments, UK). Samples were appropriately diluted with filtered purified 
water (1:100) in a quartz cell and particle size analysis was performed while heating the 
sample from 25°C up to 90°C, subsequently followed by cooling from 90°C to 25°C at a 
rate of 0.5°C/min. Particle size measurements were made every 1°C. For each sample, 
measurements were carried out in triplicate (n=3). 
 
5.3.4. Integrity of pEGFP-C1  
Protection of pEGFP-C1 loaded in both types of nanoparticles (SLN:CS:pDNA  and 
SLN:CS:pDNA:CS) was evaluated by enzymatic degradation with BstBI, an 
endonuclease with two recognition sites on pEGFP-C1 at positions 1357 and 3437. A 
complete plasmid digestion will produce two DNA fragments with 2080 and 2651 bp. 
The CS layers of SLN:CS:pDNA:CS were digested through incubation (4 h, 37°C) with 
chitosanase (10 U/mL in 50 mM acetate buffer pH 5.5) [26]. Afterwards, they were 
treated with 1 U BstBI/1 µg pDNA for 1 h at 65°C with 1x CutSmart® buffer. The 
reactions were stopped using a stop solution composed by 50% (v/v) glycerol, 50 mM 
EDTA and 0.2% (w/v) bromophenol blue. The integrity of pEGFP-C1 was then analysed 
by gel electrophoresis, as described above, and compared with pEGFP-C1 controls (one 
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with and another without BstBI treatment). The physicochemical properties (mean 
particle size, PI and surface charge) of the SLN:CS:pDNA:CS after digestion by 
chitosanase were also assessed as previously described in section 5.3.3.1.. 
 
5.3.5. In vitro cell viability studies 
The cytotoxicity of nanoformulations was assessed using MTT reduction and propidium 
iodide assays. The MTT is a yellow, water-soluble tetrazolium dye that is converted by 
viable cells to a water-insoluble and purple compound, formazan [27]. Cell viability was 
assessed in A549 and Calu-3 cells after 24, 48 and 72 h of incubation of the cell lines in 
the presence of the different formulations. The Calu-3 and A549 respiratory epithelial cell 
lines have been frequently used in this context to evaluate the behaviour of systems aimed 
to be used as respiratory drug delivery systems, either nasal or pulmonary [28]. The day 
before the experiment, A549 and Calu-3 cells were seeded in sterile flat bottom 96 well 
tissue culture plates (Greiner, Germany) in RPMI 1640 culture medium, supplemented 
with 10% foetal serum bovine, 100 units/mL of penicillin G (sodium salt), 100 μg/mL of 
streptomycin sulfate and 2 mM L-glutamine, at a cell density of 1x10
5
 cells/mL and 
0.5x10
5
 cells/mL for the Calu-3 and A549 cell lines, respectively. Cells were incubated at 
37°C on 5% CO2 atmosphere. On the following day, the culture medium was replaced by 
fresh one containing the different samples. A negative control (K-), cells only with 
culture medium, and a positive control (K+), cells with SDS (1 mg/mL) in order to 
promote lysis, were used. Each sample was tested in six wells per plate. After incubation, 
culture medium was replaced by 0.3 mM propidium iodide in culture medium (stock 
solution 1.5 mM in DMSO, diluted with culture medium 1:5). Fluorescence was 
measured (excitation, 485 nm; emission, 590 nm) in a microplate reader (FLUOstar 
Omega, BMGLabtech, Germany) and then, the MTT assay was performed. Briefly, 
existing culture medium was replaced by fresh one containing 0.25 mg/mL MTT. The 
cells were further incubated for 3 h. The medium was then removed and the intracellular 
formazan crystals were solubilized and extracted with 100 µL DMSO. After 15 min at 
room temperature, the absorbance was measured at 570 nm in a microplate reader 
(FLUOstar Omega, BMGLabtech, Germany). The relative cell viability (%) compared to 
control cells was calculated for the MTT assay using the following equation: 
                              
         
          
                                                        (Eq. 5.1) 
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where Abssample is the absorbance value obtained for cells treated with nanoparticles and 
Abscontrol is the absorbance value obtained for cells incubated with culture medium (K-). 
For propidium iodide, cell viability was obtained by: 
                                     
                  
                   
                                         (Eq. 5.2) 
where Fluorescencesample is the URF values obtained for cells treated with nanoparticles 
and Fluorescencecontrol is the URF values obtained for cells incubated with culture 
medium (K-). 
 
5.3.6. In vitro transfection studies 
The Calu-3 and A549 respiratory epithelial cell lines were used in transfection assays. 
They were cultured as a monolayer in RPMI 1640 culture medium, supplemented with 
10% foetal serum bovine (Invitrogen, UK), 100 units/mL of penicillin G (sodium salt), 
100 μg/mL of streptomycin sulphate (Invitrogen, UK) and 2 mM L-glutamine, at a cell 
density of 1x10
5
 cells/mL and 0.5x10
5
 cells/mL for Calu-3 and A549 respectively, at 
37°C in a humidified atmosphere with 5% CO2. Cell transfection was performed in 24 
well plates (Greiner, Germany) with nanoparticles containing 0.5 µg of pDNA per well 
encoding a red-shifted variant of wild-type green fluorescent protein (GFP) which has 
been optimized for brighter fluorescence and higher expression in mammalian cells [29]. 
Transfection with SLN:CS:pDNA:CS was performed in 500 μL RPMI 1640 culture 
medium without supplementation for 4 h. The medium pH was adjusted with HEPES 
buffer to 6.8 as previously described [30], since it is considered as an optimum pH for a 
high transfection rate. After incubation, 500 μL fresh medium supplemented with 20% 
foetal serum bovine was added. Lipofectamine reagent (Invitrogen) according to the 
manufacturer's instructions was used as a positive control. Wells only with culture 
medium, i.e. without nanoparticles, were used as a negative control. After incubation in 
the presence of the particles (72 h), cells were rinsed 3 times with 10 mM PBS containing 
20 mM glycine at pH 7.4 before and after being fixed for 15 min at room temperature in 
dark with a 4% (w/v) paraformaldehyde solution. After fixation, cells were permeabilized 
with 0.1% Triton X-100 for 4 min, and then rinsed 3 times with 10 mM PBS containing 
20 mM glycine at pH 7.4 for subsequent actin staining with rhodamine phalloidin. The 
6.6 mM phalloidin-TRITC solution in 10 mM PBS was added to the cells for 30 min at 
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room temperature. Afterwards, cells were rinsed 3 times with 10 mM PBS containing 20 
mM glycine at pH 7.4, and air dried, cell slides were mounted in fluorescent mounting 
medium ProLong Gold antifade reagent with DAPI and their fluorescence was observed 
and recorded on an Axioscop 40 fluorescence microscope provided with an Axiocam 
HRc camera (Carl Zeiss, Germany). Images were processed with the software AxioVision 
Rel. 4.8.1 (Carl Zeiss, Germany). 
 
5.3.7. Microencapsulation of nanoparticles  
The nanoformulations were dispersed in aqueous mannitol and trehalose solutions at a 1:3 
SLN:excipient ratio and then spray-dried using a laboratory-scale spray-dryer (Büchi 
Mini spray-dryer, B-290, Switzerland), as previously reported in Chapters 3 and 4. 
Briefly, the spray-drying process was operated under the following conditions: a 0.7 mm 
nozzle, an air flow of 400 L/h and an Tinlet maintained at 1032°C, resulting in an Toutlet 
between 63 and 67°C. The aspirator rates were adjusted to 100% and 70% for mannitol 
and trehalose microspheres, respectively. At the end, the obtained dry powders were 
collected and kept in a dessicator until further use.  
The spray-drying PY were calculated by gravimetry, comparing the initial amount of total 
solids with the amount of resultant powder after spray-drying. The PY was calculated 
using the following equation:  
       
                                                 
                       
                                    (Eq. 5.3) 
 
5.3.8. Dry powder characterization 
5.3.8.1. Particle size, morphological characterization and moisture content 
The SEM analysis was performed in order to investigate the morphological characteristics 
of the spray-dried powders. Prior to analysis, the samples were placed on a double-side 
carbon tape mounted onto an aluminium stud and was then sputter coated with gold using 
an Emitech K550 (London, England) sputter in order to make it conducting. SEM images 
were recorded on a Zeiss Evo LS15 (UK) SEM, with an acceleration voltage of 20 kV. 
The SEM micrographs were used to calculate mean particle size, which was estimated as 
the Feret’s diameter by measuring the mean of 300 particle measurements (n=300). The 
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moisture content of the spray-dried powders was determined by loss on drying from 25°C 
to 105°C, using an electronic moisture balance (Shimadzu, EB-280 MOC, Japan), 
according to the Ph. Eur. (2.2.32. Loss on drying). The percentage of the initial dry 
powder weight that was lost during the heating process was ascribed to the moisture 
content of the powders. Measurements were carried out in triplicate. 
 
5.3.8.2. Aerodynamic properties determination 
The real  of the dry powders was measured using a helium pycnometer (AccuPyc 1330, 
Micrometrics Ltd, Dunstable, UK) at room temperature (n=3). The apparent  was 
determined under defined conditions of the apparent volumes, before and after settling the 
samples using a stampf volumeter (Stav 2003, JEF Germany). It was obtained by 
measuring the volume of a known weight of the dry powders analysed in a 10 mL test-
tube after mechanical tapping (1250 taps), according to the Ph. Eur. (2.9.34. Bulk density 
and tapped density of powders) (n=3). The daer, Carr’s index and Hausner ratio of spray-
dried particles were calculated based on the following equations 5.4, 5.5 and 5.6, 
respectively: 
     μ        
  
   
                                                                                               (Eq. 5.4) 
where dgeo is the particle geometric diameter, ρs is 1 g/cm
3
, ρe is the effective particle 
density in the same unit as ρs and λ is the dynamic shape factor of the particle. This shape 
factor is defined as the ratio of the drag force of the particle to that of a sphere of 
equivalent volume and for spherical particles is defined as 1. 
                 
            
  
                                                                             (Eq. 5.5) 
              
  
  
                                                                                                  (Eq. 5.6) 
where Vo is the unsettled apparent volume and Vf is the final tapped volume. 
 
5.3.8.3. Isothermal titration calorimetric studies 
Binding studies were performed using a VP-ITC titration microcalorimeter (MicroCal 
Inc., Northampton, MA) with a cell volume of 1.436 mL at 25°C. First, samples were 
degassed in a ThermoVac system (MicroCal). The excipient solutions containing either 
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mannitol (1160 or 1280 mM when injecting glyceryl dibehenate and glyceryl tristearate 
SLN:CS:pDNA:CS, respectively) or trehalose (397 or 450 mM) was placed in a specific 
cell, having a reference cell with buffer solution. The thermostated cell was filled with the 
SLN:CS:pDNA:CS solutions (64.7 and 31.4 mM for glyceryl dibehenate and glyceryl 
tristearate SLN, respectively) under mild stirring without causing foaming. Each titration 
consisted of an initial 2 μL injection followed by 55 subsequent 5 μL injections planned 
to take place at 400 s intervals, sufficient for the heat signal to come back to the baseline. 
The results of the ITC experiments in terms of the heat of injection normalized by the 
SLN:CS:pDNA:CS concentration added per each injection (Q*) were represented as a 
function of the SLN:CS:pDNA:CS to excipient molar ratio. The dilution heats from 
SLN:CS:pDNA:CS titrations into buffer solution were subtracted from the heats obtained 
from SLN:CS:pDNA:CS titrations into the excipient solution in order to get the net 
binding heats. Binding raw data were determined on the basis of a set of two identical 
binding sites by using the Affinimiter software as previously reported by Kim et al. [31]. 
Briefly, the two identical binding sites model employs the following fitting equation that 
encompasses Langmuir isotherm binding equilibria for two independent types of 
association, according to the following equation: 
                                                                                                 (Eq. 5.7) 
where the sub-indices 1 and 2 stand for the two sets of sites. 
One can solve for Θ1 and Θ2 using the equilibria equations for binding constants K1 and 
K2, with X being the total concentration of ligand and [X] the concentration of unbound 
ligand: 
    
  
         
    and       
  
         
   with                               (Eq. 5.8) 
To get an accurate fit, multiple assays were performed starting from random initial 
parameters. The same values were reached at the minimum χ2 regardless of the initial 
values. Alterations in free energy (ΔGi) and entropy of binding (ΔSi) for each site were 
also measured from the fitted parameters according to following thermodynamic 
equations where Rg is the universal gas constant: 
                                                                                                 (Eq. 5.9) 
All experiments were carried out at least in duplicate with 3% of reproducibility. 
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5.3.9. Nanoparticle recovery from microspheres  
The microspheres obtained by spray-drying were incubated in 10 mM PBS pH 7.4 with 
0.1% of lung surfactant (Curosurf®) under mild magnetic stirring at 37°C for 90 min. The 
particle size and morphology of the recovered nanoparticles were analysed by PCS and 
TEM respectively, as described in the previous sections. 
 
5.3.10. Integrity of pEGFP-C1 
The integrity of pEGFP-C1 was assessed throughout the spray-drying process. The 
SLN:CS:pDNA:CS were first recovered from the mannitol and trehalose microspheres in 
10 mM PBS pH 7.4 with 0.1% of lung surfactant, as described in section 5.3.9. After a 
centrifugation step to precipitate any undissolved material, the integrity of pEGFP-C1 
associated to the nanosystems was assessed using BstBI digestion, as described in section 
5.3.4.. In addition, the pEGFP-C1 integrity in dry powders was also evaluated after 
incubation with DNase I, an endonuclease that nonspecifically cleaves DNA, following 
the supplier specifications (New England Biolabs Inc., USA), and taking into account the 
previous conditions used with BstBI. Briefly, DNase I solution, in the respective reaction 
buffer, was added to the recovered nanoparticles suspension. The mixture was incubated 
at 37°C for 1 h, and a 25 µL aliquot of the suspensions was analysed using the above 
described gel electrophoresis conditions. 
 
5.3.11. Statistical analysis  
Statistical analysis of the experimental data was performed using a one-way analysis of 
variance (one-way ANOVA) and differences between groups were tested by a one-way 
ANOVA with Dunnet’s post hoc test with GraphPad Prism version 6.0 (GraphPad 
Software, San Diego, CA). Data were expressed as meanSD or 95% confidence interval. 
A p<0.05 value was considered significant. All data are shown as meanSD. 
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5.4. Results and discussion 
5.4.1. pDNA-polycationic SLN formulation and characterization 
The main purpose of using carriers for gene delivery is to protect and transport the 
genetic material into the cell and finally into the nuclear compartment while avoiding 
intracellular degradation [32]. The most frequently strategy for non-viral gene delivery is 
the formulation of DNA into condensed particles by means of cationic polymers such as 
CS. Generally, these systems can be formed by electrostatic interaction between 
oppositely charged macromolecules, e.g. cationic polymers and anionic DNA [22]. In this 
study, SLN:CS:pDNA were obtained spontaneously by electrostatic interaction upon 
incubating the pEGFP-C1 with SLN:CS under gentle stirring. The first step was the SLN 
coating with a CS layer, resulting from the deposition of CS (positively charged polymer) 
onto the negatively charged SLN surface (ca. -17 mV). The coating of SLN with CS led 
to an increase in SLN particle size (Table 5.1) with a narrow distribution. As expected, 
the surface charge of SLN:CS became positive after coating.  
 
Table 5.1: Physical characteristics of plain SLN before and after coating with CS 
(meanSD, n=3).  
SLN CS Coating Mean size (nm) PI ZP (mV) 
A 
Without 994 0.1230.009 -17.10.7 
With 21111 0.2860.008 28.40.5 
B 
Without 1917 0.1650.012 -17.80.5 
With 29716 0.2520.011 32.80.6 
A: glyceryl dibehenate SLN; B: glyceryl tristearate SLN; PI: polydispersity index, ZP: zeta potential 
 
Afterwards, the SLN:CS were loaded with a model plasmid (pEGFP-C1) by electrostatic 
interaction with the CS coating layer. The pEGFP-C1, a recombinant EGFP vector is of 
interest because it can be transfected into mammalian cells using any standard 
transfection method expressing GFP, a brighter green fluorescence. Moreover, pEGFP-C1 
can be easily synthesized through bacteria transformation [33]. Regardless of the initial 
amount added to the formulation, all the pEGFP-C1 was incorporated into the SLN:CS 
nanoparticles as shown by agarose gel electrophoresis (Figure 5.2A and B), where free 
pEGFP-C1 moved at its usual position in the gel while pEGFP-C1 adsorbed onto the 
nanoparticles did not move from the wells, indicating the SLN:CS were able to retain the 
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adsorbed pDNA. The greater the amount of plasmid used, the higher intensity of the band 
was detected in the respective well, as opposed to the wells with unloaded nanoparticles 
(without pEGFP-C1), which did not show any fluorescence. 
Plasmid incorporation caused a certain decrease in particle size and distribution (Table 
5.2), which is in agreement with the underlying strong electrostatic interactions between 
the cationic CS with negatively charged molecules such as DNA [22, 34]. Furthermore, 
by increasing the amount of plasmid, zeta potential progressively diminished due to the 
presence of negatively charged pDNA on the nanoparticles surface.  
 
 
Figure 5.2: Agarose gel electrophoresis (0.7% in TBE) of glyceryl dibehenate (A) and 
glyceryl tristearate (B) SLN:CS:pDNA and glyceryl dibehenate (C) and glyceryl 
tristearate (D) SLN:CS:pDNA:CS containing increasing amounts of pEGFP-C1 (from 0 
to 100%, w:w). The pEGFP-C1 associated to SLN:CS and SLN:CS:pDNA:CS remained 
intact. No banding was seen on the gel in both type of particles, indicating pEGFP-C1 
was still strongly attached to nanoparticles. M - molecular weight markers. 
Chapter 5 - Hybrid pDNA-polycationic nanostructured microparticles for pulmonary delivery of genetic material 
 
198 
 
As the nucleic acid in these formulations may be degraded due to direct exposition to the 
environment, SLN:CS:pDNA were further coated with a second CS layer, producing the 
so-called SLN:CS:pDNA:CS. After this second coating, the plasmid remained attached to 
the nanoparticles, with no band for free pEGFP-C1 observed, and the immobile 
nanocomplexes remaining in the starting zone of the gel, showing the incorporation 
efficiency of pEGFP-C1 was 100% for all the tested pDNA quantities (Figure 5.2C and 
D). Likewise, the greater the amount of plasmid attached to the nanoparticles, the higher 
the intensity of the band retained in the respective well, whereas the wells with unloaded 
nanoparticles did not display any fluorescence. The pEGFP-C1:CS mass ratio of 100% 
(w:w) was, hence, selected for further studies. Figure 5.2 also shows that SLN:CS:pDNA 
were retained at the positive side of the well while SLN:CS:pDNA:CS are retained at the 
negative side. This is a consequence of their different surface charges: SLN:CS:pDNA 
possess a less positive surface charge, so the nanoparticles run to the positive pole, 
whereas SLN:CS:pDNA:CS are positively charged, tending to migrate to the negative 
pole. 
 
Table 5.2: Physical characteristics of SLN:CS:pDNA and SLN:CS:pDNA:CS loaded 
with increasing amounts of pEGFP-C1 (from 0 to 100%, w:w, related to CS mass in the 
system). Results expressed as meanSD, n=3. 
  SLN:CS:pDNA SLN:CS:pDNA:CS 
SLN 
% pEGFP-
C1 
Ø (nm) PI ZP (mV) Ø (nm) PI ZP (mV) 
A 
0 21111 0.2860.008 28.40.5 21111 0.2860.008 28.40.5 
10 1985 0.2710.008 14.50.6 1987 0.2820.009 30.43.1 
20 1977 0.2980.041 15.60.4 2048 0.2910.011 30.40.8 
40 1997 0.2890.012 13.70.4 2125 0.2940.009 29.21.0 
60 1976 0.2710.012 12.20.7 2168 0.4200.009 28.70.7 
80 1865 0.2670.016 11.90.3 1985 0.2750.010 27.30.7 
100 1873 0.2670.011 10.31.7 20310 0.2870.011 24.91.0 
B 
0 29716 0.2520.011 32.80.6 29716 0.2520.011 32.80.6 
10 1986 0.2110.014 14.80.7 2168 0.2000.040 31.91.0 
20 2244 0.1810.011 12.31.1 22012 0.1770.028 28.41.1 
40 2245 0.1510.022 13.60.5 22811 0.1780.008 28.81.2 
60 2347 0.1470.021 12.30.2 23113 0.1810.027 30.21.7 
80 2274 0.1760.006 13.50.8 21611 0.1720.010 27.60.1 
100 2355 0.1650.012 10.70.5 2209 0.1660.010 28.10.3 
A: glyceryl dibehenate SLN; B: glyceryl tristearate SLN; PI: polydispersity index, ZP: zeta potential 
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Regarding nanoparticle size, the coating with a second CS layer did not produce notable 
changes, remaining within a narrow range, while zeta potential values of 
SLN:CS:pDNA:CS expectedly became more positive due to the external CS layer (Table 
5.2).  
TEM images of the SLN:CS:pDNA:CS prepared with both solid lipids are shown in 
Figure 5.3, where the polymer layers have sufficient electron density to be directly 
observed through negative staining with phosphotungstic acid. The polymer appears as a 
grey layer surrounding the denser solid lipid matrix of spherical SLN. The micrographs 
confirmed the particle size distributions previously established from the PCS studies. 
 
  
Figure 5.3: TEM micrographs of SLN:CS:pDNA:CS based on (A) glyceryl dibehenate 
and (B) glyceryl tristearate.  
 
5.4.2. DLS thermal analysis  
The effect of temperature on nanoparticle size was assessed using DLS, applying a 
heating ramp from 25°C up to 90°C and then a cooling ramp to the initial temperature. 
This assay allowed assessing nanoparticle physical stability by determining particle size 
variation when the formulations were subjected to a temperature increase followed by a 
decrease to the initial temperature. These studies are particularly meaningful whenever a 
formulation is intended for further temperature processing as it occurs during a spray-
drying procedure. The heating and cooling ramps induced particle size changes in both 
SLN:CS:pDNA (Figure 5.4A and B), confirming previous observations reported in 
Chapter 2, section 2.4.3.. A slight particle size reduction throughout the heating step 
especially at its m.p. (70°C) was evident for glyceryl dibehenate SLN. However, after 
A
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the cooling phase, the initial particle size was not fully recovered. The glyceryl tristearate 
SLN suffered a marked decrease after 50°C, suggesting some instability at high 
temperatures. During the cooling step, particle size stabilizes. Despite all these variations, 
the particle size variations of both types of SLN were always within the nanosize range. 
Interestingly both SLN:CS:pDNA:CS behaved in a different way than SLN:CS:pDNA 
(Figure 5.4C and D). Regarding glyceryl dibehenate SLN:CS:pDNA:CS, their size was 
stabilized until 60°C after which an abrupt increase took place, returning after to their 
initial size. For glyceryl tristearate SLN:CS:pDNA:CS, this abrupt increase only occurred 
at 80°C. During the cooling step, both type of particles presented unstable profiles, 
probably due to the presence of CS. However, pEGFP-C1 remained associated with 
nanoparticles throughout all the heating and cooling process, i.e. the plasmid was 
retained in the wells suggesting that its stability and integrity were maintained (Figure 
5.4E). 
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Figure 5.4: Thermal stability of hybrid nanoformulations: DLS thermogram of (A) 
glyceryl dibehenate SLN:CS:pDNA; (B) glyceryl tristearate SLN:CS:pDNA; (C) 
glyceryl dibehenate SLN:CS:pDNA:CS; (D) glyceryl tristearate SLN:CS:pDNA:CS (■ - 
heating step from 25°C to 90°C, ● - cooling step from 90°C to 25°C, meanSD, n=3); 
(E) Agarose gel electrophoresis (0.7% in TBE) of pEGFP-C1 in (1) glyceryl dibehenate 
and (2) glyceryl tristearate SLN:CS:pDNA and (3) glyceryl dibehenate and (4) glyceryl 
tristearate SLN:CS:pDNA:CS after being subjected to DLS heating and cooling (M - 
molecular weight marker). 
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5.4.3. Integrity of pEGFP-C1 loaded on nanoparticles 
For efficient in vivo delivery, particularly in gene therapy applications, the 
nanoparticulate carrier must be able to protect the genetic material from degradation 
during its transport to the target cells [35]. The ability of SLN:CS:pDNA and 
SLN:CS:pDNA:CS nanoparticles to stabilize pEGFP-C1 from endonuclease degradation 
in the body, as well as inside the cell, was studied using agarose gel electrophoresis. In 
order to check the level of protection being offered to the pEGFP-C1, the nanoparticles 
were subjected to an endonuclease treatment consisting of incubation with BstBI (1 U 
BstBI/1 µg pDNA) at 65°C/1 h in an appropriate buffer. The experimental data showed 
that naked pEGFP-C1 was partially digested by the endonuclease (Figure 5.5).  
 
 
Figure 5.5: Agarose gel electrophoresis (0.7% in TBE) of pEGFP-C1 in glyceryl 
dibehenate and glyceryl tristearate SLN:CS:pDNA and SLN:CS:pDNA:CS. BstBI caused 
degradation of naked pEGFP-C1 and pEGFP-C1 associated to SLN:CS, while pEGFP-C1 
in SLN:CS:pDNA:CS was protected from degradation and retained in the well. 
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Moreover, the pEGFP-C1 attached at SLN:CS was largely unprotected as observed by the 
presence of the two expected oligonucleotide bands (2080 and 2600 bp). In contrast, the 
plasmid attached to nanoparticles with an outer CS layer was fully protected from 
digestion (fluorescence observed only in the wells) (Figure 5.5). 
The protection conferred by SLN:CS:pDNA:CS was further investigated by incubation of 
nanoparticles with chitosanase, an enzyme that promotes the endohydrolysis of beta-
(14)-linkages between D-glucosamine residues in partly acetylated CS, thus destroying 
the CS layers of the nanoformulations. Then, nanoparticles were incubated with the 
endonuclease BstBI. The physicochemical properties of nanoparticles after chitosanase 
digestion were also measured revealing that the initial particle size of SLN was recovered 
(1077 nm and 1778 nm for glyceryl dibehenate and glyceryl tristearate SLN, 
respectively) with suitable polydispersity. The nanoparticles also recovered their negative 
surface charge corresponding to the zeta potential of initial SLN (-223 mV for glyceryl 
dibehenate SLN and -170 mV for glyceryl tristearate SLN).  
Electrophoretic analysis also demonstrated that SLN:CS:pDNA:CS, that were not 
subjected to BstBI digestion, protected the pEGFP-C1 integrity. Since pEGFP-C1 was 
released with no signs of degradation from the nanoparticles after CS layers destruction 
by chitosanase (Figure 5.6), while those subjected to chitosanase and then BstBI 
treatment, showed the bands resulting of BstBI digestion at 2080 and 2600 bp. However, 
it is also possible to observe the presence of two additional bands of pEGFP-C1, which 
may be due to the formation of CS small fragments or even monomers that may remain 
associated to pEGFP-C1 making it unavailable for BstBI digestion (Figure 5.6, arrows). 
The small size of these complexes enabled their migration into the agarose gel. 
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Figure 5.6: Agarose gel electrophoresis (0.7% in TBE) of pEGFP-C1 in glyceryl 
dibehenate and glyceryl tristearate SLN:CS:pDNA:CS after chitosanase and subsequent 
endonuclease (BstBI) treatment. Chitosanase promoted pEGFP-C1 dissociation from 
nanoparticles, making it susceptible to BstBI digestion.  
 
5.4.4. In vitro cell viability studies 
The biocompatibility of nanoparticles was assessed through cell viability assays 
performed with relevant pulmonary A549 and Calu-3 cell lines. Both cell lines are 
suitable models for evaluating biocompatibility of these particles in the pulmonary 
environment. The Calu-3 is an immortalized cell line obtained from lung adenocarcinoma 
and has been extensively used in the study of formulations designed for either nasal or 
pulmonary drug delivery, as it is considered a model of the epithelium of both regions 
[36]. The A549 cell line is representative of the alveolar epithelium, being obtained from 
human alveolar adenocarcinoma [36]. 
The viability of these pulmonary cells incubated with both formulations (SLN:CS:pDNA 
and SLN:CS:pDNA:CS) at different concentrations was assessed using the MTT 
proliferation assay. The studies revealed an important difference between negative (live 
cells, K-) and positive controls (dead cells, K+) at 24, 48 and 72 h of incubation (Figure 
5.7A and B). During the first 48 h, there was a decrease in viability of both cell lines 
induced by the nanoparticle formulations. However, cell viability increased after 72 h. 
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The general decrease in cell viability observed between 24 and 48 h for all formulations 
may be explained by the need of an accommodation period by the cells to adapt to new 
conditions. In previous studies carried out, in Chapter 2, section 2.4.5., with the same cell 
lines, the glyceryl dibehenate and glyceryl tristearate SLN showed no evidence of acute 
cytotoxicity. So, the decrease in cell viability herein detected with SLN:CS:pDNA and 
SLN:CS:pDNA:CS probably occurred due to the presence of the CS in the formulations, 
which corroborates the findings of Rodrigues et al. [37]. As the MTT assay is based on 
the enzymatic conversion of MTT in the mitochondria, the tested nanoformulations may 
have inhibited the mitochondrial respiration inducing active oxygen-related cell death 
and, consequently, the observed cytotoxicity following exposure to the nanoparticles. 
Moreover, the reactive oxygen species that can be generated within mitochondria can also 
damage mitochondrial components and therefore a cytotoxicity assay based on 
mitochondrial respiratory activity would give early signs of toxicity following exposure 
to a mitochondrial toxicant, such as in MTT assay [38]. 
In order to validate the MTT results, an additional toxicity test was carried out using the 
propidium iodide test. This dye does not permeate living cells, being commonly used to 
detect dead cells in a population since it allows detecting the breakdown of cellular 
membrane integrity [39]. The retention values of propidium iodide in the positive control 
(K+) were high, since these cells were not viable, with a damaged cell membrane 
promoting dye uptake (2 URF for both cell lines) (Figure 5.7C and D). On the other 
hand, cells incubated with only fresh medium (negative control, K-) were viable, with 
intact cell membranes, and consequently presented low values of propidium iodide uptake 
(ca. 1 URF). The cell membranes in contact with the formulations remained intact 
because values of propidium iodide assay were approximately equal to those of the 
negative control (1 URF for all formulations in both cell lines), suggesting the cell 
membranes were not disrupted irrespective of the nanoparticle concentration used. 
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Figure 5.7: Relative cell viability of (A) A549 and (B) Calu-3 cell lines measured by the 
MTT reduction and propidium iodide uptake by (C) A549 and (D) Calu-3 cell lines at 
different incubation times: () 24, () 48 and () 72 h. (K-) negative control (culture 
medium); (K+) positive control (SDS, 1 mg/mL); (F1) glyceryl dibehenate 
SLN:CS:pDNA and (F2) glyceryl tristearate SLN:CS:pDNA at 0.332 mg/mL; (F3) 
glyceryl dibehenate SLN:CS:pDNA:CS and (F4) glyceryl tristearate SLN:CS:pDNA:CS 
at 0.290 mg/mL; (F5) glyceryl dibehenate SLN:CS:pDNA and (F6) glyceryl tristearate 
SLN:CS:pDNA at 0.166 mg/mL; (F7) glyceryl dibehenate SLN:CS:pDNA:CS and (F8) 
glyceryl tristearate SLN:CS:pDNA:CS at 0.146 mg/mL. Results are expressed as 
meanSD (n=6). Statistical analysis between the control group (K-) and other groups was 
performed using one-way ANOVA with Dunnet’s post hoc test (#p<0.01 and *p<0.0001). 
 
5.4.5. In vitro transfection studies 
Due to its mucoadhesive and permeation-enhancing properties, CS binds to cell 
membranes, promoting transcellular and paracellular permeability. Therefore, CS 
nanoparticles often present high transfection efficiency being successfully used as a non-
viral gene delivery system both in vitro and in vivo [22]. Although the transfection 
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efficacy is cell line dependent, there are steps common to all cells: (i) binding to cell 
surface between the positively charged systems and the negatively charged cell 
membrane receptors by electrostatic interactions, (ii) entry into the cell by following a 
specific pathway, (iii) release of DNA into the cytoplasm and (iv) passage through the 
nuclear envelope to reach the cellular machinery for protein synthesis [40, 41] . The 
transfection capacity of CS-DNA nanoparticles to various cell types, mainly HeLa, 
HEK293 and COS-1 cells has been described [22, 42]. 
Transfection of the pulmonary cell lines A549 and Calu-3 with glyceryl dibehenate and 
glyceryl tristearate SLN:CS:pDNA:CS was established by using the pEGFP-C1 as 
reporter gene encoding GFP. Likewise, our results suggested that SLN:CS:pDNA:CS 
were able to effectively transfect both A549 and Calu-3 cell lines (Figure 5.8). The 
fluorescent GFP molecules were expressed by the transfected pEGFP-C1, being 
accumulated within the cell and localized in either the cytoplasm (red staining) or 
perinuclear regions, as evidenced by the green colour in the merged pictures (cell nuclei 
were blue-stained). It must be emphasized that the levels of transfection were of similar 
magnitude as those obtained with the commercial agent Lipofectamine, herein used as a 
positive control. Negative controls (cells without nanoparticles) were unable to show any 
fluorescence due to absence of pEGFP-C1. This observation confirmed that the 
transfection of pulmonary cell lines with pDNA can be effectively carried out by using 
polycationic SLN as a vehicle, being a promising candidate for successful gene delivery. 
These results also provided additional evidence about the retention of structural integrity 
and function of pEGFP-C1 after transfection. 
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Figure 5.8: Fluorescence microscopy analysis of pEGFP-C1 expression after (A) A549 
and (B) Calu-3 cells transfection mediated by SLN:CS:pDNA:CS. (a) nuclei were 
stained with DAPI (blue); (b) actin were stained with rhodamine phalloidin (red); (c) 
pEGFP-C1 was expressed as a green fluorescence and (d) overlapping of the three 
channels (Scale bar: 20 μm). 
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5.4.6. Microencapsulation of SLN:CS:pDNA:CS nanoparticles 
PAP- and RFB-SLN loaded mannitol and trehalose microspheres were previously 
described, in Chapters 3 and 4, as an outstanding drug delivery system of drugs and 
proteins by the pulmonary route, given the adequate morphological and aerodynamic 
characteristics presented by these powders and their ability to release nanoparticles, and 
consequently the incorporated drug/protein, upon contact with an aqueous medium. So, 
taking into account this background and highlights the purpose of using these glyceryl 
dibehenate and glyceryl tristearate SLN:CS:pDNA:CS as gene delivery following 
pulmonary administration, these hybrid pDNA-polycationic SLN were microencapsulated 
through a spray-drying procedure. In this work, dry powders were also obtained using 
mannitol and trehalose as excipients with production yields ranging from 53 to 65% 
(Table 5.3). Both these excipients were selected as they are approved by regulatory 
agencies for pulmonary delivery, and so, widely applied in aerosolization. 
The daer is a combination of the particle size, density and shape, influencing the dispersion 
and sedimentation patterns. Microspheres produced in this work presented a Feret’s 
diameter of ca. 5 and 4 m for mannitol and trehalose microspheres respectively, real  of 
approximately 1.4 g/cm
3
 and a tapped  as low as 0.5 g/cm3 (Table 5.3), which confer an 
daer suitable to reach the alveolar area as occurred with the previously reported systems in 
Chapters 3 and 4, namely RFB- and PAP-SLN incorporated in mannitol and trehalose 
microspheres. Moreover, flowability has been shown to be a key property of the DPI 
formulation as it aids in metering, fluidization and dispersion, affecting the emitted dose 
of a drug from a DPI device and, possibly, the subsequent delivery of that drug to the 
lung. The flowability indices (Hausner ratio and Carr’s index) may be calculated from 
poured and apparent densities providing a general indication of interparticulate forces. 
The results indicated poor flowability for dry powders, but further data revealed that the 
microspheres were able to sufficiently aerosolize and reach the deep lung, as previously 
described in Chapter 3, section 3.4.5. and Chapter 4, section 4.4.9.. Moreover, the powder 
residual moisture content varied from 0.55% (for mannitol as excipient) to 1.67% (for 
trehalose as excipient) (Table 5.3). The final moisture level of the spray-dried powders is 
mainly determined by the nature of the material due to its interactions with water 
molecules. Another factor which has a major impact on the moisture level of the powder 
is the Toutlet. Generally, lower moisture content is associated to higher Toutlet. In our 
experiments, a correlation between the powder residual moisture content and the Toutlet 
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was not found. The differences in moisture content of the spray-dried SLN can be related 
to the drying-aid properties. The low moisture content of the spray-dried mannitol 
particles was based on their crystalline state. In addition, this compound possesses a low 
MW and a good drying aptitude contrarily to polymers, which are characterized by high 
MW such as trehalose. 
 
Table 5.3: Physical and aerodynamic properties of dry powders (meanSD, n=3). 
Dry 
powders 
Process 
yield 
(%) 
Feret’s 
diameter 
(μm, n=300) 
Real 
density 
(g/cm
3
) 
Apparent 
density 
(g/cm
3
) 
Aerodynamic 
diameter 
(μm) 
Carr’s 
index 
(%) 
Hausner 
ratio 
Moisture 
residual 
content 
(%) 
A 61.35.2 5.440.94 1.440.00 0.560.00 6.530.00 514 2.10.2 0.550.03 
B 53.01.6 5.840.70 1.440.03 0.500.00 7.010.08 502 2.00.1 0.690.02 
C 65.40.9 4.210.88 1.430.00 0.450.04 5.040.00 394 1.70.1 1.320.03 
D 60.92.5 4.080.96 1.410.01 0.400.01 4.850.01 436 1.80.2 1.670.01 
A: glyceryl dibehenate SLN:CS:pDNA:CS microencapsulated in mannitol; B: glyceryl tristearate 
SLN:CS:pDNA:CS microencapsulated in mannitol; C: glyceryl dibehenate SLN:CS:pDNA:CS 
microencapsulated in trehalose; D: glyceryl tristearate SLN:CS:pDNA:CS microencapsulated in trehalose 
 
Although the aerodynamic behaviour of a dry powder intended for pulmonary 
administration is a key factor for the particles to be successfully inhaled, morphological 
characteristics may also influence in the powder aggregation and flowing properties [28]. 
The SEM analysis (Figure 5.9) of the spray-dried powders revealed that microspheres 
possessed a spherical shape with well-defined limits. However when mannitol was used 
as excipient, particles look like slightly convoluted (Figure 5.9A and B). Conversely, 
microspheres based on trehalose presented a smooth surface (Figure 5.9C and D), thus 
confirming previously reported results in Chapter 3, section 3.4.2 and Chapter 4, section 
4.4.6.. 
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Figure 5.9: SEM micrographs of microspheres obtained by spray-drying: (A) glyceryl 
dibehenate and (B) glyceryl tristearate SLN:CS:pDNA:CS microencapsulated in mannitol 
and (C) glyceryl dibehenate and (D) glyceryl tristearate SLN:CS:pDNA:CS 
microencapsulated in trehalose (scale bar: 30 µm). 
 
5.4.7. ITC analysis of SLN:CS:pDNA:CS binding affinity to excipients  
The SLN:CS:pDNA:CS-spray-drying excipients binding strength and complexation 
thermodynamics along the microspheres formation were characterized by ITC, which 
quantitatively measured changes in the system’s energy. Figure 5.10 depicts the injection 
heat normalized by the SLN:CS:pDNA:CS concentration added per injection, Q*, as a 
function of the nanoparticles to excipients molar ratio after subtraction of the heat 
evolved after the titration of SLN:CS:pDNA:CS suspension into water.  
Titrations of glyceryl dibehenate SLN:CS:pDNA:CS into mannitol (Figure 5.10A) led to 
a similar profile to that obtained when titrating protein-glyceryl dibehenate into mannitol, 
as described in Chapter 4, section 4.4.7.. The increase of glyceryl dibehenate 
SLN:CS:pDNA:CS titrations onto mannitol promoted a progressive increase of Hi
i
 
A B
C D
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(from -155 to -90 cal.mol
-1
 in the tested range of concentrations). As previously 
explained, this phenomenon was a consequence of an enhancement of mannitol and 
SLN:CS:pDNA:CS dehydration to support the excipient binding to all nanoparticles. 
Nonetheless, many factors may influence this condition, such as hydrophobic interactions 
between mannitol with SLN:CS:pDNA:CS, charge shielding effects and/or excipient’s 
molecular rearrangements upon excipient adsorption onto nanoparticles. Regarding the 
titrations of glyceryl dibehenate SLN:CS:pDNA:CS onto trehalose (Figure 5.10B), the 
obtained profile was also very similar to those obtained for titrations between PAP-
glyceryl dibehenate SLN and trehalose (as reported in Chapter 4, section 4.4.7.) and 
glyceryl dibehenate SLN:CS:pDNA:CS into mannitol. The observed gradual Hi
i
 
increase (from -220 to -150 cal.mol
-1
 in the tested concentration range) was probably a 
result of hydrophobic interactions established between the disaccharide rings and 
conformational rearrangements of trehalose molecules. The interaction between glyceryl 
tristearate SLN:CS:pDNA:CS with mannitol (Figure 5.10C) led to positive Hi
i
 values in 
the whole concentration tested range. Briefly, at very low nanoparticles/saccharide molar 
ratios, an abrupt decrease in the endothermic Q* values was visualized, which was 
followed by a more gradual one. This endothermic profile was probably caused by the 
breakdown of water solvation upon complex formation. By observation of the ITC profile 
from glyceryl tristearate SLN:CS:pDNA:CS with trehalose (Figure 5.10D), it was 
possible to denote similarities between this profile and those previously obtained by 
titrating glyceryl dibehenate SLN:CS:pDNA:CS in mannitol and trehalose. The observed 
exothermic profile (from -360 to -250 cal.mol
-1
 in the tested concentration range) can be 
originated, as previously explained, from the hydrophobic interaction established between 
the disaccharide rings of trehalose and their potential conformational rearrangements. 
Moreover, for all experiments, a final plateau region was not visualized probably as a 
consequence of the range of SLN:CS:pDNA:CS/excipients molar ratios here tested. 
However, it is important to emphasize that these used concentration mimics the ones used 
during the spray-drying process. 
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Figure 5.10: Isothermal titration calorimetry of glyceryl dibehenate SLN:CS:pDNA:CS 
into (A) mannitol and (B) trehalose; glyceryl tristearate SLN:CS:pDNA:CS into (C) 
mannitol and (D) trehalose. Each dot on the curve corresponds to the heat of reaction 
following 2 µL injection every 400 s at 25°C (cell volume = 1.436 mL). The solid lines in 
the plots represent the fitting to experimental data. 
 
Table 5.4 depicts the interaction enthalpy of SLN:CS:pDNA:CS with both spray-drying 
excipients (mannitol and trehalose). Data demonstrated that SLN:CS:pDNA:CS based on 
glyceryl dibehenate presented low exothermic values when titrated onto excipients when 
compared with glyceryl tristearate SLN:CS:pDNA:CS. The same behavior was observed 
by with PAP-SLN microencapsulated in mannitol and trehalose in Chapter 4, section 
4.4.7.. As previously explained, this can be related to the large presence of hydrogen 
bonding upon interaction between glyceryl dibehenate SLN with both excipients. 
However, others processes, such as electrostatic repulsions between the nanoparticles, can 
also influence these data. On the other hand, interaction enthalpies of glyceryl tristearate 
SLN:CS:pDNA:CS with both excipients presented more positive Hi
i
 values compared 
with glyceryl dibehenate SLN:CS:pDNA:CS, reaching true positive Hi
i
 values for 
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glyceryl tristearate SLN:CS:pDNA:CS titrated onto mannitol. This evidence indicated 
that, after interaction between SLN:CS:pDNA:CS and mannitol, the rupture of water 
solvation layer and/or the presence of dispersion forces took place. In addition, Table 5.4 
also reveals that both the entropy change and the binding equilibrium constants resulting 
from the spray-dried glyceryl dibehenate SLN:CS:pDNA:CS are higher than those from 
the spray-dried glyceryl tristearate SLN:CS:pDNA:CS one. This characterization 
demonstrated the spray-drying of glyceryl dibehenate SLN:CS:pDNA:CS into mannitol 
and trehalose microspheres’ formation was a more propitious process (yielding a higher 
entropy change). These variations may probably take place due to the relatively lower 
hydrophobic character and some steric restrictions of the nanoparticles, which facilitates 
the interaction with the spray-drying excipients via dipole-dipole interactions. 
 
Table 5.4: Enthalpy (Hi
i
), entropy (Si
i
), binding constant (K
i
) and stoichiometry (n
i
) of 
the interaction of glyceryl dibehenate and glyceryl tristearate SLN:CS:pDNA:CS with 
mannitol and trehalose (spray-drying excipients) at 25°C (meanSD, n=3). 
Spray-drying 
excipient 
SLN:CS:pDNA:CS 
based on 
10
-2Hi
i 
(cal/mol) 
Si
i
 
(cal/mol) 
10
-3
 K
i
 
(M
-1
)
 10
3
n
i 
Mannitol 
Glyceryl 
dibehenate 
-1.60.1 
-1.30.1 
80.912.3 
53.79.6 
18.11.8 
0.70.2 
3.00.1 
13.50.8 
Glyceryl tristearate 
6.81.9 
22.32.2 
78.221.2 
38.112.5 
9.32.1 
0.10.1 
4.70.8 
36.911.4 
Trehalose 
Glyceryl 
dibehenate 
-4.70.3 
-1.10.1 
120.611.6 
116.922.4 
2419.0300.0 
1336.0200.0 
6.80.4 
27.31.5 
Glyceryl tristearate 
-4.10.1 
-2.50.1 
103.518.2 
89.615.4 
304.075.0 
54.317.7 
6.70.1 
16.30.6 
 
5.4.8. Nanoparticle recovery from microspheres  
The microencapsulated nanoparticles were intended re-disperse as isolate 
SLN:CS:pDNA:CS when in contact with the lung lining fluid upon rapid excipient 
(mannitol and trehalose) dissolution. Moreover, these excipients were expected to protect 
the SLN:CS:pDNA:CS, not only from heat but also against particle/particle interactions 
able to promote aggregation [43]. Herein, dry powders were incubated in PBS pH 7.4 
containing 0.1% lung surfactant with the purpose to mimic the environmental conditions 
in deep lung. The physicochemical properties (mean particle size, polydispersity and 
surface charge) and the morphology of the recovered nanoparticles were then analysed 
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and compared to those of the original (fresh) ones (Table 5.5). The formulations 
maintained or presented a slight decrease in particle size after recovery from 
microspheres, keeping an acceptable polydispersity. This may be due to the partial loss of 
the CS layers that surrounds the SLN, which was supported by the change in zeta 
potential from positive values before microencapsulation (24.91.0 and 28.10.3 mV for 
glyceryl dibehenate and glyceryl tristearate SLN:CS:pDNA:CS respectively) to negative 
values after recovery. The particle size of all nanoformulations after being recovered 
obtained by PCS analysis was additionally confirmed by TEM (Figure 5.11). 
 
Table 5.5: Mean nanoparticle size (nm), polydispersity index (PI) and zeta potential (ZP) 
after recovery from dry powders in PBS pH 7.4 with 0.1% lung surfactant (meanSD, 
n=3). 
 
Glyceryl dibehenate  
SLN:CS:pDNA:CS 
Glyceryl tristearate  
SLN:CS:pDNA:CS 
 (nm) PI ZP (mV)  (nm) PI ZP (mV) 
Fresh SLN:CS:pDNA:CS 20310 0.2870.011 24.91.0 2209 0.1660.010 28.10.3 
SLN:CS:pDNA:CS recovered 
from mannitol microspheres 
1824 0.1210.030 -18.81.4 2575 0.1740.008 -17.71.1 
SLN:CS:pDNA:CS recovered 
from trehalose microspheres 
1929 0.1660.094 -20.40.4 1826 0.1700.055 -19.32.7 
 
 
Figure 5.11: TEM micrographs of (A) glyceryl dibehenate and (B) glyceryl tristearate 
SLN:CS:pDNA:CS recovered from mannitol microspheres; (C) glyceryl dibehenate and 
(D) glyceryl tristearate SLN recovered from trehalose microspheres (scale bar: 50 nm). 
 
 
 
DB CA
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5.4.9. Integrity of pDNA recovered from dry powders 
The structural integrity of pEGFP-C1 was assessed after nanoparticle recovery from 
mannitol and trehalose microspheres. For this purpose, the recovered SLN:CS:pDNA:CS 
nanoparticles were subjected to the same treatment with chitosanase and, then, with 
BstBI. Gel electrophoresis confirmed the nanoparticles protected pEGFP-C1 from 
degradation during the spray-drying procedure (Figure 5.12). This suggests that at the 
physiological environment, where endonuclease concentration is markedly lower than the 
tested concentrations, such microencapsulated pDNA-polycationic nanoparticles should 
provide a significant protection for pEGFP-C1. Finally, these dry powders were also 
analysed using a specific nuclease, DNase I. The same positive results were obtained after 
incubation of the microspheres with this nuclease, further supporting that hybrid 
nanostructured microparticles provided protection to the incorporated pEGFP-C1 against 
degradation either by BstBI or by DNase I. 
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5.5. Conclusions 
Stable polycationic SLN formulations loaded with pEGFP-C1 were successfully 
produced, showing a high affinity for the plasmid and providing protection to the 
 
Figure 5.12: Agarose gel electrophoresis (0.7% in TBE) of pEGFP-C1 associated to 
SLN:CS:pDNA:CS nanocarriers following chitosanase and endonuclease (BstBI) 
digestions after recovery from (A) mannitol and (B) trehalose microspheres. 
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encapsulated pDNA from endonuclease degradation. As the nanoformulations showed 
low cell cytotoxicity while efficiently transfecting relevant pulmonary cell lines, they are 
a promising system for gene delivery, able to withstand further formulation into dry 
powders for inhalation. These were obtained by microencapsulation in mannitol and 
trehalose through a spray-drying technique, resulting in powders for pulmonary gene 
delivery containing intact and fully active pEGFP-C1. Finally, results suggested that 
microencapsulated SLN:CS:pDNA:CS could be a safe and effective vector for gene 
delivery following pulmonary administration.  
 
5.6. References 
1. Garnett, M.C. Gene-delivery systems using cationic polymers. Crit. Rev. Ther. 
Drug, 1999, 16 (2), 1-61. 
2. del Pozo-Rodríguez, A.; Delgado, D.; Solinís, M.Á.; Pedraz, J.L.; Echevarría, E.; 
Rodríguez, J.M.; Gascón, A.R. Solid lipid nanoparticles as potential tools for gene 
therapy: in vivo protein expression after intravenous administration. Int. J. Pharm., 2010, 
385 (1), 157-162. 
3. Merkel, O.M.; Zheng, M.; Debus, H.; Kissel, T. Pulmonary gene delivery using 
polymeric nonviral vectors. Bioconjugate Chem., 2012, 23 (1), 3-20. 
4. Liu, F.; Shollenberger, L.M.; Conwell, C.C.; Yuan, X.; Huang, L. Mechanism of 
naked DNA clearance after intravenous injection. J. Gene Med., 2007, 9 (7), 613-619. 
5. Azarmi, S.; Roa, W.H.; Löbenberg, R. Targeted delivery of nanoparticles for the 
treatment of lung diseases. Adv. Drug Deliv. Rev., 2008, 60 (8), 863-875. 
6. Woodle, M.C.; Lu, P.Y. Nanoparticles deliver RNAi therapy. Mater. Today, 2005, 
8 (8), 34-41. 
7. Choi, Y.H.; Liu, F.; Park, J.S.; Kim, S.W. Lactose-poly (ethylene glycol)-grafted 
poly-L-lysine as hepatoma cell-targeted gene carrier. Bioconjugate Chem., 1998, 9 (6), 
708-718. 
8. Boussif, O.; Lezoualc'h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; 
Demeneix, B.; Behr, J.-P. A versatile vector for gene and oligonucleotide transfer into 
Chapter 5 - Hybrid pDNA-polycationic nanostructured microparticles for pulmonary delivery of genetic material 
 
219 
 
cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA, 1995, 92 (16), 
7297-7301. 
9. Haensler, J.; Szoka Jr, F.C. Polyamidoamine cascade polymers mediate efficient 
transfection of cells in culture. Bioconjugate Chem., 1993, 4 (5), 372-379. 
10. Lim, Y.-B.; Han, S.-O.; Kong, H.-U.; Lee, Y.; Park, J.-S.; Jeong, B.; Kim, S.W. 
Biodegradable polyester, poly [α-(4-aminobutyl)-L-glycolic acid], as a non-toxic gene 
carrier. Pharmaceut. Res., 2000, 17 (7), 811-816. 
11. Mao, H.-Q.; Roy, K.; Troung-Le, V.L.; Janes, K.A.; Lin, K.Y.; Wang, Y.; August, 
J.T.; Leong, K.W. Chitosan-DNA nanoparticles as gene carriers: synthesis, 
characterization and transfection efficiency. J. Control. Release, 2001, 70 (3), 399-421. 
12. del Pozo-Rodriguez, A.; Delgado, D.; Solinís, M.A.; Gascon, A.R.; Pedraz, J.L. 
Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking 
in RPE cells. Int. J. Pharm., 2008, 360 (1), 177-183. 
13. Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled 
drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50 (1), 
161-177. 
14. Heiati, H.; Tawashi, R.; Phillips, N.C. Drug retention and stability of solid lipid 
nanoparticles containing azidothymidine palmitate after autoclaving, storage and 
lyophilization. J. Microencapsul., 1998, 15 (2), 173-184. 
15. zur Mühlen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (SLN) for 
controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 
1998, 45 (2), 149-155. 
16. Videira, M.; Almeida, A.J.; Fabra, À. Preclinical evaluation of a pulmonary 
delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomed.: Nanotechnol., 
2012, 8 (7), 1208-1215. 
17. Müller, R.H.; Rühl, D.; Runge, S.; Schulze-Forster, K.; Mehnert, W. Cytotoxicity 
of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. 
Pharmaceut. Res., 1997, 14 (4), 458-462. 
18. Yang, S.C.; Lu, L.F.; Cai, Y.; Zhu, J.B.; Liang, B.W.; Yang, C.Z. Body 
distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and 
targeting effect on brain. J. Control. Release, 1999, 59 (3), 299-307. 
Chapter 5 - Hybrid pDNA-polycationic nanostructured microparticles for pulmonary delivery of genetic material 
 
220 
 
19. Zara, G.P.; Cavalli, R.; Fundarò, A.; Bargoni, A.; Caputo, O.; Gasco, M.R. 
Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). 
Pharmacol. Res., 1999, 40 (3), 281-286. 
20. Roy, K.; Mao, H.-Q.; Huang, S.-K.; Leong, K.W. Oral gene delivery with 
chitosan-DNA nanoparticles generates immunologic protection in a murine model of 
peanut allergy. Nat. Med., 1999, 5 (4), 387-391. 
21. Khatri, K.; Goyal, A.K.; Gupta, P.N.; Mishra, N.; Vyas, S.P. Plasmid DNA loaded 
chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm., 
2008, 354 (1), 235-241. 
22. Cadete, A.; Figueiredo, L.; Lopes, R.; Calado, C.C.R.; Almeida, A.J.; Gonçalves, 
L.M.D. Development and characterization of a new plasmid delivery system based on 
chitosan - sodium deoxycholate nanoparticles. Eur. J. Pharm. Sci., 2012, 45 (4), 451-458. 
23. Guliyeva, Ü.; Öner, F.; Özsoy, Ş.; Haziroğlu, R. Chitosan microparticles 
containing plasmid DNA as potential oral gene delivery system. Eur. J. Pharm. 
Biopharm., 2006, 62 (1), 17-25. 
24. Mansouri, S.; Cuie, Y.; Winnik, F.; Shi, Q.; Lavigne, P.; Benderdour, M.; 
Beaumont, E.; Fernandes, J.C. Characterization of folate-chitosan-DNA nanoparticles for 
gene therapy. Biomaterials, 2006, 27 (9), 2060-2065. 
25. Mansouri, S.; Lavigne, P.; Corsi, K.; Benderdour, M.; Beaumont, E.; Fernandes, 
J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to 
improve transfection efficacy. Eur. J. Pharm. Biopharm., 2004, 57 (1), 1-8. 
26. Gonçalves, L.M.D.; Cadete, A.; Figueiredo, L.; Calado, C.C.R.; Almeida, A.J., 
editors. Biodegradable nanoparticles of Alginate and chitosan as non-viral DNA oral 
delivery system. 1
st 
Portuguese Meeting in Bioengineering (ENBENG); 2011: IEEE. 
27. Mehanna, C.; Baudouin, C.; Brignole-Baudouin, F. Spectrofluorometry assays for 
oxidative stress and apoptosis, with cell viability on the same microplates: A 
multiparametric analysis and quality control. Toxicol. in vitro, 2011, 25 (5), 1089-1096. 
28. Grenha, A.; Seijo, B.; Serra, C.; Remuñán-López, C. Chitosan nanoparticle-loaded 
mannitol microspheres: structure and surface characterization. Biomacromolecules, 2007, 
8 (7), 2072-2079. 
Chapter 5 - Hybrid pDNA-polycationic nanostructured microparticles for pulmonary delivery of genetic material 
 
221 
 
29. Inouye, S.; Tsuji, F.I. Aequorea green fluorescent protein. FEBS letters, 1994, 341 
(2-3), 277-280. 
30. Zhao, X.; Yu, S.-B.; Wu, F.-L.; Mao, Z.-B.; Yu, C.-L. Transfection of primary 
chondrocytes using chitosan-pEGFP nanoparticles. J. Control. Release, 2006, 112 (2), 
223-228. 
31. Kim, W.; Yamasaki, Y.; Kataoka, K. Development of a fitting model suitable for 
the isothermal titration calorimetric curve of DNA with cationic ligands. J. Phys. Chem. 
B, 2006, 110 (22), 10919-10925. 
32. Bisht, S.; Bhakta, G.; Mitra, S.; Maitra, A. pDNA loaded calcium phosphate 
nanoparticles: highly efficient non-viral vector for gene delivery. Int. J. Pharm., 2005, 288 
(1), 157-168. 
33. Kremers, G.-J.; Goedhart, J.; van den Heuvel, D.J.; Gerritsen, H.C.; Gadella, 
T.W.J. Improved green and blue fluorescent proteins for expression in bacteria and 
mammalian cells. Biochemistry, 2007, 46 (12), 3775-3783. 
34. Csaba, N.; Köping-Höggård, M.; Alonso, M.J. Ionically crosslinked 
chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. 
Int. J. Pharm., 2009, 382 (1), 205-214. 
35. Raviña, M.; Cubillo, E.; Olmeda, D.; Novoa-Carballal, R.; Fernandez-Megia, E.; 
Riguera, R.; Sánchez, A.; Cano, A.; Alonso, M.J. Hyaluronic acid/chitosan-g-poly 
(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA 
delivery. Pharmaceut. Res., 2010, 27 (12), 2544-2555. 
36. Rodrigues, S.; Cordeiro, C.; Seijo, B.; Remuñán-López, C.; Grenha, A. Hybrid 
nanosystems based on natural polymers as protein carriers for respiratory delivery: 
stability and toxicological evaluation. Carbohyd. Polym., 2015, 123 (1), 369-380. 
37. Rodrigues, S.; Dionísio, M.; López, C.; Grenha, A. Biocompatibility of chitosan 
carriers with application in drug delivery. J. Funct. Biomater., 2012, 3 (3), 615-641. 
38. Fotakis, G.; Timbrell, J.A. In vitro cytotoxicity assays: comparison of LDH, 
neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium 
chloride. Toxicology letters, 2006, 160 (2), 171-177. 
Chapter 5 - Hybrid pDNA-polycationic nanostructured microparticles for pulmonary delivery of genetic material 
 
222 
 
39. Shi, L.; Günther, S.; Hübschmann, T.; Wick, L.; Harms, H.; Müller, S. Limits of 
propidium iodide as a cell viability indicator for environmental bacteria. Cytom. Part A, 
2007, 71 (8), 592-598. 
40. Gao, X.; Kim, K.-S.; Liu, D. Nonviral gene delivery: what we know and what is 
next. AAPS J., 2007, 9 (1), E92-E104. 
41. Delgado, D.; del Pozo-Rodríguez, A.; Solinís, M.Á.; Rodríguez-Gascón, A. 
Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: 
the importance of the entry pathway. Eur. J. Pharm. Biopharm., 2011, 79 (3), 495-502. 
42. Dastan, T.; Turan, K. In vitro characterization and delivery of chitosan-DNA 
microparticles into mammalian cells. J. Pharm. Pharm. Sci., 2004, 7 (2), 205-214. 
43. Tewa-Tagne, P.; Briançon, S.; Fessi, H. Preparation of redispersible dry 
nanocapsules by means of spray-drying: development and characterisation. Eur. J. Pharm. 
Sci., 2007, 30 (2), 124-135. 
 
 
 
  
 
 
 
 
 
Chapter 6 
Concluding remarks and future work 
 
 
  
Chapter 6 – Concluding remarks and future work 
 
224 
 
This page was intentionally left blank. 
 
Chapter 6 – Concluding remarks and future work 
 
225 
 
6.1. Conclusions 
The work described in this dissertation aimed at developing a novel pulmonary drug 
delivery system based on an innovative strategy involving hybrid nanostructured 
microparticles intended for deep-lung delivery of various active agents.  
Lipid based carriers, with the main focus on SLN, are a promising nanoparticulate 
delivery system for the pharmaceutical industry, allowing large scale production, while 
avoiding the use of organic solvents usually needed for polymeric nanoparticle 
production. In addition, under optimized condition, SLN can also be freeze-dried and 
spray-dried to yield stable pharmaceutical powders for inhalation.  
The present work also takes advantage of the pulmonary route for treatment of respiratory 
diseases. Drug inhalation enables a rapid and predictable onset of action and induces 
fewer side effects compared to other delivery routes, such as the oral administration. 
However, pulmonary drug delivery must target the deep lung region, which requires the 
use of particles ranging in daer from 1 to 5 μm. The control of particle size distribution is 
critical to achieve an efficient and reproducible pulmonary deposition. For this purpose, 
SLN were encapsulated in mannitol and trehalose microspheres through a suitable spray-
drying technique, resulting in dry powders with the properties required for lung 
administration.  
The SLN based on glyceryl dibehenate and glyceryl tristearate were successfully assessed 
as potential nanocarriers for the encapsulation and/or incorporation of different active 
agents, such as a low MW anti-TB drug (RFB), a model protein drug (PAP) and a model 
nucleic acid (pEGFP-C1). Nanoparticles provided adequate physicochemical properties 
and afforded stability and protection of the incorporated agent, showing that SLN could 
act as a suitable and versatile platform for the delivery of several drugs. The SLN-
containing microspheres were prepared by spray-drying using pharmaceutically 
acceptable excipients (mannitol or trehalose) and appropriately characterized in order to 
comply with the characteristics required for lung administration. Further studies, 
particularly, in vitro and in vivo approaches were carried out for the selected microsphere-
based systems. The main goals and achievements obtained are summarized as follows. 
From a technological standpoint, two different SLN compositions were formulated and 
optimized using a HSH method as a preparation technique. These SLN presented a high 
performance in terms of EE and DL regarding RFB and PAP incorporation, being 
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biocompatible when incubated with relevant pulmonary cell lines (Calu-3 e A549) and 
being easily taken up by macrophages. This is particularly important since macrophages 
are the host cells for M. tuberculosis, becoming an effective targeted approach to 
pulmonary TB therapy. Concerning pEGFP-C1 entrapment, the SLN were previously 
surface-modified with a cationic polymer (CS), allowing DL through electrostatic 
interactions between the positively charged coating material and the negatively charged 
DNA, conferring protection against specific endonucleases. 
Spray-drying of the SLN with mannitol or trehalose as excipients, resulted in free-flowing 
dry powders composed by spherical and well-defined nanostructured microparticles, with 
good handling and aerodynamic properties for lung deposition. For that purpose, the 
spray-drying process was optimized for aspirator rate, spraying air flow pressure and Tinlet 
parameters. Physicochemical characterization, including density, Carr’s index, Hausner 
ratio and residual moisture content, showed that the developed spray-drying process 
generated particles for inhalation with uniform particle size distribution and good flow 
properties. Moreover, this microencapsulation process allowed remaining intact and fully 
active the pharmaceutics incorporated in the SLN, demonstrating by the in vitro activity 
studies against M. avium for RFB formulations, by the SDS-PAGE assay for PAP dry 
powders and by endonucleases digestion for pEGFP-C1 modified nanocarriers. 
Thermodynamic analysis using ITC provided valuable insights into the energetic 
description of the interaction between SLN and the spray-drying excipients (mannitol and 
trehalose) and an additional understanding of the in vitro release behaviour of RFB and 
PAP from these SLN. Studies using the two-stage impinger (Ph. Eur. 2.9.18, Apparatus 
A) show that a high fraction of RFB- and PAP-SLN formulations could reach the airways 
with a low swallowed fraction. The spray-dried microspheres are expected to dissolve 
quickly after landing on the aqueous covered epithelium of the lung. In vitro results 
showed that the delivered nanoparticles were released immediately after contact with an 
aqueous medium containing a lung surfactant, maintaining their original physicochemical 
properties. In addition, the determination of the in vitro RFB and PAP release profiles 
from the hybrid formulations gives us a good insight on how the particles would behave 
when administered in an in vivo model. Remarkably, it could be observed that almost all 
the drug was released from SLN and dry powders under the assayed conditions. This 
sustained release could reduce the number of doses, improving patient compliance. 
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In vivo experiments were conducted to further analyze the biodistribution of 
microencapsulated RFB-loaded SLN after pulmonary administration to mice. The studies 
demonstrated that non-metabolized RFB could achieve the studied organs, reducing the 
M. tuberculosis infection of a murine model compared to untreated control. 
As a conclusion, versatile SLN-based drug delivery systems were successfully developed 
as potential carriers for the encapsulation and/or adsorption of pharmaceuticals with 
different physicochemical characteristics. Through a spray-drying technique, these 
nanocarriers were effectively microencapsulated in dry powders form for pulmonary 
delivery. The development of these hybrid nanostructured microparticles included 
optimization of composition, manufacturing process, physicochemical characteristics, in 
vitro release, stability studies, cytotoxicity, compatibility, physical interactions analysis 
between nanoparticles and spray-drying excipients and, finally, aerodynamic and flow 
performance. Furthermore, this work may provide a promising proof-of-concept for 
further clinical application in the treatment of lung diseases, such as TB. 
 
6.2. Future work 
In the follow up of this work, supplementary in vivo experiments involving 
biodistribution studies and determination of drug concentration in the target organs, as 
well as the biological evaluation in a M. tuberculosis infection model, should be pursued 
in order to prove the therapeutic efficacy of the developed anti-TB formulations. In this 
context, bioluminescence imaging studies would be useful to elucidate the nanostructured 
microparticles distribution along the pulmonary tree. 
Finally, while an ideal general drug-delivery platform for inhalation may hardly be 
achieved, hybrid drug delivery systems that incorporate the benefits of various 
approaches will be tailored to address the needs of specific applications. This appears as 
an obvious consequence of the knowledge gathered during these studies that clearly point 
out to the development of a hybrid drug delivery system. Preliminary studies not included 
in this thesis have already shown the hybrid nanostructured microparticles may integrate 
both lipophilic (within the SLN) and hydrophilic drugs (in the aqueous phase of the 
spray-drying excipient) in the same formulation, allowing the co-formulation of 
hydrophilic and lipophilic drugs, which increases the versatility of this approach.  
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